CLINICAL STUDY PROTOCOL
Study Title: A Phase 3, Randomized, Double- Blind Study  to Evaluate the 
Efficacy and Safet y of Switching from Tenofovir Disoproxil 
Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 
25mg QD in Subjects with Chronic Hepatitis B who are 
Virologically  Suppressed
Sponsor: [COMPANY_009] Sciences, Inc.
[ADDRESS_653339]
Foster City , CA [ZIP_CODE]
IND Number:
EudraCT Number :[PHONE_10530]-003632-20
Indication: Chronic Hepatitis B
Protocol ID: GS-US-320-4018
[COMPANY_009] Sciences 
StudyDirector:Name:
[CONTACT_10880]:
Fax:
Mobile:
Email:
[COMPANY_009] Sciences 
MedicalMonitor:Name:
[CONTACT_10880]:
Fax:
Mobile:
Email: 
Protocol Version/Date: Original:
30September [ADDRESS_653340] or Independent Ethics Committee. The information is only  to be used by  [CONTACT_222184]. 
You will not disclose any of the information to others wi thout written authorization from 
[COMPANY_009]Sciences, Inc., except to the extent necessary  to obtain informed consent from those 
persons to whom the drug may  be administered.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653341] OF IN- TEXT TABLES ........................................................................................................................................ 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 18
1.INTRODUCTION .............................................................................................................................................. 22
1.1.Background ............................................................................................................................................ 22
1.2.Tenofovir Alafenamide (TAF, GS -7340)............................................................................................... 24
1.2.1. General Information ............................................................................................................. 24
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 25
1.2.3. Clinical Trials of Tenofovir Alafenamide (TAF, GS -7340)................................................. 27
1.3.Information about Tenofovir Disoproxil Fumarate (TDF) ..................................................................... 45
1.4.Rationale for This Study ........................................................................................................................ 45
1.5.Risk/Benefit Assessment for the Study .................................................................................................. [ADDRESS_653342] Selection ............................................................................................ 52
4.2.Inclusion Criteria .................................................................................................................................... 52
4.3.Exclusion Criteria ................................................................................................................................... 53
5.INVESTIGATIONAL MEDI CINAL PRODUCTS........................................................................................... 55
5.1.Randomization, Blinding an d Treatment Codes .................................................................................... 55
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 55
5.2.Description and Handling of Tenofovir Alafenamide (TAF) and TDF .................................................. 56
5.2.1. Formulation.......................................................................................................................... 56
5.2.2. Packaging and Labeling ....................................................................................................... 56
5.2.3. Storage and Handling ........................................................................................................... 57
5.3.Dosage and Administration of Tenofovir Alafenamide (TAF) and TDF ............................................... 57
5.4.Prior and Concomitant Medications ....................................................................................................... 58
5.5.Accountability for Tenofovir Alafenamide (TAF), Tenofovir Disoproxil Fumarate (TDF) and 
Matched Placebos ................................................................................................................................... [ADDRESS_653343] Enrollment and Treatment Assignment ..................................................................................... 60
6.2.Pretreatment Assessments ...................................................................................................................... 60
6.2.1. Screening Visit ..................................................................................................................... 60
6.2.2. Baseline Assessments ........................................................................................................... 61
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page3 30September [ZIP_CODE].3.Treatment Assessments .......................................................................................................................... 62
6.3.1. Double Blind Visits (Visit Window  ± 3 days) ..................................................................... 62
6.3.2. Open Label Visits (Visit Window  ± 7 days) ........................................................................ [ADDRESS_653344]-Treatment Assessments .................................................................................................................. 69
6.4.1. HBsAg Loss and Seroconversion Subjects.......................................................................... 69
6.4.2. All Other Subjects Who Discontinue Study Drug ................................................................ 69
6.4.3. Treatment- Free Follow  Up Visit Assessments (All Subjects) .............................................. [ADDRESS_653345] .................................................................................................. 86
8.2.Analysis Conventions ............................................................................................................................. 86
8.2.1. Analysis Sets ........................................................................................................................ 86
8.3.Data Handling Conventions ................................................................................................................... 87
8.4.Multiplicity Adjustments ........................................................................................................................ 87
8.5.Demographic Data and Baseline Characteristics ................................................................................... 89
8.6.Efficacy Analysis ................................................................................................................................... 89
8.6.1. Primary Analysis .................................................................................................................. 89
8.6.2. Analyses of Secondary Endpoints ........................................................................................ 90
8.7.Safety Analysis ....................................................................................................................................... 90
8.7.1. Key Secondary Safety Analy ses........................................................................................... 90
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653346] (IRB)/Independent Ethics Committee 
(IEC)/Ethics Committee (EC) Revie w and Approval .......................................................... [ADDRESS_653347] Accountability and Return ............................................. 97
9.1.8. Inspections ............................................................................................................................ 97
9.1.9. Protocol Compliance ............................................................................................................ 97
9.2.Sponsor Responsibilities ........................................................................................................................ 97
9.2.1. Protocol Modifications ......................................................................................................... 97
9.2.2. Study Report and Publications ............................................................................................. 98
9.3.Joint Investigator/Sponsor Responsibilities ........................................................................................... 98
9.3.1. Payment Reporting ............................................................................................................... 98
9.3.2. Access to Information for Monitoring .................................................................................. 98
9.3.3. Access to Information for Auditing or Inspections .............................................................. 99
9.3.4. Study Discontinuation .......................................................................................................... 99
10.REFERENCES ................................................................................................................................................. 100
11.APPENDICES .................................................................................................................................................. 103
Appendix 1.Investigator Signature [CONTACT_3490] .................................................................................................. 104
Appendix 2.Study Procedures Table ........................................................................................................ 105
Appendix 3.Management of Clinical and Laboratory Adverse Events .................................................... 107
Appendix 4.GSI Grading Scale for Severity of Adver se Events and Laboratory Abnormalities .............108
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 130
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653348] OF IN -TEXT TABLES
Table1-1. Clinical Studies to Support Efficacy for the TAF Marketing Applications ............................ 30
Table1-2. GS US 320 0108 and GS US 320 0110: HBV DNA Outcome at Week 48 Using 
HBV DNA of < 29 IU/mL, Missing = Failure (Full Analysis Set) ........................................ 31
Table1-3. GS-US-320-0108 and GS -US-320-0110: Proportion of Subjects with ALT 
Normalization at Week 48, Missing = Failure (Full Analysis Set with Baseline ALT 
> ULN)................................................................................................................................... 32
Table1-4. GS-US-320-0110: Proportion of Subjects with HBeAg Loss or Seroconversion at 
Week 48, Missing = Failure (Serologically Evaluable Full Analysis Set) ............................. 33
Table1-5. GS-US-320
-0108 and GS -US-320-0110: Subjects Exposed to Study Drug for the 
TAF Phase 3 Safety Population (Safety Analysis Set) ........................................................... 35
Table1
-6. GS-US-320-0108 and GS -US-320
-0110: Overall Summary of Adverse Events in 
the TAF Phase 3 Safety Population (SafetyAnalysis Set)..................................................... 36
Table1-7. GS-US-320-0108 and GS -US-320-0110: Adverse Events Reported for ≥5% of 
Subjects in Either Treatment Group in the TAF Phase 3 Safety Population (Safety 
Analysis Set) ........................................................................................................................... 37
Table1-8. GS-US-320-0108 and GS -US-320-0110: Serious Adverse Events by [CONTACT_506452] > [ADDRESS_653349] in the TAF Phase 3 Safety Population (Safety Analysis Set) ...........38
Table1-9. GS-US-320-0108 and GS -US-320-0110: Measures of Bone Mineral Density at 
Week 48 (Hip DXAAnalysis Setand Spi[INVESTIGATOR_506413]).......................................... 40
Table1-10. GS-US-320-0108 and GS -US-320-0110: Renal Biomarkers to Urine Creatinine 
Ratios at Week 48 in the TAF Phase 3 S afety Population (Safety Analysis Set) ................... 41
Table1-11. GS-US-320-0108 and GS -US-320-0110: Treatment -Emergent Grade 3or [ADDRESS_653350] 1% ofSubjects in Either Treatment 
Group in the Overall TAF Phase3 SafetyPopulation (Safety Analysis Set) ......................... 43
Table5-1. Disallowed Concomitant Medications .................................................................................... 58
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653351]
Foster City, CA [ZIP_CODE]
StudyTitle: A Phase 3, Randomized, Double- Blind Study  to Evaluate the 
Efficacy and Safet y of Switching from Tenofovir Disoproxil 
Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 
25mg QD in Subjects with Chronic Hepatitis B who are 
Virologically  Suppressed
IND Number:
EudraCT Number:[PHONE_10530]-003632-20
Study Centers Planned: Approximately  50centers in North America, Europe, and 
AsiaPacific regions
Objectives: The primary objective s of this study  areas follows:
To evaluate the efficacy  of switching to tenofovir alafenamide
(TAF)25 mg QD versus continued tenofovir disoproxil 
fumarate ( TDF)300 mg QD in virologically  suppressed 
subjects with chronic HBV as determined b y the proportion of 
subjects with HBV DNA ≥20 IU/mL (as defined by  [CONTACT_506453] -defined snapshot algorithm) at Week 24
To compare the safety  and tolerability  ofswitching to TAF
25mg QD versus continuing TDF 300 mg QD in virologicall y 
suppressed subjects with chronic HBV at Week 24
The key secondary  objectives of this study  are as follows: 
To compare the safety  of switching TAF 25 mg QD versus 
continued TDF300 mg QD as determined b y the percent 
change from baseline in hip and spi[INVESTIGATOR_506414] e mineral density  
(BMD) at Week 24
To compare the safety  of switching to TAF 25 mg QD versus 
continued TDF 300 mg QD as determined b y the change from 
baseline in estimated creatinine clearance by [CONTACT_3158] -Gault 
method(eGFRCG) at Week24
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page7 30September 2016Othersecondary  objectives of this study  are as follows: 
To compare the safety  of switching TAF 25 mg QD v ersus 
continued TDF300 mg QD as determined b y the percent 
change from baseline in hip and spi[INVESTIGATOR_506414] e mineral density  
(BMD) at Weeks 48 and 96
To compare the safety  of switching to TAF 25 mg QD versus 
continued TDF 300 mg QD as determined b y the change from 
baseline in estimated creatinine clearance by [CONTACT_3158] -Gault 
method(eGFRCG) at Week s 48and 96
To compare the safety  and tolerability  of switching to TAF 
25 mg QD versus continued TDF 300 mg QD in virologicall y 
suppressed subjects with chronic 
hepatitis B at Week 48
To evaluate the efficacy  of switching to TAF 25 mg QD versus 
continued TDF300 mg QD as determined b y the proportion of 
subjects with HBV DNA ≥20 IU/mL (as defined by  [CONTACT_506453] -defined snapshot algorithm) at 
Weeks48and 96
To compare the serological response (loss of HBsAg and 
seroconversion to anti
-HBs, and loss of HBeAg and 
seroconversion to anti- HBe in HBeAg-positive subjects ) of 
switching to TAF 25 mg QD versus continued TDF 300 mg QD 
at Weeks 24, 48,and96
To compare biochemical response (normal ALT and normalized 
ALT)of switching to TAF 25 mg QD versus continued TDF 
300 mg QD at Weeks 24, 48,and 96
To compare the change in fibrosis as assessed b y FibroTest®
after switching to TAF 25 mg QD versus continued TDF 
300mg QD at Weeks
48and 96
To evaluate the comparative open -label efficacy  and safet y of 
switching to TAF 25 mg QD from Week 48 through Week 96 in 
subjectsinitially randomized to TAF 25 mg QD and in subjects
sequentially  treated with continued TDF 300 mg QD for 
48weeks and then switched to open -label TAF 25 mg QD
To evaluate the proportion of subjects with HBV DNA 
<20IU/mLand target detected/not detected(i.e. <LLOD)at 
Weeks 24, 48 and96
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page8 30September 2016The exploratory  objectives of this study  are as follows:
 
 
 
 
 
 
Study Design : This is a randomized, double -blind, multicenter, active -controlled 
study to evaluate the safety  and efficacy  of TAF 25 mg QD in 
virologicall y suppressed subjects who switch from TDF to TAF
compared to continued TDF treatment.
Approximately  300subjects (with approximately  50% of subjects 
being ≥50 years old) who are virologically  suppressed and activel y 
taking TDF 300 mg QD, will be randomized in a 1:1 ratio (A:B) to 
receive either TAF 25 mg QD and matched placebo of TDF 300 mg 
QD,or [COMPANY_009]-provided TDF 300 mg QD andmatched placebo of
TAF 25mg QD.At randomization, subjects will b e stratified b y 
screening HBeAg status (HBeAg -negativevs. HBeAg -
positive) and 
age (≥ 50 or
<50years).
Treatment Arm A: approximately  150subjects administered 
TAF 25 mg QD and matched placebo of TDF300 mg QD
Treatment Arm B: approximately  150subjects administered 
[COMPANY_009]-provided TDF 
300 mg QD andmatched placebo of TAF 
25mg QD
The duration of double b lind treatment is 48 weeks. All subjects 
who complete 48 weeks of treatment are eligible for participation in 
the open label TAF 25 mg extension period for an additional 
48weeks (through Week 96). During the double -blind period only , 
subjects with a confi rmed creatinine clearance by  [CONTACT_506454] (eGFR CG) < 50 ml/min, and >20% decline in estimated 
glomerular filtration r ate (eGFRCysC) by [CONTACT_9289]-EPI (cystatinC) 
compared to baseline during the stud y, will be required to undergo 
dose modification to every other day  dosing of study  drug. Subjects 
with confirmed creatinine clearance<30 mL/min during the 
double-blind period of the study  will have the study  drug 
discontinued.
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page9 30September 2016Subjects who permanently discontinue study  drug (either 
prematurely  or at the end of study  [Week 96]) for reasons other than 
HBsAg loss with confirmed seroconversion to anti -HBs will be 
followed every  [ADDRESS_653352]. Use 
of appropriate, alternative HBV therapy  is strongly encouraged.
Subjects with HBsAg loss with confirmed seroconversion to 
anti-HBs should discontinue study  drug within 3 -6 months 
following confirmation of seroconversion to anti -HBs. Subjects 
with HBsAg loss with confirmed seroconversion prior to Week 24 
are not permitted to discontinue study  drug prior to the Week 24 
visit. Subjects with HBsAg loss with confirmed seroconversion will 
be followed off treatment every  4 weeks for 12 weeks and then per 
the study visit schedule ( Appendix 2) through Week 96/ED .
Discontinuation of study  drug for subjects experiencing HBsAg 
loss with confirmed seroconversion, who have known bridging 
fibrosis or cirrhosis, should be considered on a case by  [CONTACT_413].
The primary  analysis will occur at Week 24 with the pri mary 
efficacy endpoint being the proportion of subjects with HBVDNA
≥ 20IU/mL,as determined by [CONTACT_506455] -defined 
snapshotalgorithm.
An external ,independent ,multidisciplinary  Data Monitoring 
Committee (DMC) will convene and review the progress and safet y 
of this study after the last subject enrolled completes 24 weeks of 
the study.However, [COMPANY_009] will defer to the DMC for any  decision 
to convene earlier or m ore frequently . At eachmeeting, the DMC 
will review routine safety  and dual energy  X-ray absorptiometry  
(DXA)data and will make recommendations regarding 
modification of the study treatment.
Number of Subjects 
Planned:Approximately  300 subjects (approximately  150 subjects will 
receive TAF 25mg QD and matched placebo of TDF 300 mg QD, 
and 150subjects will receive [COMPANY_009]- provided TDF 300 mg QD and 
matched placebo of TAF 25mgQD)
Target Population: Adult subjects with CHB who are currently  (≥12 weeks) 
virologically suppressed ( HBVDNA<LLOQ) while receiving 
therapy with TDF 300 mg QD for ≥ 48 weeks, and as monotherap y 
for >24 weeks prior to S creening.
Duration of Treatment: The duration of the double-blind treatment is 48 weeks. After 
completing the double -blind period, all subjects will be eligible to 
receive open label TAF 25 mg QD for an additional 48 weeks until 
Week 96. 
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page10 30September 2016Diagnosis and Main 
Eligibility  Criteria:Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be 
eligible to participate in the study :
1)Must have the ability  to understand and sign a written informed 
consent form; consent must be obtained prior to initiation of 
study procedures
2)Adult male andnon-pregnant, non-lactatingfemale subjects, 
≥[ADDRESS_653353] at Screening is required for 
female subjects of childbearing potential (as defined in 
Appendix 5
).
3)Documented evidence of chronic HBV infection previously  
(e.g., documented HBsAg positive for more than 6months)
4)Maintained on TDF [ADDRESS_653354] 24 weeks prior to screening
and with viral suppression ( HBVDNA<LLOQ)for a 
minimum of 12 weeks prior to Screening, and including a 
Screening HBV DNA value of < 20 IU/mL (by [CONTACT_21921] )
5)Estimated creatinine clearance ≥ 50ml/min(using the 
Cockcroft -Gault method) based on serum creatinine and actual 
body weight as measured at the Screening evaluation, as 
follows:
(140 –age in years) (body  weight [kg])
(72) (serum creatinine [mg/dL ])
(Note: multiply  estimated rate by  0.85 for women)
6)Normal ECG (or if abnormal, determined b y the Investigator
not to be clinically  significant)
7)Must be willing and able to comply  with all study  requirements
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to 
be enrolled in this study:
1)Pregnant women, women who are breastfeeding or who believe 
they may wish to become pregnant during the course of the 
study 
2)Males and females of reproductive potential who are unwilling 
to use an “effective”, protocol -specified method(s) of 
contraception during the study . For a list of protocol -specified 
Contracept ive methods, refer to Appendix 5.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page11 30September [ZIP_CODE])Co-infection with H CV, HDV, HIV
4)Evidence of hepatocellular carcinoma (e.g. as evidenced b y 
recent imaging)
5) Current evidence of, or recent ( ≤5 year) history of clinical 
hepatic decompensation (e.g., ascites, encephalopathy  or 
variceal hemorrhage)
6)Abnormal hematological and biochemical parameters, 
including:
a)Hemoglobin < 10 g/dL 
b)Absolute neutrophil count < 750/mm3
c)Platelets ≤ 50,000/mm3
d)AST or ALT > 5 ×ULN
e)Albumin < 3.0 mg/ dL
f)INR > 1.5 ×ULN (unless stable on anticoagulant regimen)
g)Total bilirubin > 2.5 ×ULN
7)Received solid organ or bone marrow transplant
8)Significant renal, cardiovascular, pulmonary , or neurological 
disease in the opi[INVESTIGATOR_506415]
9)Malignancy  within 5 y ears prior to screening, with the 
exception of specific cancers that are cured b y surgical r esection 
(e.g. basal cell skin cancer, etc.). Subjects under evaluation for 
possible malignancy  are not eligible.
10)Currently  receiving ther apy with immunomodulators 
(e.g.corticosteroids), nephrotoxic agents, or agents capable of 
modifying renal excretion
11)Known hypersensitivity  to study drugs, metabolites, or 
formulation excipi[INVESTIGATOR_840]
12)Current alcohol or substance abuse judged b y the investigator to 
potentially  interfere with subject compliance
13)Any other clinical condition or prior therapy  that, in the opi[INVESTIGATOR_18959], would make the subject unsuitable for the 
study or unable to comply  with dosing requirements.
14)Use of investigational agents within 3 months of S creening, 
unless allowed b y the Sponsor
15)Use of an y prohibited medications as described in Section 5.4. 
Subjects on prohibited medications, who are otherwise eligible, 
will need a wash out period of at least 30 day s prior to the 
Baseline visit.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page12 30September 2016Study Procedures/
Frequency :Screening Visit
Treatment Period Visits: Baseline/Day  1, Weeks 4, 8, 12, 24, 36 
and 48, and open labe l Weeks 60, 72, and 96/E arly 
Discontinuation (ED)
Subjects who permanently discontinue stud y drug (either 
prematurel y or at the end of study [Week 96]) for reasons other 
than HBsAg loss with confirmed seroconversion to anti- HBs 
will be followed every  [ADDRESS_653355]. Use of appropriate , alternative HBV 
therapy is strongly encouraged.
Review of concomitant medications and assess ment for adverse 
events and vital signs, and weight measurement will be 
conducted at all study  visits. 
Laboratoryanalyses (serum chemistry , hematology , eGFR CG, 
urinalysis, plasma HBV DNA levels, pr egnancy testing 
[forfemales of childbearing potential])will be conducted at all 
study visits. 
Screening Visit assessments include :
Complete p hysical examination with height, body  weight, and 
vital signs andmedicalhistory(including HBV disease and 
treatment history )
INR and Alpha-fetoprotein (AFP) ; an AFP >50 ng/mL at 
Screening must have an appropriate evaluation (i.e., CT scan) in 
order to rule out HCC prior to being permitted to enter the 
study.
Plasma HBV DNA levels ( must be < 20 IU/mL at time of 
Screening to be eligible )
HBV serology  (qualitative HBsAg, and qualitative HBeAg; 
HBeAb and HBsAb reflex testing will be performed as needed)
and quantitative HBsAg
HCV, HDV and HIV testing
Urinalysis and urine drug screen
Baseline DXA scans of the hip and spi[INVESTIGATOR_506416] b e conducted 
anytime during the S creening period, but should be conducted 
atleast [ADDRESS_653356] dose of study  drug
ECG
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page13 30September 2016Baseline and On- treatment assessments include :
Complete phy sical examinations with body weightand vital 
signswill be performed at Baseline, Weeks 24, 48, 72, and 
96/ED.A symptom driven phy sical exam will be performed at 
all other visits.
HBV serology  (qualitative HBsAg and HBeAg) and 
quantitative HBsAg will be performed atBaseline and 
Weeks12, 24, 36, 48, 60, 72, and 96/ED. HBeAb and HBsAb 
reflex testing will be performed as needed .
Fasting blood sample for metabolic assessment (glucose and 
lipid panel [total cholesterol, HDL, direct LDL, and 
triglycerides] at Baseline and Weeks12, 24, 36, 
48,60, 72, and 
96/ED.
FibroTest®at Baseline and at Weeks 24, 48, and 96 /ED.
Serum Cy statin C (Cy sC) will be assessed at baseline and 
repeated if eGFRCGis confirmed to be < 50ml/minduring the 
double blind period of the study  (to estimate eGFR by  
[CONTACT_9289]-EPI[INVESTIGATOR_506417])
Fasting blood and urine for bone and renal biomarker testing 
will be collected at Baseline and Weeks 4, 12, 24, 48, 72, and 
96/ED
Vitamin D assessment 
Fracture Risk Assessment will be evaluated at Baseline
DXA scans of the hip and spi[INVESTIGATOR_506418]24,48, 72, and 96/ED visit. The ED visit DXA should 
be done if not done within the last 12 weeks of this visit.
ECG will be performed at Weeks 48 and 96/ED.
 
 
 
 
 
 
 
 
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page14 30September 2016Sequence analysis of the HBV pol ymerase/reverse transcriptase 
(pol/RT) for resistance surveillance may  be performed at
Baselinefor subjects with HBV DNA ≥ 69 IU/mL and may be 
attempted for viremic subjects (HBV DNA ≥69 IU/mL ) at 
Weeks 24, 48, and 96/ED. As it may not be known at the time 
of the visit whether a subject is viremic or if it will be their last 
study visit, a separate virology  sample for potential resistance 
surveillance will be collected at each stud y visit.In the event of 
unconfirmed virologic rebound (HBV DNA ≥ 20IU/mL), 
subjects will be asked to return to the clinic for a sched uled or 
unscheduled blood draw. For virologic rebound occurring 
within the first [ADDRESS_653357] will be re -counseled on adherence to 
study medication.
 
Health Related Quality  of Life (HRQoL) Survey s (SF-36, 
WPAI and CLDQ) at Baseline, Weeks 24, 48, a nd 96/ED. The 
ED visit HRQoL s should be done if not done within the last 
24 weeks of this visit.
See Section 6(Study Procedures) for further information.
Test Product, Dose, and 
Mode of Administration:Double-Blind Treatment:
Tenofovir alafenamide (TAF) 25 mg QD, oral administration 
and matched placebo of Tenofovir DF
(TDF) 300 mg QD, oral 
administration
Open-Label Treatment:
Tenofovir alafenamide (TAF) 25 mg QD, oral administration
Reference Therapy, 
Dose, and Mode of 
Administration:Double-blind Treatment:
Tenofovir DF (TDF)300 mg QD, oral administration and 
matched placebo of Tenofovir alafenamide (TAF) 25 mg QD, 
oral administration
Open-label Treatment: NA
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page15 30September 2016Criteria for Evaluation:
Safety: Key secondary  safety endpoints include the percent change from 
baseline at Week [ADDRESS_653358] has a confirmed creatinine clearance 
(eGFR CG) <50 ml/min with a > 20% decline from baseline in 
eGFR by [CONTACT_9289]-EPI[INVESTIGATOR_506417], the subject will be required to undergo 
dose modification to every other day  dosing of study  drug. During 
the double-blind period, subjects with confirmed eGFR CG
<
30mL/min will have the study  drug discontinued.
The proportion of su bjects in each treatment arm with tolerability  
failure (defined as an adverse event [AE] leading to permanent 
discontinuation of study  drug) at Weeks 24 and 48 will be 
summarized. Percent change from baseline in BMD by  [CONTACT_506456][INVESTIGATOR_506419] 24 and 48. Change 
from eGFR CGwill be assessed at every  visit and summarized 
through Week 48. Adverse events and clinical laboratory  tests will 
be collected at every  visit and summarized through Week 48. 
Additionally , summaries of AEs, di scontinuations due to AEs, and 
laboratory  data including BMD measurements (via DXA scans and 
eGFRCG) by [CONTACT_506457] (TAF versus TDF) will 
continue on an annual basis through Week 96.
Efficacy: The primary efficacy endpoint is:
Proportion of su bjects with HBV DNA ≥20 IU/mL
(asdetermined by [CONTACT_506455] -defined snapshot
algorithm ) at Week 24
The secondary efficacy endpoint sare:
Proportion of subjects with HBV DNA ≥ 20 IU/mL
(asdetermined b y the modified US FDA -defined snapshot
algorithm) at Weeks48 and 96
Proportion of subjects with serological response (loss of HBsAg 
and seroconversion to anti -HBs, and loss of HBeAg and 
seroconversion to anti
-HBe in HBeAg-positive subjects ) at 
Weeks 24, 48, and96
Proportion of subjects with biochemical response (normal ALT 
and normalized ALT) at Weeks 24, 48,and 96
Change from baseline in fibrosis as assessed b y FibroTest®at 
Weeks 48 and96
Proportion of subjects with HBV DNA < 20IU/mLand target 
detected/not detected(i.e. <LLOD) at Weeks 24, 48 and 96
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page16 30September 2016Statistical Methods: The primary  analysis will be performed when the last subject has 
completed Week 24 assessments or discontinued prematurel y. The 
analysis will compare the TAF arm to the TDF arm .
Analysis Methods: The primary  analysis will consist of a non- inferiority  evaluation of 
efficacy of TAF versus TDF, with respect to the proportion of 
subjects withHBV DNA ≥ 20IU/mL(as determined by [CONTACT_506453] -defined snapshot algorithm) at Week 24. It will 
be concluded that TAF is not inferior to the TDF if the upper bound 
of the two
-sided 95% confidence interval of the difference between 
treatment arms (TAF arm –TDF arm) in the response rate is less 
than 6% (ie, amargin of 6% is applied to non -inferiority  
assessment). The 95% confidence interval will be constructed using 
the normal approximation me thod based on stratified 
Mantel-Haenszel proportions, where stratification factors are 
screening HBeAg status and age ( ≥ 50 or < 50 years).
The percent change from baseline in hip and spi[INVESTIGATOR_433800]24 and [ADDRESS_653359].
All secondary  continuous endpoints will be summarized using an 
8-number summary  (n, mean, standard deviation, median, Q1, Q3, 
minimum, and maximum). All categorical secondary  endpoints will 
be summarized by  [CONTACT_506458].
Sample Size: With respect to the primary  efficacy endpoint of proportion of 
subjects with HBV DNA ≥20 IU/mL(as determined by  [CONTACT_506453] -defined snapshot algorithm ) at Week 24, when 
the sample sizes are 150 (TAF 25mg arm) and 150 (TDF 300 mg 
arm), a two- group, large -sample normal approximation test of 
proportions with a one -sided 0.[ADDRESS_653360] 
97%power to establish non -inferiority. It is assumed that both 
treatment arms will have subjects who have HBV DNA ≥ 20 IU/mL 
(asdetermined by [CONTACT_506455] -defined snapshot
algorithm) at a rate of 1.8% 
at Week 24 based on combined data of
suppressed su bjects from studies GS -US-174-0102 and 
GS-US-174-0103 with HBeAg -negative:HBeAg -positive = 2:1), 
with a non- inferiority margin of 6%.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page17 30September 2016This sample size also provides > 99% power to detect a 1.21% 
difference in the percentage change from baseline in hip BMD at 
Week 24 (assuming a 0.99% [SD 2.09%] change from baseline in 
TAF 25 mg arm and −0.22% [SD 1.89%] change from baseline in 
the TDF 300 mg arm, with a two -sided α = 0.05); and > 99% power 
to detect a 1.69% difference in the percentage change from basel ine 
in spi[INVESTIGATOR_110075] 24 (assuming a 1.50% [SD 2.80%] change 
from baseline in the TAF 25 mg arm and −0.19% [SD 3.00%] 
change in the TDF 300 mg arm, with a two -sided α=0.05); and 
68%power to detect a 3.6 mL /min difference in the change from 
baseline i n eGFR CGat Week 24 (assuming a 1.6 mL/min [SD 13.0] 
change from baseline in the TAF 25 mg arm and −2.0 mL/min 
[SD12.4] change from baseline in the TDF 300 mg arm, with a 
two-sided α = 0.05). These assumptions were derived from an HIV 
switch study ,GS-US-292-0109, due to the unavailability of switch 
data from TAF HBV studies.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page18 30September 2016GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
°C Degrees Celsius
°F Degrees Fahrenheit
AASLD American Association for the Study of Liver Diseases
ADV Adefovir dipi[INVESTIGATOR_506420] (SGPT)
ANC Absolute neutrophil counts
ANCOVA Analysis of covariance
ANOVA Analysis of variance
Anti-HBe Anti-Hepatitis B e- antigen
AR Adverse reaction
ARV Antiretroviral
AST Aspartate aminotransferase (SGOT)
AUCinf Area under the concentration versus time curve extrapolated to infinite t ime, calculated as 
AUC0last+(Clast/z)
AUCtau Area under the plasma concentration versus time curve over the dosing interval (tau)
BMD Bone mineral density
CatA Cathepsin A
Ces1 Caboxylesterase -1
CHB Chronic hepatitis B
CI confidence interval
CKD Chronic kidney disease
CKD-EPI [INVESTIGATOR_159840] k idney disease epi[INVESTIGATOR_506421]/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CRF/eCRF case report form(s)/electronic case report form(s)
CRO Contract (or clinical) research organization
CTX C-type collagen sequence
CYP3A4 Cytochrome P450 3A4
DMC Data Monitoring Committee
DNA Deoxyribonucleic acid
DSPH Drug Safety and Public Health
DXA Dual energy x -ray absorptiometry
EC Ethics committee
EC50 50% Effective Concentration
EudraCT European clinical trials database
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page19 30September 2016E/C/F Elvitegravir/cobicistat/emtricitabine
eGFR Estimated glomerular filtration rate
eGFRCG Estimated glomerular filtration rate by [CONTACT_16424] -Gault formula
EKG / ECG Electrocardiogram
ETV Entecavir
EU European Union
EVG Elvitegravir
FAS Full analysis set
FDA ([LOCATION_002]) Food and Drug Administration
FDC Fixed-dose combination
FSH Follicle stimulating hormone
FTC Emtricitabine
GCP Good Clinical Practice (Guidelines)
GFR Glomerular filtration rate
GSI [COMPANY_009] Sciences, Inc.
GGT Gamma glutamyl transferase
HBeAg Hepatitis B e antigen
HBsAg Hepatitis B s antigen
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
HCV Hepatitis Cvirus
HDL High-density lipoprotein
HDV Hepatitis Dvirus
HDPE High-density polyethylene
hERG Human ether -à-go-go-Related Gene
HIV Human Immunodeficiency Virus
HRQoL Health Related Quality of Life
IC20 20% inhibitory concentration
IC50 50% inhibitory concentration
ICF Informed Consent Form
ICH International Conference on Harmonisation
IEC Independent ethics committee
IMP Investigational Medicinal Product
IRB Institutional review board
IVRS Interactive voice response system
IWRS Interactive web response system
IUD Intrauterine device
LDL Low-density lipoprotein
LdT Telbivudine
LAM Lamivudine
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653361]
MedDRA Medical Dictionary for Regulatory Activities
MT-2 Human T -lymphotrophic virus -1 transformed cells
M = F Missing = Failure
NDA New Drug Application
NOAEL No observed adverse effect level
NRTI Nucleoside reverse transcriptase inhibitor
OAV Oral antivirals
OL Open-label
PD Pharmacodynamic
P1NP Procollagen type 1 amino -terminal propeptide
RBP Retinol binding protein
pol Polymerase
PK Pharmacokinetic
PXR Pregnane X receptor
PT/INR Prothrombin time/International normalized ratio
QD Once daily (use only in tables)
RPV Rilpi[INVESTIGATOR_506422]-36 Short Form (36)
SOP Standard Operating Procedure
STR Single tablet regimen
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TAF Tenofovir Alafenamide, GS -7340
TAF Fumarate Tenofovir Alafenamide Fumarate, GS -7340-03
TDF Tenofovir Disoproxil Fumarate
TFV Tenofovir
TFV-DP Tenofovir diphosphate
Tmax The time (observed time point) of Cmax
t½ An estimate of the terminal elimination half -life of the drug in serum/plasma/PBMC, 
calculated by [CONTACT_337342] 2 by [CONTACT_90262] (λ z)
T3 Triiodothyronine
UACR Urine albumin -to-creatinine ratio
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653362] Upper limit of the normal range
UPCR Urine protein -to-creatinine ratio
US [LOCATION_002]
WHO World Health Organization
WPAI Work Productivity and Activity Impairment
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page22 30September [ZIP_CODE]. INTRODUCTION
1.1. Background
Chronic hepatitis B (CHB) is a major public health care issue worldwide and one of the principal 
causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). The hepatitis B 
virus (HBV) is easily transmissible through perinatal, percutaneous, and sexual exposure 
{Loketal 2009}. Following acute HBV infection, 5% to 10% of adults and up to 90% of children 
fail to produce an immune response adequate to clear the infection; these individuals become 
chronic carriers of the virus {Zuckerman 1996 }. Individuals who develop CHB are at substantial 
risk of cirrhosis, hepatic decompensation, and HCC, which will afflict 15% to 40% of subjects 
with CHB in the absence of effective treat ment {World Health Organization (WHO) 2015a , 
Wright 2006 }. Liver cancer is the third leading cause of cancer deaths globally , with the highest 
burden of dise ase found in regions where HBV is endemic {Global Burden of Disease Cancer 
Collaboration et al 2015}. Recent reports estimated that 250 to 350 million individuals were 
living with HBV (i.e., are hepatitis B surface antigen [HBsAg] positive) in 2010, representing a 
worldwide prevalence of 3.6%, with considerable geographic va riability {Schweitzer et al 2015 , 
World Health Organization (WHO) 2015b }. For example, HBV prevalence rates of 0.01%, 
0.76%, 4.0%, 5.5%, and 22.4% have been reported for the [LOCATION_008], Canada, Turkey , 
China, and South Sudan, respectively . In 2013, an estimated 686,000 deaths were due to HBV 
infection, placing it among the top 20 causes of mortality  worldwide {G. B. D. Mortality  Causes 
of Death Collaborators 2015 , Ott et al 2012 }.
Worldwide universal vaccination remains the goal for elimin ating HBV infection and its 
complications, yet despi[INVESTIGATOR_506423], new 
HBV infections are still common even in areas of low prevalence. The World Health 
Organization estimates that each year there are over 4 million acute clinical cases of HBV 
infection globally  {
World Health Organization (WHO) 2015b }. In the [LOCATION_002] (US), 
approximately  20,000 people become acutel y infected each year according to an estimate from 
the Centers for Disease Control and Prevention {Centers for Disease Control (CDC) et al 2013 }.
Thenatural history  of chronic hepatitis B virus infection and disease is complex and highly  
variable. Following acute hepatitis B infection, up to 90% of newborns who are verticall y 
infected, and 25 -50% of children who acquire HBV within the first 6 y ears oflife, will become 
chronic carriers of the virus when the immune system is thought to be immature, compared to 
immunocompetent individuals who become infected during adulthood (< 1%) 
{Fattovich et
al2008, Sarin et al 2015}. CHB has traditionally  been characterized by  
[CONTACT_506459] r esponse {Fattovich et al 2008 , Sokal et al 2013 }. In the first, or the 
immune tolerant phase, individuals have high plasma levels of HBV DNA, detectable hepatitis B 
surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), with normal or slightly  elevated 
serum alanine transaminase (ALT) levels reflective of minimal infl ammation and fibrosis. This 
phase typi[INVESTIGATOR_506424], and is followed by  [CONTACT_506460]-positive, immune -active phase wherein ALT levels are persistentl y elevated along with 
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653363] undetectable or low levels of HBV DNA (< 2000 IU /mL), the presence of 
anti-HBe antibod y, and normal or minimal elevation in serum ALT, which reflects minimal 
inflammation but with variable fibrosis. This third phase can evolve in a subgroup of individuals 
to an HBeAg -negative, immune reactivation phase, in which ALT levels and HBV DNA levels 
are increased. Subjects develop HBeAg -negative CHB as a result of variants that arise in the 
precore or core promoter region of the virus {Sarin et al 2015}. The goal of anti -HBV therap yis 
to improve long -term survival and quality  of life by  [CONTACT_506461], 
decompensated liver disease, and HCC {Sarin et al 2015, Terrault et al 2015 }. As seroclearance 
of HBsAg is a rare spontaneous occurrence in patients with CHB, dura ble anti-HBe 
seroconversion in HBeAg -positive subjects is sometimes considered a reasonable endpoint, 
associated with improved prognosis, including a reduced risk of HCC. However, in man y 
subjects who discontinue treatment following anti -HBe seroconversion , disease relapse with 
increased levels of viremia can occur {Sarin et al 2015 }. Successful reduction of viremia to 
levels below assay  detection leads to reduced inflammation and slowing or reversal of fibrosis 
{Marcellin et al 2013 }.
Currently , there are 2 approved options for treatment of CHB: injectable interferons and oral 
antiviral (OAV) agents. Of these, treatme nt with OAV agents has been more successful in 
achieving and maintaining a high degree of viral suppression in subjects with CHB. The 
development of nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI s) was a major 
breakthrough for the treatment of CHB, providing effective suppression of viral replication and 
reducing the risk of long- term complications {Marcellin et al 2013 , World Health Organization 
(WHO) 2015a }. However, several N[t]RTI s possess a low barrier for viral resistance 
development, including lamivudine (LAM), telbivudine , (TBV) and adefovir dipi[INVESTIGATOR_96471] (ADV) 
{European Association for the Study  of the Liver (EASL) 2012 , Liaw et al 2012}. Additionall y, 
while development of resistance to entecavir (ETV) is low in treatment -
naïve subjects, the 
cumulative probability  of ETV resistance increases substantially  with long -term use in subjects, 
particularl y in subjects who are refractory to lamivudine, and th ose with lamivudine resistance 
(up to 57% through 6 years of treatment) { Tenney et al 2009}. In contrast, resistance to tenofovir 
disoproxil fumarate (TDF; Viread®) has not been documented through 6 y ears of use 
{Kitrinos etal 2014}.
Tenofovir (TFV) is a nucleotide analog with limited oral bioavailabilit y that inhibits reverse 
transcription in HIV -[ADDRESS_653364] approved for the 
treatment of HIV infection in 2001 to be given in combination with other antiretroviral (ARV) 
agents and was approved for treatment of CHB as monotherap y in 2008. TDF is currentl y 
approved in over [ADDRESS_653365] -line treatment for CHB in all major 
treatment guidelines {
European Association for the Study  of the Liver (EASL ) 2012, 
Sarinet al2015, Terrault et al 2015 }. Although highly effective, use of TDF is associated with 
nephrotoxicity  and bone-related toxicity  in some subjects. 
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page24 30September 2016Tenofovir alafenamide (TAF) is a phosphonamide prodrug of TFV that is more stable in plasma 
than TDF, and provides higher intracellular levels of the activ e phosphory lated metabolite 
TFV-DP to target cells (eg, HBV-infected hepatocy tes and HIV -infected lymphoid cells) with 
approximately  90% lower circulating levels of TFV relative to TDF at therapeuticall y active 
doses {Agarwal et al 2015, Babusis et al 2013, Murakami et al 2015, Ruane et al 2013}. The 
distinct metabolism of TAF offers the potential for an improved safet y profile when compared 
with TDF. In support of this concept are recent results from a large dataset of 1733 HIV -infected, 
treatment naive subjects randomized to receive treatment with th e fixed-dose combination [FDC] 
of elvitegravir (E), cobicistat (C), emtricitabine (F), TAF [E/C/F/TAF; Genvoy a®] or E/C/F/TDF 
[STB; Stribild®]). Renal and bone parameters were significantly  less affected in subjects who 
received E/C/F/TAF compared with E/C/F/TDF 
{Sax et al 2015 }. In a recent open -label Phase 3 
study, HIV-1-infected patients were switched from a TDF -based regimen to a TAF -based 
regimen with data supporting the efficacy  and safety  of switching regime ns.In adult subjects 
with CHB, a global Phase 3 program for TAF consisting of 2 prospective, randomized, 
active-controlled studies with 1 each in HBeAg -negative ( Study GS-US-320-0108) and 
HBeAg-positive (Study  GS-US-320-0110) subjects is currently  ongoing as described below.
Efficacy and safet
y results at Week [ADDRESS_653366] been filed in the US, EU, Japan, Taiwan and other territories 
worldwide.
1.2. Tenofovir Alafenamid e(TAF, GS -7340)
1.2.1. General Information
Tenofovir alafenamide (GS- 7340, TAF, or L -Alanine, N-[(S)-[[(1R)-2-(6-amino-9H -purin-9-yl)-
1-methylethoxy] methyl]phenoxy phosphiny l]-, 1-methylethyl ester, (2E)- 2-butenedioate (2:1) is 
a next generation oral prodrug of TFV, a nucleotide analog that inhibits HIV -1 reverse 
transcription. Tenofovir is metabolized intracellularly  to the active metabolite, TFV -DP, a 
competitive inhibitor of HIV -1 reverse tra nscriptase (RT) and HBV reverse transcriptase (HBV 
RT) that terminates the elongation of the viral DNA chain. In the development of TAF, three 
forms of the drug substance have been used in various studies: GS -7340, synony m for GS-7340 
as the free base; GS -7340-02, synonym for TAF monofumarate (1:1); and GS -7340-03 as the 
hemifumarate (2:1). GS -7340-03, also known as TAF fumarate, which is being used in the 
Phase3 studies GS
-US-320-0108 and GS -US-320-0110, is considered comparable based on 
physical/chemical properties to GS -7340-[ADDRESS_653367] as the free base, TAF (GS -7340), in blood and biological 
fluids. 
For further information on TAF (GS -7340), please refer to the current Investigator’s Brochure 
for TAF.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page25 30September [ZIP_CODE].2.2. Preclinical Pharmacology and Toxicology
Virology
Following its release from the prodrug TAF, TFV is metabolized intracellularly  to the active 
metabolite, TFV-DP, a competitive inhibitor of HBV pol ymerase/reverse transcriptase (pol/RT) 
and HIV-1 RT that terminates the elongation of the viral DNA chain during the process of HBV 
and retroviral replication.
Compared to TDF, TAF is relatively  stable in plasm a, but rapi[INVESTIGATOR_506425]. 
The cellular enzy mes responsible for conversion of TAF to TFV are cathepsin A (CatA), which 
is broadly  expressed in cells, and carboxy lesterase 1 (CES1), which is highly  expressed in liver. 
In HBV target cells, primary human hepatocy tes, TAF is primaril y hydrolyzed by [CONTACT_63447]1 with 
CatA making a minor contribution {Murakami et al 2015 }.In HIV-[ADDRESS_653368] shown 
no significant variation for conversion to TFV and antiviral activity  of TAF within PBMCs and 
macrophages from multiple donor s. The covalent anti -hepatitis C virus (HCV) protease 
inhibitors (PI s) telaprevir and boceprevir were identified as the only  potent inhibitors of CatA 
mediated h ydrolysis of TAF in a biochemical assay  (PC-120- 2001).
TAF is a potent inhibitor of HBV replica tion, exhibiting in vitro activity  comparable to that of 
TDF with an effective concentration ( EC50)value of [ADDRESS_653369] wild -type genotype A-H HBV clinical isolates (PC -
320-2003). TAF also 
exhibits potent anti -HIV activity  in lymphoid T-cells, primary  human PBMCs, and macrophages 
with EC 50values rangin g from [ADDRESS_653370] HI V-1 is 
100-to600-fold greater than TFV and 4- to 6-fold greater than TDF {Robbins et al 1998}. In 
MT-2 cells, TAF shows low cy totoxicity  with a selectivity  index of > 10,000. Based on data 
generated with the parent nucleotide TFV, TAF is active against a wide range of HIV -[ADDRESS_653371] HIV -2. 
For further information on the virology  of TAF, (GS -7340), refer to the current investigator’s 
brochure for TAF.
Safety Pharmacology
The IC20and the IC 50for the inhibitory  effect of TAF fumarate on human ether -a-go-go-related 
gene (hERG) potassium current was estimated to be greater than 30 μM (PC -120-2005). TAF in 
the monofumarate form has been evaluated to determine potential functional effects on the 
central nervous s ystem (R990188), renal s ystem (R990186), cardiovas cular (D2000006), and 
gastrointestinal s ystems (R990187). Single doses did not induce pharmacologic effects on the 
central nervous s ystem of the rat (1000 mg/kg), the renal s ystem of the rat (1000 mg/kg), or the 
cardiovascular s ystem of the dog (100 mg/kg) . TAF at 1000 mg/kg reduced distal transit and 
increased stomach weights starting [ADDRESS_653372] level (NOEL) for gastrointestinal motility  was 100 mg/kg.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page26 30September 2016Nonclinical Pharmac okinetics
All nonclinical pharmacokinetic experiments were perfo rmed using TAF monofumarate 
(GS-7340-02), and all study  data described reflect the dosage of the monofumarate. For 
reference, 100 mg of TAF monofumarate is equivalent to 80 mg of the GS -7340 free base (TAF). 
Plasma pharmacokinetics of the intact prodrug, TAF, following oral administration of 
GS-7340-02 in dogs and monkey s demonstrated rapid absorption with peak plasma 
concentrations between 0.25 and 0.5 hours. 
Peak TFV plasma concentrations o ccurred following TAF absorption, with TFV T maxvalues
between 0.25 to 1.7 hours in rats, dogs, and monkeys. TFV plasma concentrations declined with
a terminal half -life of 11.2 to 16.4 hours in rats (fasted), > 24 hours in dogs (fasted) and
8.1to2.5 hou
rs in rhesus monkey s.
The tissue distribution and recovery  of [14C] radiolabeled GS -7340-[ADDRESS_653373] in kidney, PBMCs, liver, large intestine, and bile. Significant concentrations of
TFV-related radioactive material were observed in ly mph nodes from all 4 sites, suggesting that
TAFmay be selectivel y cleaved to tenofovir in the cells of the l ymphoreticular sy stem. The
primary route of elimination of tenofovir is renal excretion of unchanged drug based on
intravenous studies of TFV. Following oral administration of GS-7340 -02, approx imately
15%of a radiolabeled dose is recovered in dog urine in 24 hours. Tenofovir was the major
species present in the urine (90%), with about 3.4% of TAF also present. Biliary  excretion of
tenofovir in dogs and fecal elimination of tenofovir in rats and dogs are negligible.
Tenofovir was the only species found in the intestinal contents and feces. In human sy stems,
TAF is metabolized by  [CONTACT_506462], to a lesser extent, by  [CONTACT_097]3A4 catal yzed
oxidation (AD -120-2004). As a result of the limited m etabolism of TAF by [CONTACT_097]3A4 inhibition
or induction of this enzyme should have little consequence on TAF exposure in vivo. TAF has
limited potential to alter CYP enzy me activity  through inhibition and does not inhibit UGT1A1
function. In addition, TAF is not an activator of either the ary l hydrocarbon receptor (AhR) or
human pregnane -X-receptor (PXR). These features combined with the relatively  low plasma
exposures of TAF in humans suggest that the potential of TAF to cause or be affected b y
clinically relevant drug-drug interactions is very  low.
Nonclinical Toxicology
Because of lack of exposure to the prodrug TAF in mice and rats and achievable TFV exposures 
being less than previously  tested in studies with TDF, [COMPANY_009] and regulatory  agencies have 
agreed that neither carcinogenicity  studies nor a peri/postnatal study  with TAF were warranted as 
they would not add to the overall risk evaluation or risk management of TAF.
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653374] 
{Foran 1997 }and observations in the rat that renal kary omegaly is not sufficient to induce renal 
toxicity or predict oncogenicity  (M990205) (M990204), its toxicological significance is 
questionable and, therefore, it was not considered an adverse effect in determining the NOAEL.
The data from the 6 -month rat study  determined a NOAEL of 25 mg/kg/day ; the 9-month dog 
study defined a No observed adverse effect level ( NOAEL)of 2 mg/kg/day, and the 28 -day 
nonhuman primate study  defined a NOAEL of ≥ 30 mg/kg/day . While no NOAEL was 
determined in the [ADDRESS_653375] at the low dose of 2 mg/kg/day . There was 
some evidence at 6 and 18/12 mg/kg/day  for an effect to slightl y prolong PR intervals. 
Additionally , at Week 39, TAF appeared to reversibly  reduce heart rate with an associated mild 
QT prolongation. At Week 39, significant decreases in serum tri -iodothyronine (T3) were noted 
for animals receiving 18/12 mg/kg/day
 when compared to controls, which may  have been 
associated with the slight prolongation of PR intervals. After the [ADDRESS_653376] on fetal viability  or fetal 
development in pregnant rats administered doses of TAF monofumarate up to 200 mg/kg/day  or 
in pregnant rabbits administered TAF monofumarate up to 100 mg/kg/day  the highest doses 
tested. In the rat, a minor (7.7%) decrease in mean fetal body  weight compared to the control 
group was observed at 200 mg/kg/day , which was a maternally  toxic dose. At the NOAEL for 
embryo-fetal developm ent of 200 mg/kg/day  in rats, AUC tauvalues for TAF and TFV on Day 17 
were 0.65 and 35.7 μg•h/kg, respectively . At the NOEL for embryo-fetal development of 
100mg/kg/day  in rabbits, AUC tauvalues for TAF and T FV on Day  20 were 
10.7and23.5μg•h/kg,respectively
. The TFV exposures in both species were > 30 -fold higher 
than the TFV AUC infafter a 25-mg dose of TAF monofumarate in humans.
For further information on TAF, (GS -7340), refer to the current investigator’s brochure for TAF.
1.2.3. Clinical Trials of Tenofovir Alafenamide (TAF, GS -
7340)
As of December 2015, a total of [ADDRESS_653377] 1 dose of TAF 25 mg in the 
TAF clinical program, including 866 subjects in the TAF Phase 3 studies in subjects with CHB 
and 420 subjects in TAF single -agent Phase 1 studies. The TAF clinical development program 
for CHB includes 2 ongoing Phase 3 studies in HBeAg-negative and HBeAg- positive subjects 
with CHB, a completed Phase 1b antiviral activity and safet y/tolerability  study in subjects with 
CHB, as w ell as several completed Phase 1 safet y, pharmacokinetics ( PK)/pharmacody namics 
(PD), and drug interaction studies in healthy  subjects (including Chinese and Japanese subjects) 
and in subjects with impaired renal or hepatic function.
In some studies, TAF w as administered as a single agent or as part of the F/TAF, 
FTC/RPV/TAF, or E/C/F/TAF FDC tablets.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page28 30September 2016TAF clinical studies are listed below:
GS-US-320-0101, a Phase 1b study  to evaluate the pharmacokinetics, safet y, viral kinetics, 
and anti-HBV activity  of TAFin treatment -naive adults with CHB (completed) 
{Agarwal etal 2015
} (completed)
GS-US-
320-1228, a Phase 1 study  to evaluate the pharmacokinetics, safet y, and tolerability  
of TAF in healthy  Japanese and non -Japanese subjects (completed)
GS-US-320-1229
, a Phase 1 study  to evaluate the pharmacokinetics of a single dose and 
repeat doses of TAF 25 mg in health y Chinese subjects (completed; data analysis is ong oing)
GS-US-320-[ADDRESS_653378] of food on a single dose of TAF 
25mg in health y subjects (completed)
GS-US-320-
1615, a Phase 1 study  to evaluate the pharmacokinetics of a single dose of TAF 
25 mg in subjects with severe hepati c impairment and subjects with normal liver function 
(completed)
GS-US-320-0108
, a Phase 3 study  to evaluate the safet y and efficacy of TAF 25 mg once 
daily versus TDF 300 mg once dail y for the treatment of HBeAg -negative subjects with CHB 
(ongoing)
GS-US-320-0110
, a Phase 3 study  to evaluate the safet y and efficacy of TAF 25 mg once 
daily versus TDF 300 mg once dail y for the treatment of HBeAg -positive subjects with CHB 
(ongoing)
GS-US-320-1092
, a Phase 2 /3study to evaluate the pharmacokinetics, safety , and antiviral 
Efficacy of TAF in Adolescents with Chronic Hepatitis B Virus Infection (ongoing)
GS-US-320-[ADDRESS_653379] received a 
liver transplant
GS-US-120-[ADDRESS_653380] of GS -7340 on the QT/QTc Interval in 
Healthy Subjects (completed)
GS-US-120-0108, a Phase 1, open-label, parallel -design stud y to evaluate the 
pharmacokinetics of TAF in subjects with severe renal impairment (completed)
GS-US-120-0109, a Phase 1 mass balance study  to evaluate the pharmacokinetics, 
metabolism and excretion of TAF in healthy  subjects (completed)
GS-US-120-0114, a Phase 1 study  to evaluate the pharmacokinetics of TAF in subjects with 
normal, mild, and moderately  impaired hepatic function (completed)
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page29 30September 2016GS-US-120-1538, a Phase 1 pharmacokinetic study  that evaluated the drug interaction 
potential between TAF and MDZ (oral and intravenous) in health y subjects (completed)
GS-US-120-1554
, a Phase 1 pharmacokinetic study  that evaluated the drug interaction 
potential between TAF and RPV in healthy  subjects (completed)
GS-US-311-[ADDRESS_653381] of food on the PK of TAF and 
FTC when administered as an F/TAF fixed- dose combination tablet in healthy  subjects 
(completed)
GS-US-311-
1387, a Phase 1 study  that evaluated the drug -drug interaction (DDI) potential 
between CBZ and TAF administered as F/TAF in healthy  subjects (completed)
GS-US-311-1790, a Phase 1 study  that evaluated the DD I potential between F/TAF or 
GS-9883 and norgestimate/ethiny l estradiol in healthy  female subjects (completed)
Please refer to the latest version of the investigator’s brochure for information on the clinical 
program.
An overview of the 2 Phase 3 studies evaluating the efficacy  and safet y of TAF in Marketing 
Applications is provided in Table1-1. The Phase 3 studie s are described below as follows:
GS-US-320-0108: This ongoing Phase 3, randomized, double- blind, noninferiority , 
international, multicenter study  is comparing the efficacy , safety, and tolerability  of TAF 
25mg once dail y versus TDF 300 mg once daily for 48 weeks for the treatment of CHB 
infection in treatment -naive and treatment -experienced HBeAg-
negative subjects.
GS-US-320-0110: This ongoing Phase 3, randomized, double- blind, noninferiority , 
international, multicenter study  is comparing the efficacy , safety, and tolerability  of TAF 
25mg once dail y versus TDF 300 mg once daily for 48 weeks for the treatment of CHB 
infection in treatment -naive and treatment -experienced HBeAg- positive subjects.
In both of these similarly designed noninferiorit y studies, su
bjects were randomized in a 2:1 ratio 
to receive either TAF 25 mg or TDF 300 mg once daily  for 96 weeks. Randomization was 
stratified by  [CONTACT_506463] (< 7, ≥ 7 to < 8, and ≥ 8 log10 IU/mL for 
StudyGS-US-320-0108; < 8 and ≥ 8 log10 IU/mL for Study  GS-US-320-0110) and OAV 
treatment status (treatment naive vs treatment experienced) at screening. In both studies, all 
subjects completing 96 weeks of double -blind therapy  are eligible to continue open -label 
treatment with TAF 25 mg for an additional 48 we eks. Both protocols were amended in 
February 2016 (Amendment 3 of GS -US-320-0108 and GS -US-320-0110) to extend the 
double-blind period to 144 weeks (3 years) and the open- label phase from Week 144 to 
Week 384 (8 year total study period).
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page30 30September 2016Table1-1. Clinical Studies to Support Efficacy for the TAF Marketing 
Applications
Study Study DesignTreatment Regimen 
(Number of Subjects) Data Presented
GS-US-320-0108Phase 3, randomized, double- blind 
study to evaluate the safety and 
efficacy of TAF vs TDF in 
HBeAg-negative subjects with CHBTAF25mgoncedaily(N=285)
TDF 300 mg once daily (N = 140)Week 48 efficacy, 
PK, and safety
GS-US-320-0110Phase 3, randomize d, double-blind 
study to evaluate the safety and 
efficacy of TAF vs TDF in 
HBeAg-positive subjects with CHBTAF 25 mg once daily (N = 581)
TDF 300 mg once daily (N = 292)Week 48 efficacy, 
PK, and safety
Demographic and disease characteristics were generally similar between the TAF and TDF 
groups in both studies and are representative of patient population of HBeAg -negative subjects 
in Study GS-US-320-0108 and HBeAg -positive subjects in Study  GS-US-320-0110. In both 
studies the majority  of subjects w ere male (> 60%) and Asian (> 70%). As would be expected 
based on the [ADDRESS_653382] study  populations, subjects in Study  GS-US-
320-0108 were older 
(medianage: 47 years; range: 19 -80 years) than subjects in Study  GS-US-320-0110 (median age: 
36years; range: 1 8-69 years). Differences in baseline characteristics between the 2 studies 
included HBV DNA levels (median levels were 5.7 an d 7.9 log 10IU/mL for GS-US-320-0108
and GS-US-
320-0110, respectively ), serum ALT levels (median v alues were 67 and 85 U/L for 
GS-US-320-0108 and GS -US-320-0110, respectively ), and number of y ears positive for HBV 
(6.0 and 4.0 years [median values] for GS -US-320-0108 and GS -US-320-0110, respectivel y). 
The distribution of HBV genot ypes was similar between treatment groups in both studies with 
the most common genot ypes being C (46.1%), D (24.3%), and B (20.4%).
Efficacy of TAF in Subjects with CHB
Primary Endpoint Analysis
For both studies, the primary  efficacy endpoint was the proportion of subjects with plasma
HBVDNA < 29 IU/mL at Week 48. Table 1-2presents HBV DNA outcomes for
StudiesGS-US-320-0108 {
Buti et al 2016 }and GS-US-320-0110 { Chan et al 2016} for subjects 
at Week 48. In both studies, similar rates of HBV DNA suppression were achieved in the 
2treatment groups when assessed using the M = F method at Week 48 for the Full Anal ysis Set
(FAS). The percentages of subjects with HBV DNA levels < 29 IU/mL at Week 48 were as 
follows:
Study GS -US-320-0108: TAF 94.0%, TDF 92.9%; difference in proportions 
(baseline stratum-adjusted): 1.8%, 95% CI: 
−3.6% to 7.2%
Study GS -US-320-0110: TAF 63.9%, T DF 66.8%; difference in proportions
(baseline stratum-adjusted): −3.6%, 95% CI: −9.8% to 2.6%
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page31 30September 2016In both studies, because the lower bound of the 2 -sided 95% CI  of the difference (TAF − TDF)
in the response rate was greater than the prespecified −10% margin, t he TAF group met the
primary endpoint of noninferiorit y to the TDF group.
Table1-2. GS US 320 0108 and GS US 32 0 0110: HBV DNA Outcome at 
Week48 Using HBV DNA of < 29 IU/mL, Missing = Failure 
(FullAnalysis Set)
GS-US-320-0108 GS-US-320
-0110
TAF 25 m g
(N = 285)TDF 300 mg
(N = 140)TAF 25 m g
(N = 581)TDF 300 m g
(N = 292)
HBV DNA < 29 IU/mL 268 (94.0%) 130 (92.9%) 371 (63.9%) 195 (66.8%)
P-valuea0.47 0.25
Difference in Proportions (95% CI)b1.8% (−3.6% to 7.2%) −3.6% (−9.8% to 2.6%)
HBV DNA ≥ 29 IU/mL 7 (2.5%) 4 (2.9%) 183 (31.5%) 88 (30.1%)
No Virologic Data at Week 48 10 (3.5%) 6 (4.3%) 27 (4.6%) 9 (3.1%)
Discontinued StudyDrugDuetoLackof Efficacy 0 0 1 (0.2%) 0
Discontinued Study Drug Due to AE/Death 3 (1.1%) 1 (0.7%) 6 (1.0%) 3 (1.0%)
Discontinued Study Drug Due to Other Reasonsc6 (2.1%) 4 (2.9%) 19 (3.3%) 6 (2.1%)
Missing Data During Window but on Study Drug 1 (0.4%) 1 (0.7%) 1 (0.2%) [ADDRESS_653383] comparing the percentages of HBV DNA < 29 IU/mL was fro m the CMH test stratified by 
[CONTACT_506464].
bDifference in the proportion between treatment groups and its 95% CI were calculated based on the MH proportions 
adjusted by [CONTACT_506464].
c Discontinuation due to other reasons included subjects who prematurely discontinued study drug due to investigator's 
discretion, withdrew consent, lost to follow-up, noncompliance with study drug, protocol violation, pregnancy, and study 
termination by [CONTACT_3211] .
Source:GS-US-32 0-0108Week48CSR, Section 15.1,Table12; GS-US-32 0-0110Week48CSR, Section 15.1, Table 12. 
Biochemical Analyses
Table1-
3presents the proportion of subjects with AL T normalization at Week 48 for both 
studies (GS -US-320-0108) and (GS -US-320-0110) when determined by  [CONTACT_506465] b y AASLD criteria (upper limit of normal range: ≤ 30 U/L for males and ≤ 19 U/L 
for females 
{Lok et al 2009, Terrault et al 2015 }), respectivel y.
For Study  GS-US-320-
0108, the percentage of subjects with normalized ALT (i.e., ALT > ULN 
at baseline but within the normal range at Week 48) using the central laboratory  criteria was 
numericall y higher for the TAF group compared with the TDF group for all time points from 
Weeks 4 through 48. When assessed at Week 48, rates of ALT normalization were not 
significantl y different between the 2 treatment groups by [CONTACT_506466] = Failure ( M = F)method 
for the Full Analy sis Set (FAS). Using the AASLD criteria, th e percentage of subjects with 
normalized ALT was significantly  higher in the TAF group than in the TDF group at for all time 
points from Week [ADDRESS_653384] using the M = F method.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page32 30September 2016For Study  GS-US-320-0110, the percentage of subjects with normalized ALT using th e central 
laboratory  criteria was numericall y higher for the TAF group compared with the TDF group for 
all time points from Weeks 8 through 48. When assessed at Week 48, rates of normalization 
were not significantly different between the 2 treatment groups by [CONTACT_941] M = F method for the 
FAS. Using the AASLD criteria, the percentage of subjects with normalized AL T was 
significantl y higher in the TAF group th an in the TDF group for all time points from 
Weeks8through 48 using the M = F method.
Overall, the perc entage of subjects with normalized AL T atWeek 48 was higher in 
StudyGS-US-320-0108 compared with Study  GS
-US-320-0110 using the central laboratory  
criteria and similar across the 2 studies using the AASL D criteria.
Table1-
3. GS-US-320-0108 and GS -US-320-0110: Proportion of Subjects with 
ALT Normalization at Week 48, Missing = Failure (Full Analysis Set 
with Baseline ALT > ULN)
Normalized ALTGS-US-320-0108 GS-US-320-0110
TAF 25 m gTDF 300 m gTAF 25 m g TDF 300 mg
Central Laboratorya(N = 236) (N = 121) (N = 537) (N = 268)
Week 48 196/236 (83.1%) 91/121 (75.2%) 384/537 (71.5%) 179/268 (66.8%)
Proportion Difference (95% CI) 8.0% (−1.3% to 17.2%) 4.6% (−2.3% to 11.4%)
p-value 0.076 0.18
AASLDb(N = 276) (N = 138) (N = 572) (N = 290)
Week 48 137/276 (49.6%) 44/138 (31.9%) 257/572 (44.9%) 105/290 (36.2%)
Proportion Difference (95% CI) 17.9% (8.0% to 27.7%) 8.7% (1.8% to 15.6%)
p-value < 0.[ADDRESS_653385] for ALT are as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males
≥ 69years; ≤ 34 U/L for females18to<69 years and ≤ 32U/Lfor females ≥ 69years.
bAASLD ULN for ALT criteria areas follows: ≤ 30 U/Lformalesand≤ 19 U/L for female s.
P-value was fromthe Cochra n-Mantel-Haenszel tests stratified by [CONTACT_506467] 95% CI were calculated based on the Mantel-Haenszel proportions 
adjusted by [CONTACT_506464].
Source:GS-US-32 0-0108Week48CSR, Section 15.1,Tables 23.1.1and23 .2.1; GS-US-[ADDRESS_653386] in either treatment group experienced HBsAg loss by
[CONTACT_10585] 48. I n Study GS-US-320-0110, 4 subjects (0.7%) in the TAF group and [ADDRESS_653387] (0.3%)
in the TDF group experienced HBsAg loss at Week 48. Three of the 4 subjects in the TAF group
and none in the TDF group also experienced HBsAg seroconversion at Week 48.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page33 30September 2016In Study GS-US-320-0110, the proportion of subjects with HBeAg loss or seroconversion to
anti-HBe at Week 48 was also evaluated; these data are presented on Table1-4
. A total of
78(13.8%) and 34 (11.9%) subjects in the TAF and TDF groups, respectively , had HBeAg loss
at Week 48. A total of 58 (10.3%) and 23 (8.1%) subjects in the TAF and TDF groups,
respectivel y, experienced HBeAg seroconversion at Week 48.
Table1-4. GS-US-320-0110: Proportion of Subjects with HBeAg Loss or 
Seroconversion at Week 48, Missing = Failure 
(Serologically Evaluable Full Analysis Set)
GS-US-320-0110
TAF 25 m g
(N = 565)TDF 300 m g
(N = 285)TAF 25 m gvs TDF 300 m g
p-valueProp Diff
(95% CI)
HBeAg Loss, n (%) 78/565 (13.8%) 34/285 (11.9%) 0.471.8%
(−3.0% to 6.5%)
HBeAg Seroconversion, n (%) 58/565 (10.3%) 23/285 (8.1%) 0.322.1%
(−2.0% to 6.3%)
P-values were from the Cochran -Mantel-Haenszel test stratified by [CONTACT_506468]. Differences in the proportion between treatment groups and its 95% CI were calculated based on the Mantel -Haenszel 
proportions adjusted by [CONTACT_506469] o ral antiviral treatment status strata.
Serologically Evaluable Full Analysis Set for HBeAg loss/seroconversion included subjects who were HBeAg positive and 
HBeAb negative/missing at baseline. HBeAg loss was defined as changes from HBeAg -positive at baseli ne to HBeAg -negative 
at a post-baseline visit with baseline anti -HBe negative/missing. HBeAg seroconversion was defined as HBeAg loss and 
anti-HBe change from negative/missing at baseline to positive at a post -baseline visit.
Source: GS-
US-320-0110 Week 48 CSR, Section 15.1, Table 19.1
Virologic Resistance Analysis
In an integrated anal ysis of Studies GS -US-320-0108 and GS -US-320-0110, 24 subjects (2.8%)
in the TAF group and 14 subjects (3.2%) in the TDF group qualified for population -based
sequence analysis after up to 48 weeks of treatment. Among the 24 subjects in the TAF group
who qualified for population- based sequence anal ysis, 15 had no changes detected in the pol/RT
sequence from baseline, 4 were unable to be sequenced, and 5 had pol ymorphic site
substitutions. Among the 14 subjects in the TDF treatment group who qualified for
population -based sequence analy sis, 6 had no changes detected in the pol/RT sequence from
baseline, 4 were unable to be sequenced, 2 had poly morphic site substitutions, a nd2 had a 
conserved site substitution. Overall, no HBV pol/RT amino acid substitutions associated with 
resistance to TFV were detected by [CONTACT_506470] [ADDRESS_653388] 1 dose of stud y drug.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page34 30September 2016Overall Extent of Exposure
Of the 2387 subjects screened in Studies GS- US-320-0108 and GS -US-320-0110 combined,
1301 were randomized (TAF 867 subjects; TDF 434 subjects), and [ADDRESS_653389] 1 dose
of study drugs (TAF 866 subjects; TDF 432 s ubjects); 3 subjects (TAF [ADDRESS_653390]; TDF 
2subjects) did not receive study  drug due to withdrawal of consent. As of the Week 48 data
cutoff date for each Phase 3 study , a total of 1208 subjects (TAF 93.1%, 806 subjects; 
TDF93.1%, 402 subjects) were conti
nuing double -blind study  drugs, and 27 subjects
(TAF2.1%, 18 subjects; TDF 2.1%, 9 subjects) had entered the open -label phase as of the
Week48 data cutoff date. Of the 1298 subjects randomized and treated, 63 subjects (4.9%)
discontinued blinded study  drugs (TAF 4.8%, 42 subjects; TDF 4.9%, 21 subjects), and
61subjects (TAF 40 subjects; TDF 21 subjects) discontinued from the study prior to the
Week48 data cutoff date. Similar rates of discontinuation and reasons for treatment
discontinuation were observe d for TAF compared with TDF. The most common reasons for
premature discontinuation of blinded study  treatment were withdrew consent (TAF 1.6%,
14subjects; TDF 1.6%, 7 subjects); adverse event (AE; TAF 1.0%, 9 subjects; TDF 1.2%,
5 subjects); and lost to f ollow-
up (TAF 0.7%, 6 subjects; TDF 0.7%, 3 subjects). The most
common reasons for discontinuation from the study  were: subjects withdrew consent (TAF 2.0%,
17 subjects; TDF 2.1%, 9 subjects), lost to follow- up (TAF 0.8%, 7 subjects; TDF 0.7%, 
3subjects), and AEs (TAF 0.3%, 3 subjects; TDF 0.9%, 4 subjects).
Table1-5summarizes the duration of exposure to blinded study  drug in the TAF Phase 3 Safety
Population. Median (first quartile [Q1], third quartile [Q3]) exposures were nearl y identical
between the 2 treatment groups (TAF 56.1 [48.1, 64.4] weeks; TDF 56.1 [48.1, 64.7] weeks.
More than half of the subjects in each treatment group had received blinded study  drug for
≥ 56weeks at the time of the Week 48 data cutoff date for each Phase 3 study  (TAF 60.5 %,
524subjects; TDF 62.0 %, 268 subjects). There was no statistically  significant difference
between groups in the overall Kaplan -Meier estimate of time to premature discontinuation of
blinded study  drug.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page35 30September 2016Table1-5. GS-US-320-0108 and GS -US-320-0110: Subjects Exposed to Study 
Drug for the TAF Phase 3 Safety Population (Safety Analysis Set)
Duration of Exposure to Study Regim en (Weeks)GS-US-320-0108 and GS-US-320
-0110
TAF 25 m g
(N = 866)TDF 300 m g
(N = 432)
N 866 432
Mean (SD) 58.9 (14.71) 59.0 (15.58)
Median 56.1 56.1
Q1, Q3 48.1, 64.4 48.1, 64.7
Min, Max 0.1, 96.3 0.1, 96.3
Total Exposure to Study Drug n(%)
≥ 4 Weeks [28 days] 860 (99.3%) 426 (98.6%)
≥ 8 weeks [56 days] 858 (99.1%) 426 (98.6%)
≥ 12weeks [84 days] 854 (98.6%) 423 (97.9%)
≥ 16 Weeks [112 days] 851 (98.3%) 422 (97.7%)
≥ 20 Weeks [140 days] 851 (98.3%) 422 (97.7%)
≥ 24 Weeks [168 days] 851 (98.3%) 419 (97.0%)
≥ 28 Weeks [196 days] 849 (98.0%) 418 (96.8%)
≥ 32 Weeks [224 days] 843 (97.3%) 418 (96.8%)
≥ 36 Weeks [252 days] 838 (96.8%) 418 (96.8%)
≥ 40 Weeks [280 days] 835 (96.4%) 418 (96.8%)
≥ 44 Weeks [308 days] 832 (96.1%) 418 (96.8%)
≥ 48 Weeks [336 days] 669 (77.3%) 346 (80.1%)
≥ 56 Weeks [392 days] 524 (60.5%) 268 (62.0%)
≥ 64 Weeks [448 days] 356 (41.1%) 174 (40.3%)
≥ 72 Weeks [504 days] 190 (21.9%) 92 (21.3%)
≥ 80 Weeks [560 days] 89 (10.3%) 46 (10.6%)
≥ 88 Weeks [616 days] 36 (4.2%) 24 (5.6%)
Duration of exposure to blinded study drug was the number of weeks between the first dose and the last dose of blinded study 
drug. If the last dose date of blinded study drug is missing for subjects prematurely discontinued blinded study drug, or for 
subjects still on blinded study drug, the latest of nonmissing blinded study drug start and end dates or clinic and laborato ry visit 
dates (excluding ope n-label and treatment -free follo w-up visits) was used to impute the last dose date of blinded study drug.
Source: TAF Week 48 ISS, Table4
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653391] 
1AE (TAF 70.2 %, 608 subjects; TDF 67.4%, 291 subjects) and had experienced at least
1 Grade 3 or 4 AE (TAF 4.5 %, 39 subjects; TDF 3.9 %, 17 subjects). In addition, 57 subjects
(TAF 4.2%, 36 subjects; TDF 4.9 %, 2 1 subjects) had at least 1 SAE, with no subjects
experiencing a treatment-
related SAE. A similar percentage of subjects in each treatment group
experienced an AE leading to discontinuation of study  drugs (TAF 1.0%, 9 subjects; TDF 1.2%,
5 subjects). No dea ths occurred in any  subject on treatment. There were 2 deaths which occurred
after treatment was discontinued and were considered non -treatment emergent ([ADDRESS_653392] in each
treatment group).
Table1-6. GS-US-320-0108 and GS -US-320-0110: Overall Summary of 
AdverseEvents in the TAF Ph ase 3 Safety Population 
(SafetyAnalysis Set)
Adverse EventsTAF 25 m g
(N = 866)TDF 300 m g
(N = 432)
Subjects Experiencing Any AE 608 (70.2%) 291 (67.4%)
Subjects Experiencing Any Grade 2, 3, or 4 AE 221 (25.5%) 120 (27.8%)
Subjects Experiencing Any Grade 3 or 4 AE 39 (4.5%) 17 (3.9%)
Subjects Experiencing Any Study Drug -Related AE 123 (14.2%) 68 (15.7%)
Subjects Experiencing Any Grade 2, 3, or 4 Study Drug-Related AE 33 (3.8%) 21 (4.9%)
Subjects Experiencing Any Grade 3 or 4 Study Drug -Related AE 6 (0.7%) 2 (0.5%)
Subjects Experiencing Any SAE 36 (4.2%) 21 (4.9%)
Subjects Experiencing Any Study Drug -Related SAE 0 0
Subjects Experiencing Any AE Leading to Premature Study Drug 
Discontinuation9 (1.0%) 5 (1.2%)
Subjects Experiencing Any AE Leading to Dose Modification or 
StudyDrug Interruption17 (2.0%) 7 (1.6%)
Deatha0 [ADDRESS_653393] dose date (inclusive). Adverse 
events were mapped according to MedDRA Version 18.
Treatment -emergent AEs was defined as follows:
1)Any AEs with onset date of on or after the study drug start date and no later than the study drug stop date for those who 
discontinued study drug permanently, or
2)Any AE with an onset date on or after the study drugs start date for those who had not discontinued study drug permanently, 
or
3)Any AEs leading to study drug discontinuation
Source: TAF Week 48 ISS, Table 6
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page37 30September 2016Common Adverse Events
Table1-7presents AEs reported for ≥ 5% of subjects for any  treatment group by  [CONTACT_506471] (SOC) and preferred term (PT) in the TAF Phase [ADDRESS_653394] frequently  reported AEs by
[CONTACT_110095]:
TAF group —upper respi[INVESTIGATOR_2826] (9.9%, 86 subjects), nasophary ngitis 
(9.9%,86 subjects), and headache (9.5%, 82 subjects)
TDF group —headache (8.3%, 36 subjects), upper respi[INVESTIGATOR_2826]
(7.4%,32subjects), and nasophary ngitis (7.2%, 31 subjects)
Table1-7. GS-US-
320-0108 and GS -US-320-0110: Adverse Events Reported for
≥5% of Subjects in Either Treatment Group in the TAF Phase 3 
Safety Population (Safety Analysis Set)
Adverse Events by [CONTACT_11875] m Organ Class and Preferred Terma,b,cTAF 25 m g
(N = 866)TDF 300 m g
(N = 432)
Number of Subjects Experiencing Any Adverse Event 608 (70.2%) 291 (67.4%)
Gastrointestinal disorders 227 (26.2%) 108 (25.0%)
Nausea 43 (5.0%) 22 (5.1%)
General disorders and administration site conditions 125 (14.4%) 62 (14.4%)
Fatigue 49 (5.7%) 23 (5.3%)
Infections and infestations 259 (29.9%) 121 (28.0%)
Upper respi[INVESTIGATOR_1092] 86 (9.9%) 32 (7.4%)
Nasopharyngitis 86 (9.9%) 31 (7.2%)
Nervous system disorders 149 (17.2%) 60 (13.9%)
Headache 82 (9.5%) 36 (8.3%)
Respi[INVESTIGATOR_696], thoracic and mediastinal disorders 106 (12.2%) 44 (10.2%)
Cough 55 (6.4%) 27 (6.3%)
aAdverse events were mapped according to MedDRA Version 18.
bSOC were presented alphabetically, and PT was presented by [CONTACT_506472].
cMultiple AEs were counted only once per subject for each SOC and PT, respectively.
Source: TAF Week [ADDRESS_653395] 1 Grade 3 AE (TAF 4.5%,
39 subjects; TDF 3.9%, 17 subjects). No subjects in either group had a Grade 4 AE. The only
Grade 3 AE that occurred in more than 2 subjects in either treatment group were increased ALT
(TAF 0.6%, 5 subjects; TDF 0.7%, 3 subjects) and hepatocellular carcinoma (HCC)
(TAF0 subjects; TDF 0.7%, 3 subjects). Four Grade 3 ALT increases (TAF 3 subjects;
TDF1subject) were assessed as related to study  drug.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page38 30September 2016Serious Adverse Events
Table1-8presents SAEs reported for > 1 subjects for an y treatment group in the TAF Phase 3
Safety Population. A similar percentage of subjects experienced SAEs in each treatment group
(TAF 4.2%, 36 subjects; TDF 4.9%, 21 subjects). None of the SAEs were considered related to
study drugs by [CONTACT_506473]. Hepatocellular carcinoma was reported for 6 subjects
(TAF0.1%, 1 of 866 subjects; TDF 1.2%, 5 of 432 subjects). Other SAEs reported in > [ADDRESS_653396]
in either treatment group were cellulitis, hand fracture, dizziness, and calculus ureteric.
Table1-
8. GS-US-320-0108 and GS -US-320-0110: Serious Adverse Events by 
[CONTACT_506474] > [ADDRESS_653397] in the TAF Phase 3 Safety 
Population (Safety Analysis Set)
Preferred Terma,bTAF 25 m g
(N = 866)TDF 300 m g
(N = 432)
Number of Subjects (%) Experiencing Any SAE 36 (4.2%) 21 (4.9%)
Hepatocellular carcinoma 1 (0.1%) 5 (1.2%)
Cellulitis 0 3 (0.7%)
Hand fracture 2 (0.2%) 0
Dizziness 2 (0.2%) 0
Calculus ureteric 2 (0.2%) [ADDRESS_653398] for each SOC and PT, respectively.
Source: TAF Week 48ISS,Table14
Summary of Bone Safety
Bone safet y was assessed in the TAF Phase 3 Safety Population due to decreases in bone mineral 
density (BMD) and mineralization defects that have been seen in subjects treated with TDF.
Summary of Fractures
In the TAF Phase 3 Safety Population, the incidence of fr acture events was uncommon 
(TAF0.7%, 6 of 866 subjects; TDF 0.2%, 1 of 43 2 subjects; p = 0.44). Six of the [ADDRESS_653399], in the TAF group, had a spi[INVESTIGATOR_506426] a computed tomography  (CT) scan. In the TA F group, 
4fractures were reported as SAEs (hand fracture [3 subjects] and 1 spi[INVESTIGATOR_121532]). 
In the TDF group, 1 fracture (lower limb fracture) was reported as an SAE. Of the 7 subjects 
who had fractures, 4 subjects in the TAF group (tibia fracture, spi[INVESTIGATOR_506427] , hand fracture [2 subjects]) had normal hip and spi[INVESTIGATOR_9210] T- scores at all 
timepoints, 2 subjects in the TAF group (hand fracture and traumatic spi[INVESTIGATOR_506428]) had hip and/or spi[INVESTIGATOR_506429] T -scores consistent w ith osteoporosi s at baseline, 
[ADDRESS_653400] in the TDF group (lower limb fracture) had normal hip and spi[INVESTIGATOR_506430]. All fractures were considered unrelated to the study  drugs 
by [CONTACT_87690], none resulted in discontinuatio n of study  drugs.
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653401] and second key  
alpha-controlled safet y endpoints, respectivel y, for both studies. Subjects receiving TAF 
experienced significantl y less BMD reduction than those receiving TDF. At Week 48, the mean 
(SD) percentage decreases from baseline were as follows:
Hip: TAF −0.163% (2.2437 %); TDF −1.860 % (2.4525 %)
Spi[INVESTIGATOR_050]: TAF −0.570 % (2.9147 %); TDF −2.366 % (3.2051 %)
Table1-9presents measure of BMD at Week 48. Percentage changes from baseline in hip and 
spi[INVESTIGATOR_506431]-controlled sa fety endpoints in 
StudiesGS-US-320-0108 and GS -US-
320-0110. Mean percentage decreases from baseline in 
BMD at the hip or spi[INVESTIGATOR_506432] s maller in the TAF group c ompared with the TDF group 
(p<
0.001). A lower percentage of subjects in the TAF group had a > 3% decrease in hip BMD 
compared with subjects in the TDF group (8.4% TAF; 26.7% TDF). Similarly , a lower 
percentage of subjects in the TAF group had a > 3% decrease in spi[INVESTIGATOR_506433] (TAF 19.5%; TDF 38.1%). At W eek 48, fewer subjects had 
≥ 7%
decrease in hip BMD (TAF 0.4%; TDF 2.0%) and ≥ 5% decrease in spi[INVESTIGATOR_9210] 
(TAF6.3%; TDF 20.4%) in the TAF group co mpared with the TDF group.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page40 30September 2016Table1-9. GS-US-320-0108 and GS -US-320-0110: Measures of Bone Mineral 
Density at Week 48 (Hip DXAAnalysis Setand 
Spi[INVESTIGATOR_506434])
NTAF 25 mg NTDF 300 mg
Hip DXA Analysis Set
Mean (SD) Percent Change in Hip BMD 807−0.163(2.2437) 404−1.860(2.4525)
P-Valuea< 0.001
Difference in LSM 1.697 (1.420, 1.974)
Subjects with > 3% Decrease in Hip BMD, n (%) 807 68 (8.4%) 404 108 (26.7%)
P-Valueb< 0.001
Subjects with > 3% Increase in Hip BMD, n (%) 807 55 (6.8%) 404 8 (2.0%)
P-Valueb< 0.001
Subjects with no Decrease ( ≥ Zero %Change) in Hip BMD, n (%) 807 383 (47.5%) 404 83 (20.5%)
Spi[INVESTIGATOR_506435] (SD) Percent Change in Spi[INVESTIGATOR_9210] 814−0.570 (2.9147) 407−2.366 (3.2051)
P-Valuea< 0.001
Difference in LSM 1.796 (1.437, 2.155)
Subjects with > 3% Decrease in Spi[INVESTIGATOR_9210], n (%) 814 159 (19.5%) 407 155 (38.1%)
P-Valueb< 0.001
Subjects with > 3% Increase in Spi[INVESTIGATOR_9210], n (%) 814 89 (10.9%) 407 11 (2.7%)
P-Valueb< 0.001
Subjects with no Decrease ( ≥ Zero %Change) in Spi[INVESTIGATOR_9210], n (%) 814 331 (40.7%) 407 89 (21.9%)
DXA = dua l-energyx-ray absorptiometry; LSM = leas t-squares mean
a P-values, difference in least squares means, and its 95% CI were fromtheANOVA modelincluding treatment as a 
fixedeffect.
b P-values were calculated from the Cochra n-Mantel-Haenszel test for ordinal data (row mean scores differ statistic was used).
Source: TAF Week 48 ISS, Tables 23.1.2,23.2.2,25.1, and25.2 andRequest7633Tables 2.1and2.2
Renal Safety
In the TAF Phase 3 Safety Population in Studies GS- US-320-0108 and GS -US-
320-0110
(TAF25 mg N = 866, TDF 300 mg N = 432; Total N = 1301), no cases of proximal renal
tubulopathy  (including Fanconi syndrome) or renal failure were reported in either treatment
group. No subject in the TAF Phase [ADDRESS_653402] key  alpha-controlled safet y endpoint.
Overall, increases from baseline in mean values for serum creatinine were smaller in the TAF
group compared with the TDF group. Mean (SD) changes from baseline at Week 48 wer e
0.010(0.1140) mg/dL for the TAF group and 0.024 (0.0974) mg/dL for the TDF group
(p=0.012). Graded serum creatinine abnormalities were reported for 6 subjects (0.7%) in the
TAF group; all of which were Grade 1 or 2. Of the 6 subjects, 5 subjects had i solated serum
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page41 30September 2016relevant medical history  of hypertension and diabetes, had multiple instances of graded
creatinine elevations and eGFR ≤ 50 mL/min. No subjects in the TDF group had graded serum
creatinine elevations.
In the TAF group, decreases from baseline in median eGFR CGvalues were significantl y smaller
compared with the TDF group. Median (Q1, Q3) changes from baseline at Week 48 were
−1.2(−8.4, 7.5) mL/min in the TAF group and −5.4 (−12.0, 3.0) mL/min in the TDF group
(p<0.001).The overall number of subjects who had an y confirmed renal laboratory  abnormality
(ie, confirmed increases from baseline in creatinine of at least 0.5 mg/dL, or eGFR CGbelow
50mL/min, or confirmed phosphorus < 2 mg/dL, was small (TAF 0.6%, 5 subjects; TDF 1.6%,
7 subjects). Most instances were isolated, transient, and resolved without treatment.
Summary of Proteinuria by [CONTACT_190240] (Dipstick) and by [CONTACT_506475]
A similar percentage of subjects in each treatment group had at least 1 recorded, graded
proteinuria b y dipstick while on study ; most of which were Grade 1. Table1-10presents a
summary of the quantitative markers of proteinuria, urine protein to creatinine ratio (UPCR) and
urine albumin to creatinine ratio (UACR). There was a significant dif ference between the
2treatment groups in median percentage changes from baseline in 1 of the quantitative markers
of proteinuria UPCR at Week 48. The median (Q1, Q3) percentage change in UPCR was
6.0 (−31.0, 57.6) mg/g in the TAF group and 16.5 (−21.6, 72 .4) mg/g in the TDF group
(p=0.010). Although not statistically  significant, the median percentage change from baseline in
UACR was lower in the TAF group compared with the TDF group. Median percentage changes
from baseline in the markers of proximal tub ular dysfunction, urine retinol binding protein
(RBP) to creatinine ratio and urine beta -2-microglobulin to creatinine ratio were smaller in the
TAF group compared with the TDF group (p < 0.001 for the differences between the 2 groups at
Weeks 24 and 48).
Table1-
10. GS-US-320-0108 and GS -US-320-0110: Renal Biomarkers to Urine 
Creatinine Ratios at Week 48 in the TAF Phase 3 Safety Population 
(Safety Analysis Set)
ParameterMedian Percentage Change (%) (Q1, Q3)
P-ValueaTAF 25 m g
(N = 866)TDF 300 m g
(N = 432)
UPCR (mg/g) 6.0 (−31.0, 57.6) 16.5 (−21.6, 72.4) 0.010
UACR (mg/g) 6.9 (−25.8, 46.7) 12.2 (−21.0, 63.5) 0.073
Urine RBP to Urine Creatinine Ratio ( μg/g) −0.3 (−23.2, 33.3) 25.1 (−7.9, 73.2) < 0.001
Urine Beta-2- Microglobulin to Creatinine Ratio (μg/g) −3.5 (−34.3, 32.0) 37.9 (−4.6, 152.4) < 0.001
UACR = urine albumin to creatinine ratio; UPCR = urine protein to creatinine ratio
% Change = Change from baseline at a postbaseline visit/baseline × 100%.
a P-values were from the [ADDRESS_653403] to compare the 2 treatment groups.
Source: TAF Week 48 ISS, Tables 34.1, 34.2, 34.3, and 34.4
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653404] 1 laboratory  abnormality  of Grade 1 or higher (TAF 94.8%, 814 of 859 subjects; TDF
91.1%, 390 of 428 subjects). The majority  of subjects had abnormalities that were Grade [ADDRESS_653405] severit y (TAF 63.4%, 545 subjects; TDF 61.7%, 264 subjects). Grade 3 laboratory
abnormalities occurred in 26.2% (225 subjects) in the TAF group and 22.4% (96 subjects) in the
TDF group; Grade 4 laboratory  abnormalities were less common, occurring in 5.1% 
(44subjects) in the TAF group and 7.0% (30 subje cts) in the TDF group. In total, a similar 
percentage of subjects in each group had at least 1 Grade 3 o r 4 laboratory  abnormality  
(TAF31.3%,269 subjects; TDF 29.4%, 126 subjects).
Table1-
11presents a summary  of the subject incidence of Grade 3 or 4 serum chemistry  or
urinalysis abnormalities reported for ≥ 1% in either treatment group for the overall TAF Phase 3
Safety Population. The only  Grade 3 or 4 serum chemistry  laboratory  abnormality  that occurred
in > 5% of subjects overall in each of the tre atment groups individually  was ALT elevation
(TAF8.1%, 70 subjects; TDF 9.3%, 40 subjects). In the TDF group, Grade [ADDRESS_653406] also occurred in > 5% of subjects overall (TAF 3.3%, 28 subjects; TDF 5.4%, 23 subjects).
Grade 3 urinal ysis abnormalities included occult blood (TAF 7.7%, 66 subjects; TDF 7.0%,
30subjects), urine ery throcytes (TAF 7.7%, 59 subjects; TDF 9.1%, 35 subjects), and urine
glucose (TAF 4.8%, 41 subjects; TDF 1.2%, 5 subjects). The majorit y of subjects (88.6%;
124 of
140 subjects) who had Grade 3 urine occult blood or urine ery throcytes were women of
child bearing potential (defined as age ≤ 54 years). The abnormalities were generall y
asymptomatic and not associated with AEs; none of the events were considered related to study
drugs. Among the 41 subjects in the TAF group with Grade 3 urine glucose on treatment,
18subjects (43.9%) had Grade 3 urine glucose at either screening or baseline, while the majorit y
of the remaining 23 subjects had a medical history  relevant for dia betes mellitus and/or had a 
graded elevation in blood glucose, or experienced an isolated and transient occurrence of 
Grade3 urine glucose.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page43 30September 2016Table1-11. GS-US-320-0108 and GS -US-320-0110: Treatment -Emergent 
Grade3or [ADDRESS_653407] 
1%ofSubjects in Either Treatment Group in the Overall TAF 
Phase3 SafetyPopulation (Safety Analysis Set)
TAF 25mg
(N=866)TDF 300 mg
(N=432)
Maximum Postbaseline Toxicity Grade (N) 859 428
Grade 3 225 (26.2%) 96 (22.4%)
Grade 4 44 (5.1%) 30 (7.0%)
Chemistry
Alanine Aminotransferase (N) 859 428
Grade 3 52 (6.1%) 27 (6.3%)
Grade 4 18 (2.1%) 13 (3.0%)
Amylase (N) 859 427
Grade 3 22 (2.6%) 9 (2.1%)
Aspartate Aminotransferase (N) 859 428
Grade 3 25 (2.9%) 18 (4.2%)
Grade 4 3 (0.3%) 5 (1.2%)
Creatine Kinase (N) 859 428
Grade 3 16 (1.9%) 7 (1.6%)
Grade 4 9 (1.0%) 6 (1.4%)
Fasting Glucose (Hyperglycemia) (N) 857 425
Grade 3 9 (1.1%) 0
Fasting LDL Cholesterol (N) 837 417
Grade 3 37 (4.4%) 1 (0.2%)
Nonfasting Glucose (Hyperglycemia) (N) 856 426
Grade 3 25 (2.9%) 7 (1.6%)
Urinalysis
Occult Blood (N) 859 426
Grade 3 66 (7.7%) 30 (7.0%)
Urine Erythrocytes (N) 768 386
Grade 3 59 (7.7%) 35 (9.1%)
Urine Glucose (N) 859 426
Grade 3 41 (4.8%) 5 (1.2%)
Denominator for percentage (N) is the number of subjects in the safety analysis set with at least [ADDRESS_653408]. For urinalysis (ie, urine glucose, 
urine protein, and urine RBC), the highest grade is Grade 3.
For nonfasting glucose, the maximum postbaseline toxicity grades, ins tead of treatmen t-emergent abnormalities, were 
summarized, because nonfasting glucose test was not done at baseline.
‘Hyper’ means high and ‘Hypo ’means low.
Source: TAF Week 48 ISS, Table20
Hepatic Laboratory Abnormalities
In Studies GS -US-320-0108 and GS-US-320-0110 the incidence of graded hepatic laboratory
abnormalities through the Week 48 data cutoff date was generall y lower for subjects in the TAF
groupcompared with subjects in the TDF group, and included ALT increas ed 
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page44 30September 2016(TAF22.8%,196 subjects; TDF 30.4%, 130 subjects), AST increase d (TAF 22.2%, 191 subjects; 
TDF25.2%,108 subjects), total bilirubin increased (TAF 12. 7%, 109 subjects; TDF 10.0%, 
43subjects), gamma-glutamyltransferase (GGT) increased (TAF 7.5%, 64 subjects; TDF 10.0%, 
43 subjects), alkaline phos phatase increased (TAF 2.2%, 19 subjects; TDF 5.4%, 23 subjects), 
and albumin decreased (TAF 0.9%, 8 subjects; TDF 1.9%, 8 subjects).
Hepatic laboratory  abnormalities in both treatment groups were generally  Grade 1 or 2 at
maximum severity ; Grade [ADDRESS_653409] abnormalities were
observed in lower percentages of subjects in the TAF group compared with the TDF group
(ALT: TAF 8.1%, 70 subjects; TDF 9.3%, 40 subjects; AST: TAF 3.3%, 28 subjects; TDF 5.4%,
23 subjects), while Grade 3 or 4 bilirubin elevations were observed in comparable percentages of
subjects in the TAF group (0.3%, 3 subjects) compared with the TDF group (0.2%, [ADDRESS_653410]).
Hepatic laboratory  abnormalities were generall y not associated with he patic AEs.
Hepatic Flares
An ALT elevation was defined as treatment -emergent serum ALT > 2 × baseline value and
>10× ULN, with or without associated s ymptoms. Through Week 48, ALT elevations were
observed for 16 subjects (1.8%) in the TAF group and 9 sub
jects (2.1%) of subjects in the TDF
group. Most of the events were at isolated time points within the first [ADDRESS_653411] remained on study  drug. An AL T elevation that
was confirmed at 2 consecutive pos tbaseline visits was considered an ALT flare. The incidence
of these events was balanced between the treatment groups. Five subjects (0.6%) in the TAF
group and 4 subjects (0.9%) in the TDF group had a treatment- emergent ALT flare. With the
exception of 2 events, ALT flares occurred earl y in the dosing period; for [ADDRESS_653412] remained on study  drug.
Metabolic Laboratory Parameters
Administration of TDF has been associated with lower fasting low- density lipoprotein (L DL) 
and high-density lipoprotein (HDL) as compared with other antiviral agents. As plasma TFV
exposures are approximately  90% lower with TAF administration than with TDF, fasting lipid
concentrations remained relativel y stable through Week [ADDRESS_653413] LDL, HDL, and trigl ycerides (p < 0.001). Median (Q1, Q3) changes from
baseline at Week 48 for fasting lipid parameters were as follows:
Total cholesterol: TAF −2 (−17, 17) mg/dL; TDF −24 (−42, −6) mg/dL
LDL: 
TAF 4 (−9, 20) mg/dL; TDF −9 (−25, 5) mg/dL
HDL: TAF −3 (−10, 2) mg/dL ; TDF −9 (−17, −3) mg/dL
Triglycerides: TAF 6 ( −13, 26) mg/dL; TDF −7 (−27, 10) mg/dL
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page45 30September 2016The median (Q1, Q3) change from baseline at Week 48 in total cholesterol to HDL  ratio was
0.2 (−0.1, 0.5) in the TAF group and 0.2 ( −0.2, 0.5) in the TDF group (p = 0.16 for the di fference 
between treatment groups).
Eight subjects (0.9%) in the TAF group had Grade 3 elevated fasting cholesterol; 
7 ofthe8subjects had a history  of hyperlipi[INVESTIGATOR_83281]/or elevated fasting cholesterol at baseline.
There were no subjects with Grade 4 elevated fasting cholesterol in the TAF group, and none
with Grade 3 or 4 elevated fasting cholesterol in the TDF group. Thirt y-seven subjects (4.4%) in
the TAF group and [ADDRESS_653414] (0.2%) in the TDF group had Grade 3 elevated fasting LDL.
Overall, changes in median values of total cholesterol, LDL, HDL, and trigly cerides in the TAF
group were not clinically relevant, and none of the subjects with Grade 3 elevations in fasting
lipi[INVESTIGATOR_506436] A Es associated with lipid abnormalities.
1.3. Information about Tenofovir Disoproxil Fumarate (TDF)
For further information on TDF ( Viread®), refer to the current investigator’s brochure for TDF 
(Viread®).
1.4. Rationale for This Study
Given improved treatment options for CHB, more patients are living longer lives while on 
prolonged treatment. However, as these patients age, comorbidities increase and they  are at 
greater risk for bone and renal disease. Because TAF is more stable in plasma than TDF, and
also provide shigher intracellular levels of the active phosphory lated metabolite TFV -DP to 
target cells (eg, HBV -infected hepatocy tes) with approximately  90% lower circulating levels of 
TFV relative to TDF at therapeutically  active doses {Agarwal et al 2015 , Babusis et al 2013, 
Murakami et al 2015 }, an improved safet y profile has been demonstrated with TAF when 
compared with TDF through 48 Weeks {Buti et al 2016 , 
Chan et al 2016 }. In HIV infection, 
switching virologicall y suppressed (HIV RNA < 50 copi[INVESTIGATOR_014]/mL ) patients from TDF -based 
antiretroviral regimen s to a once -a-day, single tablet TAF -based regimen E/C/F/TAF resulted in 
noninferior efficacy  (i.e. maintenance of viral suppression) and improved bone mineral densit y 
and renal function at Week 48 compared with those who continued taking their TDF
-based 
regimen {Mills et al 2016}.
Thus, patients with CHB, particularl y those with advanced age, who are currently  virally 
suppressed on TDF, may benefit from switching therapy  to TAF by [CONTACT_506476] y of bone and renal parameters compared to TDF
treatment .
1.5. Risk/Benefit Assessment for the Study
This concept is supported by  [CONTACT_506477] a large dataset of 1733 HIV- infected, treatment 
naive subjects randomized to receive treatment with the FDC of E/C/F/TAF or E/C/F /TDF [STB; 
Stribild®]). Renal and bone parameters were significantly  lessaffected in subjects who received 
E/C/F/TAF compared with E/C/F/TDF {Sax et al 2015 }. Moreover, in a large, prospective, 
randomized (2:1) open -label switch study  in 1443 virally  suppressed, HIV -infected subjects 
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page46 30September 2016(959subjects randomized to E/C/F/TAF and 477 to continue TDF -based antiretrovir al regimens), 
results at Week 48 showed that viral suppression was maintained while bone and renal 
parameters were significantly  improved in the E/C/F/TAF group {Mills et al 2016 }. In adult 
subjects with CHB, a global Phase 3 program for TAF consisting of 2 prospective, randomized, 
active-controlled studies with 1 each in HBeAg -negative ( Study GS-US-320-0108) and 
HBeAg-positive (Study GS-US-320-0110) subjects is currently  ongoing. Primary  endpoint data 
shows that TAF is as effective as TDF for viral suppression at Week 48 .
In addition , renal and 
bone safet y parameters wereimprov edwith TAF treatment relative to TDF . In a pooled analy sis 
of both studies, patients receiving T AF experienced 
significantl y smaller mean percentage 
decreasesfrom baseline in hip and spi[INVESTIGATOR_506437] y at week 48 (p <0.001), and the 
median chang e in estimated glomerular filtration rate (eGFR CG) from baseline to week 48 was 
lesswith TAF compared with TDF (- 1.2 mL/min vs. -5.4 mL/min; p <0.001). In addition, 
significantl y smaller changes in biomarkers of bone turnover (bone forma tion markers: 
osteocalcin, bone -specific alkaline phosphatase, and procollagen t ype 1 N-terminal propeptide, 
and the bone resorption marker, C- type collagen sequence) and quantitative markers of proximal 
tubular function (beta -2 microglobulin to creatinine and retinol bind
ing protein to creatinine 
ratios) were seen in TAF subjects compared with TDF subjects at Week 48.
TDF has been used in clinical practice for the treatment of CHBfor many years and its use and 
safety profile is very well understood by [CONTACT_15098]. Moreover, in ongoing HBV studies 
GS-US-320-[ADDRESS_653415] similar rates of HBV DNA 
suppression as the TDF group, with TAF meeting the primary  endpoint of noninferiority  to the 
TDF grou p at Week 48.Thus, patients with CHB who are cur rently virally suppressed on TDF, 
should experience no greater risk as pertains to viral suppression by [CONTACT_506478] .Moreover, throughout the study , subjects will be closely  monitored at intervals that 
are above those recommended by  [CONTACT_506479], therefore subjects 
who remain on TDF therapy  will benefit from additional monitoring. 
For subjects receiving TAF, adult data from the Phase 3 studies indicates that TAF is safe and 
effective. 
The benefit/risk for this study  is therefore considered positive.
1.6. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page47 30September [ZIP_CODE]. OBJECTIVES
The primary objective s of this study  areas follows:
To evaluate the efficacy  of switching to tenofovir alafenamide (TAF)25 mg QD versus 
continued tenofovir disoproxil fumarate ( TDF)300 mg QD in virologically  suppressed 
subjects with chronic HBV as determined b y the proportion of subjects with HBV DNA 
≥ 20IU/mL (as defined by  [CONTACT_506455] -defined snapshot algorithm) at Week 24
To compare the safety  and tolerability  of switching to TAF 25 mg QD versus continued TDF 
300 mg QD in virologically  suppressed subjects with chronic HBV at Week 24
The key secondary objectives of this study  are as follows: 
To compare the safety  of switching to TAF 25 mg QD versus continued TDF 300 mg QD as 
determined b y the percent change from baseline in hip and spi[INVESTIGATOR_110075] 24
To compare the safety  of switching to TAF 25 mg QD versus continued TDF 300 mg QD as 
determined by [CONTACT_506480] -Gault 
method(eGFRCG)at Week24
Othersecondary  objectives of this study  are as follows: 
To compare the safety  of switching to TAF 25 mg QD versus continued TDF 300 mg QD as 
determined b y the percent change from baseline in hip and spi[INVESTIGATOR_110085] 48 and 96
To compare the safety  of switching to TAF 25 mg QD versus continued TDF 300 mg QD as 
determined b y the change from baseline in estimated creatinine clearance by [CONTACT_3158] -Gault 
method(eGFRCG)at 
Weeks 48 and 96
To compare the safety  and tolerability  of switching to TAF 25 mg QD versus continued TDF 
300 mg QD for virologically  suppressed subjects with chronic hepatitis B at Week 48
To evaluate the efficacy  of switching to TAF 25 mg QD versus continued TDF300 mg QD 
as determined b y the proportion of subjects with HBV DNA ≥ 20 IU/mL (as defined b y the 
modified US FDA -defined snapshot algorithm) at Weeks 48 and 96
To compare the serological response (loss of HBsAg and seroconversion to anti- HBs, and 
loss of HBeAg and seroconversion to anti- HBe in HBeAg -positive subjects ) of switching to 
TAF 25 mg QD versus continued TDF 300 mg QD at Weeks 24, 48, and 96
To compare bioc hemical response (normal ALT and normalized AL T)of switching to TAF 
25 mg QD versus continued TDF 300 mg QD at Weeks 24, 48, and 96
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page48 30September 2016To compare the change in fibrosis as assessed b y FibroTest®after switching to TAF 25 mg 
QD versus continued TDF 300 mg QD at Weeks 48 and 96
To evaluate the comparative open -label efficacy  and safet y of switching to TAF 25 mg QD 
from Week 48 through Week 96 in subjects initially randomized to TAF 25 mg QD and in 
subjectssequentially  treated with continued TDF 300 mg QD for 4 8weeks and then switched 
to open-label TAF 25 mg QD
To evaluate the proportion of subjects with HBV DNA < 20 IU/mL and target 
detected/notdetected(i.e. <LLOD) at Weeks 24, 48, and 96
The exploratory  objectives of this study  are as follows:
 
 
 
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page49 30September [ZIP_CODE]. STUDY DESIGN
3.1. Study Treatment Plan and Regimen
This is a randomized, double -blind, multicenter, active -controlled stud y to evaluate the safet y 
and efficacy  of TAF 25 mg QD in virologicall y suppressed subjects who switch from TDF to 
TAFcompared to continued TDF treatment.
Approximately  300subjects (with approxi mately 50% of subjects being ≥ 50 years old) will be 
randomized in a 1:1 ratio (A:B) to receive either TAF 25 mg QD and matched placebo of TDF 
300 mg QD or [COMPANY_009]-provided TDF 300 mg QD andmatched placebo of TAF 25mg QD.
At randomization, subjects will b e stratified by  [CONTACT_506481] (HBeAg-negativevs. 
HBeAg-
positive) and age ( ≥ 50 or < 50 years).
Treatment Arm A: approximately  150subjects administered TAF 25 mg QD and matched 
placebo of Tenofovir DF (TDF) 300 mg QD
Treatment Arm B: approximately  150subjects administered [COMPANY_009]- provided TDF 300 mg 
QD andmatched placebo of TAF 25mg QD
The duration of double blind treatment is 48 weeks. All subjects who complete 48 weeks of 
treatment are eligible for participation in the open label TAF 25 mg extension period for an 
additional 48 weeks (through Week 96). During the double -blind period, subjects with a 
confirmed creatinine clearance b y Cockcroft Gault Method (eGFR CG)< 50 ml/min, and >20% 
decline in eGFR by  [CONTACT_9289]-EPI (cystatin C) compared to baseline during the study , will be 
required to undergo dose modification to every  other day  dosing of study  drug. Subjects with 
confirmed creatinine clearance < 30 mL/min during the double blind phas e of the study  will have 
the study drug permanently  discontinued. Subjects with confirmed eGFR CG<50 mL/min will 
not undergo dose modification to every  other day  during the open- label TAF 25 mg extension 
period, nor will treatment be permanently  discontin ued for confirmed eGFR CG<30 mL/min 
during the open -label extension period.
Subjects who permanently discontinue stud y drug (either prematurel y or at the end of stud y 
[Week 96]) for reasons other than HBsAg loss with confirmed seroconversion to anti -HBs w
ill 
be followed every  [ADDRESS_653416]. Use of appropriate ,alternative HBV therap y is 
strongly encouraged.
Subjects with HBsAg loss, and confirmed seroco nversion to anti -HBs should discontinue study  
drug within 3- 6 months following confirmation of seroconversion to anti- HBs. Subjects with 
HBsAg loss with confirmed seroconversion prior to Week 24 are not permitted to discontinue
study drug prior to the Week 24 visit. Subjects with HBsAg loss with confirmed seroconversion
will be followed off treatment every  4 weeks for 12 weeks and then per the study  visit schedule 
(Appendix 2) through Week 96
/ED. Discontinuation of study  drug for subjects experiencing 
HBsAgloss with confirmed seroconversion, who have known bridging fibrosis or cirrhosis, 
should be considered on a case b y case basis.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page50 30September 2016The primary  analysis will occur at Week 24 with the pri mary efficacy endpoint being the 
proportion of subjects with HBVDNA≥20 IU/mL, as determined b y the modified US FDA -
defined snapshot algorithm
.
An external ,independent ,multidisciplinary  DMC will review the progress and safet y of this 
study. The committee will convene after the last subject enrolled completes Week 24 of th e 
study. However, [COMPANY_009] will defer to the DMC for any  decision to convene earlier or more 
frequently. At eachmeeting, the DMC will review routine safet y and DXAdata and will make 
recommendations regarding modification of the study treatment.
Subjects wi th a history  of or current diagnosis of compensated cirrhosis (i.e. those with cirrhosis 
without laboratory  or clinical evidence of decompensated liver disease) are eligible for 
enrollment. Acceptable diagnostic criteria for cirrhosis include a Metavir or Knodell fibrosis 
score ≥ 4 or Ishak fibrosis score ≥ [ADDRESS_653417] score ≥ 0.75, or previous 
Fibroscan result > 12kPa (in countries where locally approved). Available information regarding 
the presence or absence of cirrhosis b y these crit eria will be captured in the electronic case report 
forms at Baseline, and any  other time during the trial should an investigator opt to undertake 
additional studies. The change in fibrosis as assessed by  [CONTACT_187807]®will be performed in all 
subjects partic ipating in the trial at Baseline, and Weeks 24, 48, and 96/ED.
3.2. Biomarker Testing
3.2.1. Biomarker Samples to Address the Study Objectives
The following biological specimens will be collected in this study  and will be used to evaluate 
the association of explorato ry biomarkers with study  drug response, including efficacy  and/or 
adverse events and to increase knowledge and understanding of the biology of chronic he patitis 
B and related diseases. The specific anal yses will include, but will not be limited to, the 
biomarkers listed below. Because biomarker science is a rapi[INVESTIGATOR_204935], 
and adverse events in particular are difficult to predict, it is not possible to specify  prospectivel y 
all tests that will be 
done on the specimens provided. The testing outlined below is based upon 
the current state of scientific knowledge. It maybe modified during or after the end of the study  
to remove tests no longer indicated and/or to add new tests based upon the growing state of art 
knowledge.
Fasting Uri ne Biomarkers including, but not limited to, retinol binding protein (RBP) and
beta-2 microglobulin 
Fasting Serum Bone Biomarkers including, but not limited to, C -type collagen sequence 
(CTX) and procollagen ty pe 1 N-terminal propeptide (P1NP)
These speci mens will be collected from all subjects in a fasted state at Baseline and 
Weeks4, 12,24, 48, 72, and 96 /ED. Samples may be stored b y [COMPANY_009] Sciences for a period of 
15 years at the end of the study .
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653418] has completed their stud y participation, the long -term care of the participant will 
return tothe responsibility  of their primary  treating phy sicians.
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653419] Selection
Approximately  300subjects (wi th approximately  50% of subjects being ≥ 50 years old) will be 
randomized in a 1:1 ratio (A:B) to receive either TAF [ADDRESS_653420] meet allof the following 
inclusion criteriato be eligible to participate in the study :
1)Must have the ability  to understand and sign a written informed consent form; consent must 
be obtained prior to initiation of study  procedures
2)Adult male and non-pregnant, non-lactatingfemale subjects, ≥[ADDRESS_653421] at Screening is required for 
female subjects of childbearing potential (as defined in Appendix 5).
3)Documented evidence ofchronic HBV infection previously  (e.g., documented HBsAg 
positive for more than 6months)
4)Maintained on TDF [ADDRESS_653422] 24weeks prior to screening and with viral suppression ( HBVDNA<LLOQ)for a 
minimum of 12 weeks prior to Screening , and including a Screening HBV DNA value of
<20 IU/mL (by [CONTACT_12115])
5)Estimated creatinine clearance ≥ 50ml/min(using the Cockcroft -Gault method) based on 
serum creatinine and actual body  weight as m easured at the Screening evaluation, as follows:
(140 –age in years) (body  weight [kg])
(72) (serum creatinine [mg/dL ])
(Note: multiply  estimated rate by  0.85 for women)
6)Normal ECG (or if abnormal, determined b y the Investigator not to be clinically  significant)
7)Must be willing and able to comply  with all study  requirements
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page53 30September [ZIP_CODE].3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
1) Pregnant women, women who are breastfeeding or who believe they  may wish to become 
pregnant during the course of the stud y 
2)Males and females of reproductive potential who are unwilling to use an “effective”, 
protocol-specified method(s) of contraception during the stud y. For a list of 
protocol-specified Contraceptive methods, refer to 
Appendix 5.
3)Co-infection with HCV, HIV, or HDV
4)Evidence of hepatocellular carcinoma (e.g. as evidenced b y recent imaging)
5) Current evidence of, or recent ( ≤5 years)history ofclinical hepatic decompensation 
(e.g.,ascites, encephalopathy  or variceal hemorrhage)
6)Abnormal hematological and biochemical parameters, including:
a)Hemoglobin < 10 g/dL 
b)Absolute neutrophil count < 750/mm3
c)Platelets ≤ 50,000/mm3
d)AST or ALT > 5
×ULN
e)Albumin < 3.0 mg/dL
f)INR > 1.5 ×ULN (unless stable on anticoagulant reg imen)
g)Total bilirubin > 2.5 ×ULN
7)Received solid organ or bone marrow transplant
8)Significant renal, cardiovascular, pulmonary, or neurological disease in the opi[INVESTIGATOR_1070]
9)Malignancy  within 5 y ears prior to Screening, with the exception of sp ecific cancers that are 
cured by [CONTACT_78043] (e.g. basal cell skin cancer, etc.). Subjects under evaluation for 
possible malignancy  are not eligible.
10)Currently  receiving therapy  with immunomod ulators (e.g. corticosteroids) , nephrotoxic 
agents, or ag ents capable of modifying renal excretion
11)Known hy persensitivity  to study drugs, metabolites, or formulation excipi[INVESTIGATOR_506438] (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page54 30September 201612)Current alcohol or substance abuse judged b y the investigator to potentiall y interfere with 
subject compliance
13)Any other clinical condit ion or prior therap y that, in the opi[INVESTIGATOR_2511] I nvestigator, would 
make the subject unsuitable for the stud y or unable to comply with dosing requirements.
14)Use of investigational agents within 3 months of screening, unless allowed by  [CONTACT_1034]
15)Use of an y prohibited medications as described in Section 5.4. Subjects on prohibited 
medications who areotherwise eligible will need a wash out period of at least 30 day s prior 
to the Baseline visit.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page55 30September [ZIP_CODE]. INVESTIGA TIONAL  MEDICINAL PRODUCTS
5.1. Randomization, Blinding and Treatment Codes
A centralized randomization procedure via an Interactive Voice/Web Response Sy stem 
(IVRS/IWRS) will be used for this study , whereby  [CONTACT_506482]. A unique subject number will be provided during 
randomization. Eligible subjects (n =300) will be randomized 1:1 to receive either blinded TAF 
25 mg and TDF matched placebo (n = 150) or TDF 300 mg and TAF matched placebo (n = 150) 
for [ADDRESS_653423] ratifiedby [CONTACT_96477] (HBeAg -negative [and anti -HBe 
positive] vs. HBeAg -positive) and age (> 50 years vs. < 50 y ears). At Week 48, all subjects will 
be switched to open -label TAF 25 mg QD for an additional 48 weeks (through Week 96/ED). 
For the entire d uration of the study , subjects and investigators will remain blinded to the initial 
treatment regimen to which the subjects were randomized.
5.1.1. Procedures for Breaking Treatment Codes
In the event of a medical emergency  where breaking the blind is required t o provide medical care 
to the subject, the investigator may  obtain treatment assignment directly from the IXRS sy stem 
for that subject . [COMPANY_009] recommends but does not require that the investigator contact [CONTACT_506483] d. Treatment assignment should remain blinded 
unless that knowledge is necessary  to determine subject emergency  medical care. The rationale 
for unblinding must be clearl y explained in source documentation and on the case report form/ 
electronic case report form (CRF/eCRF), along with the date on which the treatment assignment 
was obtained. The investigator is requested to contact [CONTACT_506484] y treatment unblinding .
In the event of a medical emergency  where breaking the b lind is required to provide medical care 
to the subject, the investigator may  obtain treatment assignment for that subject . [COMPANY_009] 
recommends but does not require that the investigator contact [CONTACT_335240]. Treatment assignment should remain blinded unless that knowledge is 
necessary  to determine subject emergency  medical care. The rationale for unblinding must be 
clearly explained in source documentation and on the case report form/ electronic case report 
form (CRF/e CRF), along with the date on which the treatment assignment was obtained. The 
investigator is requested to contact [CONTACT_337351] y treatment 
unblinding.
Blinding of stud y treatment is critical to the integrity
 of this cli nical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued. All subjects will be followed until study  completion unless consent to do 
so is specificall y withdrawn by t he subject.
[COMPANY_009]Drug Safet y and Public Health (DSPH) may independentl y unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (S[LOCATION_003]Rs).
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page56 30September [ZIP_CODE].2. Description and Handling of Tenofovir Alafenamide (TAF) and TDF
5.2.1. Formulation
[IP_ADDRESS]. Tenofovir Alafenamide (TAF) Tablets
TAF 25 mg tablets contain 28 mg of tenofovir alafenamide fumarate, which is equivalent to
25mg of tenofovir alafenamide (TAF). The tablets are yellow, round- shaped, and film-coated. 
The tablets are debossed with “GSI” on one side and “25” on the other side. I naddition to the 
active ingredient, each film- coated tablet contains the following inactive ingredients: lactose 
monohydrate, microcry stalline cellulose, croscarmellose sodium, magnesium stearate, 
polyethylene glycol, polyv inyl alcohol, talc, titanium dioxide, and yellow iron oxide.
[IP_ADDRESS]. Placebo to Match TAF Tablets
Placebo tablets to match TAF 25 mg are yellow, round-shaped, and film- coated. The tablets are 
debossed with “GSI” on one side and “25” on the other side. Each tablet contains the following 
inactive ingredients: lactose monohy drate, microcry stalline cellulose, croscarmellose sodium, 
magnesium stearate, pol yethylene gl ycol, polyvinyl alcohol, talc, titanium dioxide, and y ellow 
iron oxide.
[IP_ADDRESS]. T enofovir Disoproxil Fumarate (V iread®,Tenofovir DF, TDF)
TDF 300 mg tablets contain 300 mg of tenofovir disoproxil fumarate (TDF), which is equivalent 
to 245 mg of tenofovir disoproxil. The tablets are light blue, almond -shaped,plain-faced, and 
film-coated. Each tablet contains the fo llowing inactive ingredients: microcrystalline cellulose, 
lactose monohy drate, pregelatinized starch, croscarmellose sodium, and magnesium stearate. The 
film coating contains lactose monohy drate,hypromellose (hy droxypropyl methylcellulose), 
glycerol triacetate, titanium dioxide, and indigo carmine aluminum lake.
[IP_ADDRESS]. Placebo to Match TDF Tablets
Placebo tablets to match TDF 300 mg are light blue, almond- shaped, plain- faced, film -coated
tablets. Each tablet contains the following inactive ingredients: denatonium benzoate, lactose
monohydrate, pregelatinized starch, croscarmellose sodium, and magnesium stearate. The film 
coating contains the following inactive ingredients: lactose monohy drate, hypromellose
(hydroxypropyl methylcellulose), triacetin, titanium dioxi de, and indigo carmine aluminum lake.
5.2.2. Packaging and Labeling
TAF,TDF, and their matche d placebo tablets are packaged in white, high density polyethylene 
(HDPE) bottles. Each bottle contains 30 tablets and a silica gel desiccant and pol yester packing 
material. Each bottle is enclosed with a white, continuous thread, child- resistant poly propylene 
screw cap with an induction-
sealed and aluminum- faced liner.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page57 30September 2016Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice −Annex 13 (I nvestigational Medicinal 
Products), and/or other local regulations.
5.2.3. Storage and Handling
TAF, TDF, and their matche d placebo tablets should be stored at controlled room temperature of 
25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Storage 
conditions are specified on the label.Until dispensed to the subjects, all bottles of stu dy drugs 
should be stored in a securely  locked area, accessible only  to authorized site personnel. 
To ensure the stability and proper identification, study drug(s) should not be stored in a container 
other than the container in which they  were supplied. 
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact [CONTACT_10850] . Appropriate precautions should be followed to avoid direct 
eye contact [CONTACT_90265].
5.3. Dosage and Administration of Tenofovir Alafenamide (TAF) and TDF
Subjects will be randomly assigned (1:1) to receive one of the following treatments in a blinded 
fashion:
Treatment Arm A: approximately  150subjects administered TAF 25 mg QD and matched 
placebo of Tenofovir DF (TDF) 300 mg QD
Treatment Arm B: approximately  150subjects administered [COMPANY_009]
-provided TDF 300 mg 
QD andmatched placebo of TAF 25mg QD
It is preferred that subjects take their study  drug according to a morning dosing schedule; 
however, evening dosing is allowa ble.
All study drugs should be taken at approximately  the same time each day with or without food. 
Subjects taking TDF 300 mg QD with food prior to randomization should continue to take study  
drug with food; subjects taking TDF 300 mg QD without food prior to randomization should 
continue to take study  drug without food during the study  period.
Study drug should be 
administered after assessing adverse events and concomitant medication(s).
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page58 30September [ZIP_CODE].4. Prior and Concomitant Medications
Concomitant/previous medications taken within [ADDRESS_653424] study  visit, need to be recorded i n the source documents and eCRFs.
The following medications are excluded while subjects are participating in the study . These 
medications are prohibited during the screening period and for a minimum of
30days prior 
to the Baseline/Day 1 visit through the end of treatment:
Investigational agents or devices for an y indication
Nephrotoxic agents (e.g., aminogl ycosides, amphoterecin B, vancomycin, cidofovir, 
foscarnet, cisplatin, pentamidine, cy closporine, tacrolimus)
Probenecid
Agents that reduce renal function or compete for active tubular s ecretion with tenofovir 
(e.g.,cidofovir, acy clovir, valacy clovir, ganciclovir, valganciclovir)
Systemic che motherapeutic agents, sy stemic corticosteroids (except short -term use of 
prednisone as a steroid burst [ ≤ 1 week of use], immunosuppressant, or immunomodulating 
agents
Concomitant use of certain medications or herbal/na tural supplements ( inducers of drug 
transporters i.e., P -gp) with study  drug(s) may  result in PK interactions.
Examples of representative medications which are prohibited from 21 days prior to Day 1 
through the end of treatment are listed below:
Table5-
1. Disallowed Concomitant Medications
Medication Class Prohibited Medications Medications to be used with caution
AnticonvulsantsCarbamazepi[INVESTIGATOR_050], Oxcarbazepi[INVESTIGATOR_050], 
Phenobarbital, Phenytoin : may lower 
concentration of TAF and/or TFV
Antimycobacterials Rifapentine, Rifabutin, Rifampin
Herbal/Natural SupplementsSt. John’s Wort, Echinacea, Milk thistle 
(i.e., silymarin), Chinese herb 
sho-saiko-to (or Xiao -Shai-Hu-Tang)
Should subjects have a need to initiate treatment with any  excluded concomitant medication, 
including herbal/natural products/therapi[INVESTIGATOR_014], and over the counter medications, the 
[COMPANY_009]Sciences Medical Monitor must be consulted prior to initiation of the new medication. In 
instances where an excluded medication is initiated prior to discussion with the Sponsor, the 
investigator must notify  [COMPANY_009] Sciences as soon as he/she is aware of the use of the excluded 
medication.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page59 30September [ZIP_CODE].5. Accountability for Tenofovir Alafenamide(TAF), Tenofovir Disoproxil 
Fumarate (TDF) and Matched Placebos
The investigator or designee (i.e., pharmacist)is responsible for ensuring adequate accountability  
of all used and unused investigational medicinal product (IMP) bottles. This includes 
acknowledgement of receipt of each shipment of IMP(quantity and condition). All used and 
unused IMP bottlesdispensed to subjects must be returned to the site.
Investigational product accountability  records will be provided to each study  site to:
Record the da te received and quantity  of IMP bottles
Record the date, subjectnumber, subject initials, the IMPbottle number dispensed
Record the date, quantity of used and unused IMPbottles returned, along with the initials of 
the person recording the information
5.5.1. In vestigational M edicinal Product Return or Disposal
At the start of the stud y, the study monitor will evaluate each study center’s study drug disposal 
procedures and provide appropriate instruction for return or destruction of unused study  drug 
supplies. I fthe site has an appropriate Standard Operating Procedure (SOP) for drug destruction, 
the site may  destroy used and unused study  drug supplies performed in accordance with the site’s 
(hospi[INVESTIGATOR_307]/pharmacy ) SOP. If the site does not have acceptab le procedures in place for 
drugdestruction, arrangements will be made between the site and [COMPANY_009] Sciences
(or[COMPANY_009]Sciences’ representative) for return of unused study  drug supplies. A copy  of the site’s 
SOP will be obtained for central files. Where possible, study drug will be destroy ed at the site. 
Upon study  completion, a copy  of the Investigational Drug Accountability records must be filed 
at the site. Another cop y will be returned to [COMPANY_009]Sciences. If drug is destroy ed on site, the 
investigator must maintain a ccurate records for all study  drug bottles destroyed. Records must 
show the identification and quantity  of each unit destroy ed, the method of destruction, and 
person who disposed of the drug. All study  drug records must be maintained at the site and 
copi[INVESTIGATOR_506439] . 
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653425] research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the investigator to ensure that subjects are eligi ble to participate in the 
study prior toenrollment . Once consent has been obtained, all screening tests and procedures 
have been completed , and study  eligibility has been confirmed, subjects will be randomized
within 45 day s using an IVRS/I WRS. Subjects w ill receive stud y drugs within their assigned 
treatment group as described in Section 3.1.
Candidates who fail to meet eligibility  criteria by  [CONTACT_384764]-screened once 
after the initial screen if there is a reasonable expectation that the candidate will be eligible after 
repeat screening.
Retestingof an exclusionary  laboratory  value during the Screening 
period ispermitted only  if in 
the Principal Investigator’s opi[INVESTIGATOR_1649], the retest value will be within accepted parameters; if the 
initial value was deemed to be inaccurate, inconsistent with the subject’s previous result (s);in 
error (e.g. mishandled sample) ;or due to an extenuating circumstance .
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened within 45 days before randomization to determine eligibility for 
participation in the study . The following will be performed and documented at screening:
Obtain written informed consent
Review of inclusion/exclusion criteria
Obtain medical history  (including HBV disease and tre atment history)
Review concomitant medications
Record an y serious adverse events and all adverse events related to protocol mandated 
procedures occurring after signing of the consent form
Complete physical examination with vital signs (blood pressure, pulse, respi[INVESTIGATOR_427671]) , body weight, and height
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page61 30September 2016ECG (subjects must rest quietly in the supi[INVESTIGATOR_19636] a minimum of 5 minutes prior to 
the recording)
DXA scan of hip and spi[INVESTIGATOR_050]. The Baseline DXA scan can be performed at any  time during the
Screening 
periodto ensure the results are received prior to the first dose of the study  drug 
and therefore should be completed at least 14 days priorto the Baseline visit
Blood sample for :
plasma HBV DNA (must be < 20 IU/mL at time of S creening to be eligible)
Serum chem istry and liver function tests, hematology , serum HBsAg (quantitative), 
HBVserology (qualitative HBsAgand HBeAg), ruling out HIV
-1, HDV, HCV ,serum 
pregnancy test (for females of child- bearing potential), 
α-fetoprotein (AFP) and INR . An 
AFP > 50 ng/mL at Screening must have an appropriate evaluation (i.e., CT scan) in 
order to rule out HCC prior to being permitted to enter the study .
Estimated creatinine clearance (using the Cockcroft -Gault method)
Urine sample for urinal ysisand drug screen
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within [ADDRESS_653426] all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adverse events cas e report form (CRF/eCRF).
All other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical historyare to be captured on the medical history  CRF/eCRF. 
See Section7Adverse Events and Toxicity  Management for additional details.
6.2.2. Baseline Assessments
All baseline tests and procedu res must be completed prior to the receipt of the first dose of study  
drug. Subjects screened within [ADDRESS_653427] on the day  of theBaseline visit. 
The following will be performed at the Baseline visit:
Review of inclusion/exclusion criteria and confirm medical history (including HBV disease 
and treatment history )
Complete phy sical examination withvital signs (blood pressure, pulse, respi[INVESTIGATOR_39870] n rate and 
temperature) andbody weight
Review concomitant medications
Review adverse events 
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page62 30September 2016Randomization
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL , direct LDL, and trigl ycerides]) -no food or drinks, except water, at 
least 8 hours prior to blood collection 
Fasting urine sample for renal biomarkers
Dispense blinded study  drugs
Blood sample fo rserum chemistry and liver function tests, hematology , plasma HBV DNA , 
serum HBsAg (quantitative), HBV serology  (qualitative HBsAgand HBeAg), virology  
(
resistance surveillance) ,  and vitamin D assessment
Serum 
Cystatin C testing for estimated glomerular filtration rate (eGFR) by [CONTACT_9289] -EPI 
(ChronicKidney Disease Epi[INVESTIGATOR_8849] )
Estimated creatinine clearance (using the Cockcroft -Gault method)
Blood sample for Fibrotest®
Urine sample for urinal ysis, pregnancy test (for females of child -bearing potential; in case of 
a positive urine test, a serum preg nancy test will be done), 
 
Health Related Quality  of Life (HRQoL) Survey s (CLDQ,SF-36, WPAI )
Complete the “Fracture Risk Assessment” (FRAX®) eCRF
6.3. Treatment Assessments
6.3.1. Double Blind Visits ( Visit Window ± 3 days)
[IP_ADDRESS]. Week 4
Symptomdirected phy sical exam
Body weight
Vital signs: bloodpressure, pulse, respi[INVESTIGATOR_1487], and temperature
Review concomitant medications
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page63 30September 2016Review adverse events 
Perform study  drugaccountability
Fasting bl ood sample for bone biomarkers
Fasting urine sample for renalbiomarkers
Dispense blinded study  drugs
Blood sample for serum chemistry  and liver function tests, hematology , plasma HBV DNA, 
virology(resistance surveillance),  
Estimated creatinine cleara nce (using the Cockcroft- Gault method)
Urine samplefor urinal ysis, pregnancy test (for females of child -bearing potential ; in case of 
a positive urine test, a serum pregnancy  test will be done ), 
[IP_ADDRESS]. Week 8
Symptomdirected phy sical exam
Body weight
Vital signs : blood pressure, pulse, respi[INVESTIGATOR_1487], temperature
Review 
concomitant medications
Review adverse events 
Perform study  drug accountability
Dispense blinded studydrugs
Blood sample for serum chemistry  and liver function tests, hemato logy, plasma HBV DNA,
virology (resistance surveillance), 
Estimated creatinine clearance (using the Cockcroft -Gault method)
Urine sample for 
urinalysis, pregnancy  test (for females of child- bearing potential ; in case of 
a positive urine test, a serum pregnancy  test will be done ), 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page64 30September [ZIP_CODE].3.1.3. Week 12
Symptom directedphysical exam
Body weight
Vital signs: blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature
Review concomitant medications
Review adverse events 
Perform study drug accountability
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL , direct LDL, and trigl ycerides]) −no food or drinks, except water, at 
least 8 hours prior to blood collection 
Fasting urinesample for renal biomarkers
Dispense blinded study  drugs
Blood sample for serum chemistry  and liver function tests, hematology , plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology  (qualitative HBsAgandHBeAg), virology 
(resistance surveillance), 
Estimated creatinine clearance (using the Cockcroft -Gault method)
Urine sample for urinal ysis, pregnancy test (for females of child -bearing potential; in case of 
a positive urine test, a serum pregnancy  test will be done), 
[IP_ADDRESS]. Week 24 (visit window is –14 days)
Complete phy sical examination withvital signs (blood pressure, pulse, respi[INVESTIGATOR_427671]) andbody weight
DXA scan of hip and spi[INVESTIGATOR_050] (within −14 days of the expected visit date)
Reviewconcomitant medications
Review adverse events 
Perform study  drug accountability
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL , direct LDL, and trigl ycerides]) −no food or drinks, except water, at 
least 8 hours prior to bloodcollection
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page65 30September 2016Fasting urine sample for renal biomarkers
Dispense blinded study  drugs
Blood sample for serum chemistry  and liver function tests, hematology , plasma HBV DNA, 
serum HBsAg (quantitative), HBV serolog y (qualitative HBsAgand HBeAg), virology  
(resistance surveillance ), 
Estimated creatinine clearance (using the Cockcroft -Gault method)
Blood sample for Fibrotest®
Urine samplefor urinal ysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy  test will be done), 
Health Related Quality  of Life (HRQoL) Survey s (SF-36, WPAI  and CLDQ) 
[IP_ADDRESS]. Week 36
Symptomdirected phy sical exam
Body weight
Vital signs : blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature
Review concomitant medications
Review adverse events 
Perform 
studydrug accountability
Dispense blinded study  drugs
Fasting blood sample for metabolic assessment (glucose and lipid panel [ total cholesterol, 
HDL, direct LDL, and trigl ycerides]) -no food or drinks, except water, at least 8 hours prior 
to bloodcollection
Blood sample for serum chemistry  and liver function tests, hematology , plasma HBV DNA, 
serum 
HBsAg(quantitative), HBV serology  (qualitative HBsAgand HBeAg), virology  
(resistance surveillance ), 
Estimated creatinine clearance (using the Cockcroft -Gault method)
Urine sample for urinal ysis, pregnancy test (for females of child -bearing potential; in case of 
a positive urine test, a serum pregnancy  test will be done), 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page66 30September [ZIP_CODE].3.1.6. Week 48 (visit window is −6 weeks)
Complete phy sical examination withvital signs (blood pressure, pulse, respi[INVESTIGATOR_427671]) andbody weight
ECG (subjects must rest quietly  in the supi[INVESTIGATOR_19636] a minimum of 5 minutes prior to 
the recording )
DXA scanof hipand spi[INVESTIGATOR_050] (within −6 weeksof the expected visit date)
Review concomitant medications
Review 
adverseevents 
Perform study drug accountability
Fasting blood sample for bone biomarkers and metabolic assessment ( glucose and lipid panel 
[total cholesterol, HDL , direct LDL, and trigl ycerides]) −no food or drinks, except water, at 
least 8 hours prior to blood collection 
Fasting urine sample for renal biomarke rs
Blood sample for serum chemistry  and liver function tests, hematology , plasma HBV DNA, 
serumHBsAg (quantitative), HBV serology  (qualitative HBsAgand HBeAg) , virology  
(resistance surveillance)
, 
Estimated creatinine clearance (using the Cockcroft -Gault method)
Blood sample for Fibrotest®
 
Urine sample for urinal ysis, pregnancy test (for females of child -bearing potential; in case of 
a positive urine test, a serum pregnancy  test will be done), 
Health Related Quality  of Life (HRQoL) Survey s (CLDQ,SF-36, WPAI)
Retrieve blinded study drug and dispense open label study drug
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page67 30September [ZIP_CODE].3.2. Open Label Visits (Visit Window± 7 days)
[IP_ADDRESS]. Week60
Symptomdirected phy sical exam
Body weight 
Vital signs : blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature
Reviewconcomitant medications
Reviewadverse events 
Perform study  drug accountability
Dispense open label study drugs
Fasting blood sample for metabolic assessment (glucose and lipid panel [ total cho
lesterol, 
HDL, direct LDL, and trigl ycerides]) −no food or drinks, except water, at least 8 hours prior 
to bloodcollection
Blood sample for serum chemist ry and liver function tests, hematology , plasma HBV DNA, 
serumHBsAg (quantitative), HBV serology  (qualitative HBsAgand HBeAg) virology  
(resistance 
surveillance ), 
Estimated creatinine clearance (using the Cockcroft -Gault method)
Urine sample for urinal ysis,pregnancy  test (for females of child- bearing potential; in case of 
a positive urine test, a serum pregnancy  test will be done), 
[IP_ADDRESS]. Week 72
Complete phy sical examination withvital signs (blood pressure, pulse, respi[INVESTIGATOR_427671]) andbody weight
DXA scan of hip and spi[INVESTIGATOR_050](within ± 14 days of the expected visit date)
Review concomitant medications
Review adverse events
Perform study  drug accountability
Dispense open label study drugs
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page68 30September 2016Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol , HDL, direct LDL, and trigl ycerides]) −no food or drinks, except water, at 
least 8 hours prior to blood collection 
Fasting urine sample for renal biomarkers
Blood sample for serum chemistry  and liver funct ion tests, hematology , plasma HBV DNA,
serumHBsAg (quantitative) ,HBV serology  (qualitative HBeAg and HBsAg), virology  
(resistance surveillance),
Estimated creatinine clearance (using the Cockcroft -Gault method)
Urine sample for urinal ysis, pregnancy  test (for females of child- bearing potential; in case of 
a positive ur ine test, a serum pregnancy test will be done), 
[IP_ADDRESS]. Week 96
Complete phy sical examination with vital signs (blood pressure, pulse, respi[INVESTIGATOR_427671]) andbody weight
ECG (subjects must rest quietly  in the supi[INVESTIGATOR_19636] a mi nimum of 5 minutes prior to 
the recording)
DXA scan of hip and spi[INVESTIGATOR_050] (within ± 14 days of the expected visit date)
Review concomitant medications
Review adverse events 
Perform study  drug accountability (no study drug will be dispensed at Week 96 visit)
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL , direct LDL, and trigl ycerides]) -no food or drinks, except water, at 
least 8 hours prior to blood collection 
Fasting urine sample for rena l biomarkers
Blood sample for serum chemistry  and liver function tests, hematology , plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology  (qualitative HBsAgand HBeAg ), virology 
(resistance surveillance), 
 
Estimated creatinine clearance (using the Cockcroft -Gault method)
Blood sample for Fibrotest®
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page69 30September 2016Urine sample for urinal ysis, pregnancy test (for females of child-bearing potential; in case of 
a positive urine test, a serum pregnancy  test will be done), 
Health Related Quality  of Life (HRQoL) Survey s (CLDQ, SF-36 and WPAI )
6.4. Post-Treatment Assessments
6.4.1. HBsAg Loss and Seroconversion Subjects
Subjects who discontinue study  drug due to HBsAg loss with confirmed seroconversion to
anti-HBs on or after the Week 24 visit, will be followed off treatment every  4 weeks for
12weeks and then per the original study  visit schedule through Week 96/ED (excluding drug 
dispensation and accountability ).
6.4.2. All Other Subjects Who Discontinue Study Drug
Subjects who have received at least one dose of study  drug and permanently  discontinue study  
drug for reasons other than HBsAg loss with confirmed seroconversion to anti -HBs will be 
followed every  [ADDRESS_653428].
6.4.3. Treatment -Free Follow Up Visit Assessments (All Subjects)
Symptom directed phy sical exam
Body weight
Vital sign
s: blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature
Review concomitant medications
Review adverse events
 
 
Estimated creatinine clearance (using the Cockcroft -Gault method)
Urine for urinal ysis
6.5. Assessments for Premature Discontinuation from Study
If a subject discontinues study  dosing (for example, as a result of an AE), every attempt should 
be made to keep the subject in the study  and continue to perform the required study -related 
follow-up and procedures (see Section 6.6, Criteria for Discontinuation of Study  Treatment ). If 
this is not possible or acceptable to the subje ct or investigator, the subject may  be withdrawn 
from the study .
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page70 30September 2016The ED Visit should be performed within 72 hours (i.e., visit window is ± 3days)of the last 
study drug dose.
Complete phy sical exam with vital signs (blood pressure, pulse, respi[INVESTIGATOR_427671]) and body weight
ECG (subjects must rest quietly in the supi[INVESTIGATOR_19636] a minimum of 5 minutes prior to 
the recording)
DXA scan of spi[INVESTIGATOR_506440] ±14days of the expected v isit date and is
doneonly if not done within the past 12 weeks of the ED visit
Review concomitant medications
Review adverse events 
Fasting blood sample for bone biomarkers and metabolic assessment (glucose and lipid panel 
[total cholesterol, HDL , directLDL, and trigl ycerides]) −no food or drinks, except water, at 
least 8 hours prior to blood collection (only collected if not done in the last 12 weeks)
Fasting urine sample for renal biomarkers (only collected if not done in the last 12 weeks)
Blood sample for serum chemistry  and liver function tests, hematology , plasma HBV DNA, 
serum HBsAg (quantitative), HBV serology  (qualitative HBsAgand HBeAg), virology 
(resistance surveillance),  
Estimated creatinine clearance (using the Cockcroft -Gault method)
Blood sample for Fibrotest®
Urine sample for urinal ysis, pregnancy test (for females of child -bearing potential; in case of 
a positive urine test, a serum pregnancy  test will be done), 
Health Related Quality  of Life (HRQoL) Survey s (SF-36, WPAI  and CLDQ) are done onl y if 
not done within the past 24 weeks of the ED visit
6.6. Criteria for Discontinuation of Study Treatment
Study medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree . Following resolution of intercurrent illness, the subject 
may resume study  
dosingat the discretion of the investigator.
Unacceptable toxicity , ortoxicitythat, in the judgment of the investigator, compromises the 
ability to continue study -specific procedures or is considered to not be in the subject
’s best 
interest
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page71 30September 2016Subjects with confirmed creatinine clearance of < 30 mL /min during the double blind phase 
ofthe study will have their study  drug permanently  discontinued
HBsAg loss with seroconversion to anti- HBs. These subjects should discontinue study  drug 
within 3-6 months following confirmation of seroconversion to anti- HBs. Subjects with 
HBsAg loss with co nfirmed seroconversion before Week 24 are not permitted to discontinue 
study drug prior to the Week 24 visit
Discontinuation of study  drug for subjects experiencing HBsAg -loss with confirmed 
seroconversion to anti- HBs, who have known bridging fibrosis or c irrhosis, should be 
considered on a case b y case basis
Therapeutic failure 
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 5
Discontinuation of the study  at the request of [COMPANY_009], aregulatory  agency or an institutional 
review board or independent ethics committee ( IRB/IEC)
6.7. Other Evaluations
6.7.1. Bone and Renal Markers
The following biological specimens will be collected in this study  and will be used to evaluate 
the association of explor atory biomarkers with study  drug response, including efficacy  and/or 
adverse events and to increase knowledge and understanding of the biology of chronic 
hepatitisB and related diseases. The specific analyses will include, but will not be limited to, the 
biomarkers listed below. 
Fasting (no food or drinks, except water, at least 8 hours prior to blood collection ) urine 
Biomarkers including, but not limited to, retinol binding protein (RBP) and
beta-2microglobulin 
Fasting (no food or drinks, except water , at least 8 hours prior to blood collection ) serum 
Bone Biomarkers including, but not limited to, C- type collagen sequence (CTX) and 
procollagen t ype 1 N-terminal propeptide (P1NP)
These specimens will be collected from all subjects at Baseline and Weeks 4,12, 24, 48, 72, and 
96 or ED.  
 
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page72 30September [ZIP_CODE].8. Resistance Surveill anceand Virologic Rebound Management
Sequence anal ysis of the HBV pol ymerase/reverse transcriptase (pol/R T)for potential resistance 
mutations may be attempted for an y subject with HBV DNA > 69 IU/mL  at Baseline and for 
subjects who experience viremia (HB V DNA ≥ 69 IU/mL ) at Weeks 24, 48, and 96/ED. 
As it may  not be known at the time of the visit whether a patient is viremic or if it will be their 
last study  visit, a separate serumsample for potential resistance surveillance will be collected at 
each study  visit. 
In the event of unconfirmed virologic rebound (HBV DNA ≥ 20IU/mL), subjects will be asked 
to return to the clinic for a sched uled or unscheduled blood draw. For virologic rebound 
occurring within the first [ADDRESS_653429] will be re -counseled on adherence to stud y medication.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page73 30September [ZIP_CODE]. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and 
SeriousAdverseEvents
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study subject 
administered a medicinal product,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and /orunintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal product. AEs may also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also b
e considered AEs.
An AE does not include the following:
Medical or surgical procedures such assurgery, endoscopy ,tooth extraction, andtransfusion.
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases,conditions, or laboratory  abnormalities present or detected beforethe 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (e.g. ,hospi[INVESTIGATOR_10800] , socialand/or convenience admi ssions)
Overdose without clinical sequelae (see Section 7.6.1)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. It is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospi[INVESTIGATOR_26109] p rolongation of existing hospi[INVESTIGATOR_059]
Persistent or significant disability /incapacit y
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page74 30September 2016A congenital anomal y/birth defect
A medically important eventor reaction: such events may  not be immediately  
life-threatening or result in death or hospi[INVESTIGATOR_506441]. Medical and 
scientific judgment mustbe exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of m edically important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a m edically i
mportant e vent and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1and 7.1.2. If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, dec reased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5. 
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity , and for final review and confirmation of accuracy  of event
information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsib le for assessing t he relationship to IMP
therapy using clinical judgment and the following considerations:
No:Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by [CONTACT_10853].
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page75 30September 2016It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed usi ng the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures, (eg.,venipuncture)
7.2.2. Assessment of Severity
Severity of adverse events is to be determined based on GSI Grading Scale for Severit y of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4). A distinction should be drawn 
between seriousness and severit y of AEs. An AE that is assessed as Grade 4 (potentially  
life-threatening) should not be confused with an SAE. Severit y is a category utilized for rating 
the intensity  of an event: both AEs and SAEs can be assessed as Grade4. An event is defined as 
“serious” when it meets one of the predefined outcomes described above in Section7.1.2.
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009]
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, th e following t ypes of events 
should be reported on the case report form (CRF/eCRF): all SAEs and adverse events related to 
protocol-mandated procedures.
Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or relatio nship, 
until 30-daysafter last administration of study  IMP must be reported to the CRF/eCRF database 
as instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
[COMPANY_009] Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol -required post treatment follow-up period, must be reported to the 
CRF/eCRF database and [COMPANY_009] Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653430] dose of study  IMP, regardless of causalit y, should also be reported. 
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period; 
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly  document and report 
the event to [COMPANY_009] DSPH.
All AEs and SAEs will be recorded in the CRF/eCRF database within the timelines outlined 
in the CRF/eCRF completion guideline .
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of the even t. 
Detailed instructions can be found in the eCRF completion guidelines.
If for any reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record t he SAE on the paper serious adv erse event reporting 
form and submit within 24 hours to:
[COMPANY_009] DSPH: Fax: 
Email: 
Medical Monitor:
Phone:
Fax:
Email:
As soon as it is possible to do so, any  SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
For fatal or life -
threatening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are alsoto be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject iden
tification, 
maintaining the traceability of a document to the subject identifiers.
Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
form.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page77 30September [ZIP_CODE].4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulation s, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, [COMPANY_009] may  berequired to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs) ,or 
suspected 
unexpected serious adverse reactions (S[LOCATION_003]Rs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), [COMPANY_009] or a specified designee will notify  worldwide regulatory  
agenciesand the relevant IECin concerned Member States of applicable S[LOCATION_003]Rs as outlined in 
current regulations.
Assessment of e xpectedness forSAEs will be determined by  [CONTACT_10855] i nvestigator’s brochure or relevant local label as applicable. 
All investigators will receive a safety letter notifying them of relevant S[LOCATION_003]R reports associated 
with any study IMP. The investigator should notify  the IRB or IEC of S[LOCATION_003]R reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.5. Toxicity Management
All clinical and clinically significant laboratory toxicities will be managed according to 
uniform guidelines detailed in Appendix 3.
Grade [ADDRESS_653431] discontinuation, unless such a delay  is not consistent with good medical practice.
Clinical events and clinically significant laboratory  abnormalities will be graded according to 
the Table for GSI Grading Scale for Severity  of Adverse Events and Laboratory  
Abnormalities ( Appendix 4)
.
When restarting investigational medicinal product following resolution of the adverse event, 
the investigatio nal medicinal product should be restarted at full dose or modified dose that is 
dependent upon discussion with the [COMPANY_009] Sciences Medical Monitor .
Any recurrence of the investigational medicinal product-related Grade
[ADDRESS_653432] .
Administration of study  drug may  be discontinued due to a clinical or laboratory  event. The 
[COMPANY_009] Medical Monitor should be c onsulted prior to dose discontinuation of study  drug 
unless the investigator believes that immediate action is warranted to ensure the continued 
safety of subject .
Any questions regarding toxicity  management should be directed to the [COMPANY_009] Sciences 
Medical Monitor .
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page78 30September [ZIP_CODE].5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue investigational medicinal product at the discretion of the investigator.
7.5.2. Grade 3 Laboratory Abnormality or Clinical Event
For Grade [ADDRESS_653433].
For a Grade [ADDRESS_653434] should be withheld until the toxicity  returns to ≤Grade2.
If a laboratory  abnormality  recurs to ≥ Grade3 following rechallenge with investigation al 
medicinal product and is considered related to investigational medicinal product, then 
investigational medicinal product should be permanently  discontinued and the subject 
managed according to local practice. Recurrence of laboratory  abnormalities consi dered 
unrelated to investigational medicinal product may not require permanent discontinuation.
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event
For a Grade [ADDRESS_653435]. A clinically  significant Grade 4 laboratory  abnormalit y that is not confirmed b y 
repeat testing should be managed according to the algorithm for the new toxicity  grade.
Investigational medicinal product may  be continued without dose interruption for a clinically  
non-significant Grade 4 laboratory  abnormality  (e.g., Grade 4 CK after strenuous exercise, or 
triglyceride elevation that is non -fasting or that can be medicall y managed) or a clinical event 
considered unrelated to investigational medicinal product.
7.5.4. Management of Bone Evaluation
As there is uncertainty surrounding the clinical significance and management of decreases in 
bone mineral densit y for chronic HBV -infected patients, [COMPANY_009] recommends that any  subject 
who has a DXA scan that demonstrates a decrease from baseline of > 5% in bone mineral densit y 
of the spi[INVESTIGATOR_506442].
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653436] -Treatment Exacerbation of Hepatitis 
Management
On-Treatment ALT Flare is defined as:
Confirmed (within 3 days of receipt of initial laboratory  results) serum ALT > 2 ×baseline 
value and >10 ×ULN, with or without ass ociated sy mptoms
[IP_ADDRESS]. Management of ALT Flare in Subjects Receiving Study  Medication
If laboratory  results indicate elevation of ALT >2 ×baseline and >10 × ULN, the following is 
recommended:
Schedule the subject to return to the clinic as soon as possible (i deally within 3 days after 
initial laboratory  results were drawn). During the visit, a clinical assessment of the subject 
will be performed. The assessment should include a physical examination and evaluation of 
the subject’s mental status. 
Check the following laboratory  parameters: serum AL T and AST, total bilirubin, I NR, and 
serum albumin.
If the ALT elevation is confirmed, the central clinical laboratory  will conduct reflex testing 
for plasma HBV DNA, serology for HBV (HBsAg and HBsAb), HDV, HAV IgM , HCV, and 
HEV.
Based on the results of the confirmatory  tests, the following treatment modifications are 
recommended:
Elevated Liver Enzymes, Normal or Stable relative to baseline Liver Function Tests
If ALT levels are elevated (i.e., >2 ×baseline and >10 × ULN) with normal or stable total 
bilirubin and I NR relative to baseline, the subject may  remain on study  medication and should be 
monitored weekl y as long as ALT levels return to normal or baseline level. 
During monitoring, if the AL T values remain persistently  elevated, the investigator should 
discuss with the [COMPANY_009] Medical Monitor whether the study drug should be discontinued.
For subjects with bridging fibrosis or cirrhosis, study  drug discontinuation with treatment -free 
follow-up is to be avoide d due to the potential risk of exacerbation of hepatitis in the setting of low 
hepatic reserve which could lead to decompensation. Subjects with bridging fibrosis or cirrhosis 
should be placed on commerciall y available HBV therapy  following study  drug disc ontinuation.
Elevated Liver Enzymes, Elevated Liver Function Tests
If ALT values are elevated (i.e.,>2 ×baseline and >10 × ULN), and total bilirubin is confirmed 
to be 2 × baseline value, and INR is 0.5 above baseline, provided both are > ULN, the 
investigator should consider discontinuing stud y medication (upon discussion with the 
[COMPANY_009]Medical Monitor, unless the safet y of the subject is of immediate concern). 
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653437] should be monitored weekl y as long as ALT, total bilirubin, and INR values remain 
elevated or above baseline values.
During monitoring, if the AL T values and the liver function tests remain persistently  elevated, 
the investigator should discuss with the [COMPANY_009] Medical Monitor whether the study  drug should 
be discontinued.
For subjec ts with bridging fibrosis or cirrhosis, study  drug discontinuation with treatment -free 
follow-up is to be avoided due to the potential risk of exacerbation of hepatitis in the setting of 
low hepatic reserve which could lead to decompensation. Subjects with bridging fibrosis or 
cirrhosis should be placed on commerciall y available HBV therap y following stud y drug 
discontinuation.
[IP_ADDRESS]. Management of Exacerbation of Hepatitis in Subjects Who Have Discontinued 
Study Medication
If laboratory  results indicate (1) an ALT elevation >2 ×baseline and>10 × ULN alone OR 
associated with (2) abnormal laboratory  parameters suggestive of worsening hepatic function 
(total bilirubin 2 × baseline, INR 0.5 above baseline, provided both are > ULN) and the subject is 
on no post -study therapy for HBV, the following is recommended:
Schedule the subject to return to the clinic as soon as possible (ideall y no later than 3 days 
after the initial laboratory values were drawn). During the visit, perform a clinical assessment 
of the subject . 
Check the following laboratory  parameters: serum AL T and AST, total bilirubin, I NR, and 
albumin.
If the ALT elevation is confirmed, the central clinical laboratory  will conduct reflex testing 
for plasma HBV DNA, serology  for HBV (HBsAg and HBsAb), HDV, HAV IgM, HCV and 
HEV. If Plasma HBV DNA is increasing, the investigator should consider immediate 
initiation of approved therap y. 
The subject should be followed until laboratory  parameters (ALT, total bilirubin, I NR) return 
to normal or baseline up to a m aximum of [ADDRESS_653438] dose 
of TAF (12-18mg/kg) had minimal mononuclear cell infiltration in the posterior uvea, 
considered secondary  to general debilitation; this finding did not occur in animals given lower 
doses and it has not occurred in other animal studies. In the TAF HIV program, there is one 
report of SAEs of Grade [ADDRESS_653439] from Uganda in Study  GS-US-292-0106. Onset of both events was Day  14 and 
both were considered related to study  drug (E/C/F/TAF) by  [CONTACT_093]. The SAE of 
autoimmune uveitis resolved on Day  166, and the visual impairment was ongoing at Day  418 of 
study drug treatment.
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653440] the [COMPANY_009] 
MedicalMonitor to discuss the need for additional ophthalmologic evaluat ion including dilated 
fundoscop y and optical coherence tomograph y (OCT).
7.5.7. Management of Potential Nephrotoxicity
Creatinine clearance (CL Cr), estimated according to the Cockcroft -Gault formula, will be 
followed post -baseline during the stud y. All subjects w ith estimated CL Cr < 50mL/min must 
have serum creatinine measured again within 3 calendar day s of receipt of results. At the time of 
this repeat serum creatinine assessment, serum Cystatin C will also be measured and the 
estimated glomerular filtration ra te (eGFR) b y CKD-EPI (cystatin C) will be calculated and 
compared with the baseline measurement of this parameter. During the double -blind period, an y 
subject who 
has a confirmed CL Crestimated b y the Cockroft -Gault formula < 50 mL /min and 
also experiences a > 20% reduction in eGFR by  [CONTACT_9289]-EPI (cystatin C) from baseline, will be 
managed as described below:
CKD-EPI (cystatin C) formula adjusted for age and sex :
eGFR (mL/min/1.73m2) = 133 × min(Scy s/0.8, 1)−0.499× max (Scy s/0.8, 1)−1.328×
0.996Age[× 0.932 if female],
where Scy s is serum cy statin C (mg/L), min (Scy s/0.8,1) indicates the minimum of Scys/0.8 or 1, 
and max (Scy s/0.8,1) indicates the maximum of Scy s/0.8 or 1.
During the double -blind period, subjects meeting the above eGFR criteria (i.e. confirme d CLCr
<50 mL/min by [CONTACT_3158]- Gault equation and > 20% reducti on from baseline in eGFR by  
[CONTACT_9289]-EPI [INVESTIGATOR_10908]) will be managed as follows:
If the CL Cr is confirmed to be ≥ 30 mL/min and < 50mL/min, the subject will be required to 
undergo dose modification to every other day  dosing of stud y drug.
If the CL Cris confirmed ≥ 30 mL/min to < 50 mL/min and the subject has undergone dose 
modification to every  other day  dosing of study  drugandsubsequentl y develops a confirmed 
CLCr≥ 50mL/min, the subject may  revert to once daily  dosing of study  drug after discussion 
with the [COMPANY_009] Medical Monitor.
If the CL Cris confirmed to be < 30mL/min, the subject will be required to permanentl y 
discontinue study  drug.
During the open- label TAF 25 mg extension period, su
bjects who meet the above eGFR criteria 
(i.e. confirmed CL Cr≥ 30 mL/min to < 50 mL/min and > 20% reduction from baseline in eGFR 
by [CONTACT_9289]-EPI [INVESTIGATOR_10908]) are not required to undergo dose modification to every  other day  dosing 
of study drug, and subjects with confirmed CL Cr<30 mL/min are not required to permanently  
discontinue study  drug.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page82 30September 2016All subjects with negative or trace proteinuria at baseline that develop ≥ 1+ proteinuria on 
urinalysis are recommended to have a urinal ysis repeated, with a concurrent urin alysis and urine 
chemistry , within two weeks of receipt of results. Upon confirmation of new proteinuria, subjects 
will be asked to return to the clinic for a scheduled or unscheduled follow up visit for evaluation.
It is recommended that the Investigator contact [CONTACT_506485] a nephrologist is clinically  warranted .
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse , overdose, reports of 
adverse events associated with product complaints, occupational exposure with an AE, pregnancy  
reports regardless of an associated AE and AE in an infant following exposure from breastfeeding.
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a qu antity of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug a ccountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
Occupational exposure with an AE is defined as exp osure to a medicinal product as a result of 
one’s professional or non -professional occupation.
7.6.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study medication and throughout the study , including the post study drug follow -up 
period, to the [COMPANY_009] DSPH using the pregnancy  report form within 24 hours of becoming aware 
of the pregnancy .
Refer to S ection7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of pregnancy reporting.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page83 30September 2016The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pr egnancy (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within [ADDRESS_653441] in formation is as follows: 
Email:  and Fax: 
Pregnancies of female partners of male stud y subjects exposed to [COMPANY_009] or other study  drugs 
must also be reported and relevant informat ion should be submitted to [COMPANY_009] DSPH using the 
pregnancy  and pregnancy  outcome forms within [ADDRESS_653442] should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the outcome should be reported directl y to [COMPANY_009] DSPH, fax number 
 or email 
Refer to 
Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
[IP_ADDRESS]. Reporting Othe r Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] DSPHwithin [ADDRESS_653443] of situations that involve study  IMPand/or [COMPANY_009] concomitant 
medications, but do not apply to non-[COMPANY_009] concomitant medications. 
Special situations involving non-[COMPANY_009] 
concomitant medications doesnot need to be reported on 
the special situat
ions report form; however, f or special situations that result in AEs due to a 
non-[COMPANY_009] concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by  [CONTACT_10857] “misuse,” but may  be moreappropriately  documented as a protocol deviation.
Refer to S ection 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page84 30September [ZIP_CODE]. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary objectives of this study  are as follows:
To evaluate the efficacy  of switching to tenofovir alafenamide (TAF)25 mg QD versus 
continued tenofovir disoproxil fumarate ( TDF)300 mg QD in virologically  suppressed 
subjects with chronic HBV as determined b y the proportio n of subjects with HBV DNA 
≥ 20IU/mL (as defined by  [CONTACT_506455] -defined snapshot algorithm) at Week 24
To compare the safety  and tolerability  ofswitching TAF25 mg QD versus continuingTDF 
300 mg QD in virologically  suppressed subjects with chronic HBV at Week 24
The key secondary  objectives of this study  are as follows: 
To compare the safety  ofswitching to TAF 25 mg QD versus continued TDF 300 mg QD as 
determined b y the percent change from baseline in hip and spi[INVESTIGATOR_506414] e mineral density  
(BMD) at Week 24
To compare the safety  of switching to TAF 25 mg QD versus continued TDF 300 mg QD as 
determined b y the change from baseline in estimated creatinine clearance by [CONTACT_3158] -Gault 
method(eGFRCG) at Week24
Other secondary  objectives of this study  are as follows: 
To compare the safety  of switching to TAF 25 mg QD versus continued TDF 300 mg QD as 
determined b y the percent change from baseline in hip and spi[INVESTIGATOR_1928]  
(BMD) at Weeks 48 and 96
To compare the safety  of switching to TAF 25 mg QD versus continued TDF 300 mg QD as 
determined b y the change from baseline in estimated creatinine clearance by [CONTACT_3158] -Gault 
method(eGFRCG) at Week s 48and 96
To compare the safety  and tolerability  of switching to TAF 25 mg QD versus continued TDF 
300 mg QD in virologically  suppressed subjects with chronic hepatitis B at Week 48
To evaluate the efficacy  of switching to TAF 25 mg QD versus continued TDF300 mg QD 
as determined b y the proportion of sub
jects with HBV DNA ≥ 20 IU/mL (as defined b y the 
modified US FDA -defined snapshot algorithm) at Weeks 48and 96
To compare the serological response (loss of HBsAg and seroconversion to anti -HBs, and 
loss of HBeAg and seroconversion to anti -HBe in HBeAg -positive subjects) of switching to 
TAF 25 mg QD versus continued TDF 300 mg QD at Week s 24, 48,and 96
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page85 30September 2016To compare biochemical response (normal ALT and normalized AL T)of switching to TAF 
25 mg QD versus continued TDF 300 mg QD at Weeks 24, 48,and 96
To compare the change in fibrosis as assessed b y FibroTest®for switching to TAF 25 mg QD
versuscontinued TDF 300 mg QD at Weeks
48and 96
To evaluate the comparative open -label efficacy  and safet y of switching to TAF 25 mg QD 
from Week 48 through Week 96 insubjectsinitially randomized to TAF 25 mg QD and in 
subjectssequentially  treated with continued TDF 300 mg QD for 48 weeks and then switched 
to open-label TAF 25 mg QD
To evaluate the proportion of patients with HBV DNA <20 IU/mL and target detected/not 
detected(i.e. <LLOD)at Weeks 24, 48,and96
The exploratory  objectives of this study  are as follows:
 
 
8.1.2. Primary Endpoint
The primary  efficacy endpoint is the proportion of subjects with HBV DNA ≥20 IU/mL
(asdetermined b y the modified US FDA -defined snapshot algorithm) at Week 24.
8.1.3. Secondary Endpoint
The secondary efficacy endpoints are:
The proportion of subjects with HBV DNA ≥ 20 IU/mL (as determined b y the 
modified 
USFDA-defined snapshot algorithm) at Week s48 and 96
The proportion of subjects with HBV DNA < 20 IU/mL and target detected/not detected
(i.e.<LLOD) at Weeks 24, 48 and 96 ,as determined by  [CONTACT_506486] -defined 
snapshotalgorithm
The proportion of subjects with HBeAg loss and proportion with seroconversion to anti- HBe 
at Weeks 24, 48, and 96
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page86 30September 2016The proportion of subjects with HBsAg loss and proportion with seroconversion to anti -HBs 
at Weeks 24, 48, and 96
The proportion of subjects with normal AL T and proportion with normalized AL T 
(by[CONTACT_506487]) at Weeks 24, 48, and 96
The change from baseline in fibrosis as assessed by  [CONTACT_291147]®at Weeks 48 and 
96
The key secondary  safetyendpointsare:
The percent change from baseline in hip bon e mineral densit y (BMD) at Week 24 
The percent change from baseline in spi[INVESTIGATOR_506443] y (BMD) at Week 24
The change from baseline in eGFRCG(measured by  [CONTACT_3158] -Gault method) at Week 24
The secondary  safety endpoints are:
The percent change from baseline in hip bon e mineral densit y (BMD) at Week s48 and 96
The percent change from baseline in spi[INVESTIGATOR_506444]
e mineral density (BMD) at Week s48 and 96
The change from baseline in eGFRCG(measured by  [CONTACT_3158] -Gault method) at 
Weeks
48and96
8.1.4. Other Endpoints of Interest
The change from baseline in serum markers of bone turnover at Weeks 24, 48, and 96
The change from basel ine in urine markers of renal tubular dy sfunction at 
Weeks24, 48,and96
The effect of treatment 
on health related to quality of life (via SF -36, CLDQ and WPAI  
questionnaires) at Weeks 24, 48 and 96
8.2. Analysis Conventions
8.2.1. Analysis Sets
[IP_ADDRESS]. Randomized Analy sis Set
The randomized Anal ysis Set includes all subjects who were randomized into the study . This is 
the primary  analysis set for by -subject listings.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page87 30September [ZIP_CODE].2.1.2. Efficacy
The primary  analysis set for efficacy  analysis the Full Anal ysis Set (FAS), defined as all
randomiz ed subjects who receive at least one dose of study  drug. Subjects will be analy zed
according to the randomized treatment assignment.
[IP_ADDRESS]. Safety
The primary  analysis set for safety anal yses is the Safety  Analysis Set (SAS), defined as all
randomized subjects wh o receive at least one dose of study  drug. Subjects will be analy zed
according to the treatment actually  received. All data collected during treatment will be included 
in the safet y summaries. Data collected during treatment free follow up will be summariz ed or 
listed separatel y.
[IP_ADDRESS]. Biomarkers
The Biomarker anal ysis set will include all subjects who have evaluable biomarkers data.
[IP_ADDRESS]. DEXA
[IP_ADDRESS].1. Hip DXA Anal ysis Set
The Hip DXA Analysis Set includes all subjects who were randomized and had received at least
1dose of st udy drug, and had nonmissing baseline hip BMD values. Subjects will be analy zed 
according to the treatment they  actually received.
[IP_ADDRESS].2. Spi[INVESTIGATOR_506445] 1doseof study drug,and had nonmissing baseline spi[INVESTIGATOR_506446]. Subjects will be 
analyzed according to the treatment they  actually received.
8.3. Data Handling Conventions
For key secondary  safety endpoints, an anal ysis will be performed using the last observation 
carried forward (LOCF) method to impute missing data.
For other categorical secondary  efficacy endpoints, missing data will be handled using a 
missing= failure approach except for the endpoints of H BV DNA ≥ 20 IU/mL  and HBV DNA 
<20 IU/mL.
For the remai ning endpoints, values for missing data will not be imputed, unless specified 
otherwise.
8.4. Multiplicity Adjustments
To control ty pe I error for the assessment of the primary  efficacy endpoint and key secondary  
safety endpoints, the h ypothesis testing will beperformed in a sequential order. The primary  
hypothesis of non- inferiority  ofTAF [ADDRESS_653444] to the 
proportion of subjects with HBV DNA ≥ 20 IU/mL 
(as defined by[CONTACT_506455] -defined 
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page88 30September 2016snapshotalgorithm) at Week [ADDRESS_653445] will be performed 
using a two -sided, 0.05 alpha level. If non-inferiority  is established, then multiplicity  adjustments 
will be performed for the following endpoints using a fallback procedure {Wiens et al 2005} in 
the sequential order given below with a pre-specified two- sidedalpha level :
a)Percentage change from baseline in Hip BMD at Week 24 (alpha =0.02)
b)Percentage change from baseline in Spi[INVESTIGATOR_110075] 24 (alpha =0.01)
c)Change from baseline in Creatinine clearance (eGFR CG) at Week 24 (alpha =0.02)
d)Superiority  testfor proportion of subjects with HBV DNA ≥ 20 IU/mL at Week 24 
(alpha=0.00)

Tenofovir Alafenamide (TAF), GS -[ADDRESS_653446] descriptive 
methods by  [CONTACT_6654].
Demographic summaries will include sex, race/ethnicity , geographical region, randomization 
stratification group , 
and age.
Baseline data will include a summary  ofbody weight, height, body  mass index, HBV DNA 
level, years positive for HBV, ALT level ( ≤ ULN,> ULN), previous TDF use and other oral 
nucleoside/nucleotide treatment experience, previous interferon experience, and HBV genot ype 
by [CONTACT_969].
8.6. Efficacy Analysis
8.6.1. Primary Analysis
The primary  analysis will be performed when the last subject has completed Week [ADDRESS_653447] to the proportion of subjects with HBV
DNA ≥ 20IU/mL at Week 24 (as defined b y the modified FDA snapshot Algorithm ).It will be 
concluded that TAF is not inferior to the TDF if the u
pper bound of the two- sided 
95%confidence interval of the difference between treatment arms (TAF arm – TDF arm) in the 
response rate is less than 6% (i.e., a margin of 6
% is applied to non- inferiority  assessment). The 
95%confidence interval will be constructed using the normal approximation method based on 
stratified Mantel
-Haenszel proportions, where stratification factors are HBeAg status 
(HBeAgpositive or negative) a nd age (≥50 or <50 years).
[IP_ADDRESS]. Modified US FDA -Defined Snapshot Alogrithm
The US FDA -definedsnapshot algorithm, developed for HIV- 1 clinical trials, has been modified 
for use in HBV {U. S. Department of Health and Human Services et al 2015 }using on-treatment 
HBV DNA value s of < 20 IU/mL  and≥20 IU/mL.
The analysis window at Week 24 is defined as from Study  Day 126to Study Day 209, inclusive.
AllHBV DNA data collected on -treatment will be used in the snapshot algo rithm. Virologic 
outcome will be defined as the following categories: 
HBV DNA < 20 IU/mL :this includes subjects who have the last available on- treatment 
HBVDNA< 20 IU/mL in the Week 24 analysis window
HBV DNA ≥20 IU/mL :this include ssubjectswho
1)
Have the last available on-treatment H BV DNA ≥ 20 IU/mL  in the Week 24 analysis 
window, or
2) Do not have on -treatment HBV DNA data available in the Week 24 analysis window and
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page90 30September 2016a)Discontinue study  drug prior to or in the Wee k 24analysis window due to lack of 
efficacy, or
b) Discontinue study drug prior to or in the Week [ADDRESS_653448] available on -treatment HBV DNA 
≥ 20IU/mL
No Virologic Data in the Week 24Analysis Window :this includes subjects who do not
have on-treatment HBV DNA dataavailable in the Week 24analysis window for any  
of the 
following reasons:
1)Discontinuation of study  drug prior to or with
in the Week 24analysis window due to 
reasons other than lack of efficacy  and the last available on -treatment HBV DNA value is 
<20copi[INVESTIGATOR_014]/mL, or
2)Missing data within the window but who areon study drugtreatment
8.6.2. Analyses of Secondary Endpoints
Continuous secondary  endpoints will be summarized using conventional descriptive statistics
(n,mean, standard deviation, median, Q1, Q3, minimum, and maximum) by [CONTACT_506488]. A Wilcoxon rank sum test may  be used to compare the treatment groups, in an
exploratory  manner.
Categorical secondary  endpoints will be summarized by  [CONTACT_422293]. A two -sided Mantel -Haenszel test, controlling for the randomization strata, 
may be used to compare the treatment groups, in an exploratory  manner. Missing data will be 
handled b y the missing = failure approach except for the endpoint s of 
HBVDNA ≥20 IU/mL
and HBV DNA < 20IU/mL.
8.7. Safety Analysis
All safety data collected on or after the date that IMP was first dispensed up to the date of last 
dose of IMP will be summarized by [CONTACT_1570] ( according to the IMP received) . Data for 
the pretreatment and treatment -free follow -up periods will be included in data listings.
8.7.1. Key Secondary Safety Analyses
The percent change from baseline in hip and spi[INVESTIGATOR_110085] [ADDRESS_653449]. The details are 
provided in the Statistical Analy sis Plan (SAP).
The change from baseline in in eGFRCGat Weeks [ADDRESS_653450] to compare the 2 treat ment groups. The details are provided in the SAP.
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653451]’s extent of exposure to IMPdata will be generated from the IMP administration data. 
Exposure data will be summarized by  [CONTACT_1570].
8.7.3. Adverse Events
Clinical and laboratory adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT),and Lower -Level Term (LLT) will be 
attached to the clinical d atabase.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event will be defined as an y adverse event that begins on or after the date of first dose of 
IMPup to the date of last dose of IMP. Continuing adverse events diagnosed prior to the start of 
treatment and worsening in severity  grade, or non- serious adverse events at baseline which 
become serious, or adverse events resulting in treatment discontinuation after the start of
treatment will also be co nsidered treatment -emergent. Summaries (number and perce ntage of 
subjects) of treatment -
emergent adverse events (b y SOCand PT) will be provided by  [CONTACT_6490]:
Treatment -emergent adverse events
Treatment -emergent study  drug-related adverse events
Grade 3 or 4 treatment -emergent adverse event
Grade 3 or 4 treatment -emergent study  drug-related adverse event
Grade 2, 3, or 4 treatment -emergent adverse event
Grade 2, 3, or 4 treatment -emergent stud y drug-related adverse event
AE that caused permanent disco ntinuation from study  drug
AE that caused change in dose or temporary  interruption of study  drug
Treatment -emergent serious adverse event
Treatment -emergent study  drug-related serious adverse event
8.7.4. Laboratory Evaluations
Selected laboratory  data (usingconventional units) will be summarized using onl y observed data. 
Data and change from baseline at all scheduled time points will be summarized.
Graded laboratory  abnormalities will be defined using the grading scheme in Appendix 4.
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653452]
dose of treatment will be summarized by  [CONTACT_1570]. If baseline data are missing, then an y
graded abnormality  (i.e., at least a Grade 1) will be considered treatment emergent .
Laboratory  abnormalities that occur before the first dose of IMPor after the subject has been 
discontinued from treatment will be included in a data lis ting.
8.8. Biomarker Analysis
Selected bone biomarkers, including C- type collagen sequence (CTX) and procollagen t ype 1
N-terminal propeptide (P1NP), and selected renal biomarkers, including urine retinol binding
protein, and urine beta -2-microglobulin, will be summarized by  [CONTACT_506489]. The difference in change from baseline in these biomarkers between 
two treatment arms will be tested using Wilcoxon rank sum test.
8.9. Sample Size
With respect to the primary  efficacy endpoint of proportion o
f suppressed subjects with 
HBVDNA ≥20 IU/mL (current assay  LLOQ), as determined b y the modified US FDA -defined 
snapshotalgorithm, at Week24, when the sample sizes are 150 (TAF 25 mg arm) and 150 
(TDF300 mg arm), a two -group, large -sample normal approximation test of proportions with a 
one
-sided 0.[ADDRESS_653453] 97% power to establish non- inferiority of TAF to 
TDF. It is assumed that both treatment arms will havesubjects who have HBV DNA ≥ 20 IU/mL 
(as defined b y the modified US FDA -defined snapshot algorithm) at a rate of 1.8% at Week 24 
(based on the rates of suppressed subjects having HBV DNA ≥ 29 IU/mL [the LLOQ of assay  
during those studies] after24 weeks of treatment from t he combined data of studies GS -US-174-
0102 and GS -US-174-0103 with the ratio of HBeAg-to HBeAg+ subjects assumed to be 2:1 ), 
with a non- inferiority margin of 6%.
The proposed sample size (n=150 for the TAF 25 mg arm, n = 150 for the TDF 300 mg arm) 
also provides > 99% power to detect a 1.21% difference in the percentage change from baseline 
in hip BMD at Week 24 (assuming a 0.99% [SD 2.09%] change from baseline in TAF 25 mg 
arm and −0.22% [SD 1.89%] change from baseline in the TDF 3 00 mg arm, with a two -sided 
α=0.05); a > 99%power to detect a 1.69% difference in the percentage change from baseline in 
spi[INVESTIGATOR_110075] 24 (assuming a 1.50% [SD 2.80%] change from baseline in the TAF 25 mg 
arm and −0.19% [SD 3.00%] change in the TDF 300 mg arm, wi th a two-sided α = 0.05); 
a68%power to detect a 3.6 mL /min difference in the change from baseline in eGFR CGat 
Week24 (assuming a + 1.6 mL/min [SD 13.0] change from baseline in the TAF 25 mg arm and 
−2.0 mL/min [SD 12.4] change from baseline in the TDF 300 mg arm, with a two
-sided 
α=0.05). These assum ptions were derived from an HIV switch study (GS-US-292-
0109)due to 
the unavailability  of switch data from TAF HBV studies.
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653454] enrolled completes 24 weeks of the study . However, 
[COMPANY_009] will defer to the DMC for an y decision to convene earlier or more frequentl y.At each
meeting, the DMC will review routine safet y and DXAdata and wi ll make recommendations 
regarding modification of the study treatment.
The DMC’s specific activities will be defined b y a mutually  agreed charter, which will define the 
DMC’s membership, conduct and meeting schedule.
While the DMC will be asked to advise G ilead regarding future conduct of the study , including 
possible earl y study termination, [COMPANY_009] retains final decision -making author ity on all aspects of 
the study treatment .
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page94 30September [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investi gator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki, International Conference on Harmonisation (ICH) guidelines, or with 
the laws and regulations of the country  in which the research is conducted, whichever affords the 
greater protection to the study  subject.These standards are consistent with the European Union 
Clinical Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR312, subpart D, “Responsibilities of Sponsors and Investigators,” 
[ADDRESS_653455] be provided prior to 
the investigator’s (and any  subinvestigator’s) par ticipation in the study . The investigator and 
subinvestigator agree to notify  [COMPANY_009] of an y change in reportable interests during the stud y and 
for [ADDRESS_653456] (IRB)/Independent Ethics Committee 
(IEC)/Ethics Committee (EC) Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC/EC . The investigator will not begin an y study subject activities 
until approval from the IRB/IEC/EC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
theIRB/IEC/EC any modifications made to the protocol or any  accompan ying material to be 
provided to the subject after initialapproval, with the exception of those necessary  to reduce 
immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed co nsent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y study-
related procedures. The 
investigator must use the most current IRB/IEC/E Capproved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653457]’s legally authorized representative and the person 
conducting the consent discussion, and also by  [CONTACT_279392]/IEC/EC. 
 
9.1.4. Confidential ity
The investigator must assure that subjects’ anon ymity will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identi fication cod ewill be recorded on an y 
form or biological sample submitted to the Sponsor, IRB/IEC/EC, or laboratory . Laboratory  
specimens must be labeled in such as way  as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to specific laboratory  instructions for further detail s. 
NOTE: The investigator must keep a screening log showing codes, names, and addresses for all 
subjects screened and for all subjects enrolled in the trial. Subject data will be processe d in 
accordance with all applicable regulations.
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator brochure, this protocol, CRF /eCRF, the IMP, and any other study information, 
remain the sole a nd exclusive propert y of [COMPANY_009] during the conduct of the study and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior writte n consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study  
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms,and 
governmental approval with correspondence, informed consent, drug records, staff curriculum 
vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documen tation that subject meets eligibility  criteria, ie, history , physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page96 30September 2016Participation in study (including study number);
Study discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality and severity);
Concomitant medication (including start and end dat e, dose if relevant; dose changes);
Date of study completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_653458] approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_653459] been received.Subsequent to data entry , a study monitor will perform source data 
verification within the EDC sy stem.Original entries as well as an y changes to data fields will be 
stored in the audit trail of the sy stem.Prior to database lock (or an y interim time points as 
described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have be en reviewed, and that the entries accuratel y reflect 
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653460] or updating the original entry, and providing the reason 
for the update (e.g. data entry  error).At the conclusion of the trial, [COMPANY_009] will provide the site 
with a read -only archive copy  of the data ent ered by [CONTACT_10867]. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
At the start of the stud y, the study monitor will evaluate the study center’s study  drug disposal
procedures and provide appropriate instruction for return or destruction of unused study  drug
supplies. I f the site has an appropriate Standard Operating Procedure (SOP) for drug destruction,
the site may  destroy used and unused study  drug supplies performed in accordance with the site’s 
(hospi[INVESTIGATOR_307]/pharmacy ) SOP. If the site does not have acceptable procedures in place for
drugdestruction, arrangements will be made between the site and [COMPANY_009] Sciences
(or[COMPANY_009]Sciences’ r epresentative) for return of unused study  drug supplies. A copy  of the site’s
SOP will be obtained for central files. Where possible, study  drug will be destroy ed at the site.
Upon study  completion, a copy  of the Investigational Drug Accountability records must be filed
at the site. Another cop y will be returned to [COMPANY_009] Sciences. If drug is destroy ed on site, the
investigator must maintain accurate records for all study  drug kits and/or bottles destroy ed.
Records must show the identification and quantity of each unit destro yed, the method of
destruction, and person who disposed of the drug. All study  drug records must be maintained at
the site and copi[INVESTIGATOR_422250] .The study 
monitor will review IMP supplie s and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]’s appointed stud y monitors , toIRB/IEC/EC , or to regulatory  authority  or health authority 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by [CONTACT_10866]. The investigator must submit a ll protocol modifications to the IRB/IEC/EC
in accordance with local requirements and receive documented approval from all necessary  
bodies bef ore modifications can be implemented.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page98 30September [ZIP_CODE].2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency (ies). [COMPANY_009] 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investigators in this study  may communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed by [CONTACT_337370], manuscript, or presentation form or the stud y has been completed at 
all study sites for at least 2 years.
The investigator will submit to [COMPANY_009] any  proposed publication or presentation along with 
the respective scientific journal or presentation forum at least 30 day s before submission of 
the publication or presentation. 
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.4).
The investigator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide s ervices performed under this 
protocol, e.g. attendance at I nvestigator's Meetings. If required under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including any  clinical trial pay ments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy of the data recorded in the 
CRF/eCRF.
The monitor is responsible for routine review of the CRF /eCRFat regular intervals throu ghout 
the study to verify adherence to the protocol and the completeness, consistency , and accuracy  of 
the data being entered on them. The monitor should have access to an y subject records needed to 
verify the entries on the CRF /eCRF. The investigator agre es to cooperate with the monitor to 
ensure that an y problems detected through any  type ofmonitoring (central, on site) are resolved.
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653461] of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessar y, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory  authority(ies), IRBs, and IECs. In terminating the study , [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the su bjects’ interests.
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653462] E, Ry der SD, et al. Twenty -eight day safety, 
antiviral activity , and pharmacokinetics of tenofovir alafenamide for treatment of 
chronic hepatitis B infection. J Hepatol 2015;62 (3):533 -40.
Babusis D, Phan TK, Lee WA, Watkins WJ, Ray  AS. Mechanism for Effective Ly mphoid Cell 
and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS -
7340. Mol Pharm 2013;10 (2):459-66.
Buti M, Gane E, Seto WK, Chan HLY, Chuang WL , Stepanova T, et al. Tenofovir alafenamide 
versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg -
negative chronic hepatitis B virus infection: a randomised, double -blind, phase 3, 
non-inferiority trial. Lancet 2016.
Centers for Disease Control (CDC), Division of Viral Hepatitis. Viral Hepatitis Surveillance 
[LOCATION_002], 2013.  2013.
Chan HLY, Fung S, Seto WK, Chuang WL , Chen CY, Kim HJ, et al. Tenofovir alafenamide 
versus tenofovir disoproxil fumarate for the treatme nt of HBeAg -positive chronic 
hepatitis B virus infection: a randomised, double -blind, phase 3, non -inferiority  
trial. Lancet 2016.
European Association for the Study  of the Liver (EASL ). EASL Clinical Practice Guidelines: 
Management of chronic hepatitis B virus infection [published version]. J 
Hepatology  2012;57:167-
85.
Fattovich G, Bortolotti F, Donato F. Natural history  of chronic hepatitis B: special emphasis on 
disease progression and prognostic factors. J Hepatol 2008;48 (2):[ADDRESS_653463] 1997;105 (1):18 -20.
G. B. D. Mortality  Causes of Death Collaborators. Global, regional, and national age -sex specific 
all-cause and cause -specific mortality  for 240 causes of death, 1990 -2013: a 
systematic anal ysis for the Global Burden of Disease Study  2013. Lancet 
2015;385 (9963):117-71.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, 
Moradi-Lakeh M, et al. The Global Burden of Canc er 2013. JAMA oncology  
2015;1 (4):505 -27.
Kitrinos KM, Corsa A, Liu Y, Flaherty  J, Snow-Lampart A, Marcellin P, et al. No detectable 
resistance to tenofovir disoproxil fumarate after 6 years of therap y in patients with 
chronic hepatitis B. Hepatology  2014;59 (2):434- 42.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page101 30September 2016Liaw Y-F, Kao J-H, Pi[INVESTIGATOR_96470] T, Chan HL Y, Chien R -N, Liu C-J, et al. Asian- Pacific 
consensus statement on the management of chronic hepatitis B: a 2012 update. 
Hepatol International 2012;6:531-61.
Lok AS, McMahon BJ. AASLD Practice Guideli ne Update: Chronic hepatitis B: update 2009. 
Hepatology  2009;50 (3):661-2.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I M, et al. Regression of cirrhosis 
during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5 -
year open-label follow -up study. Lancet 2013;381 (9865):468-75.
Mills A, Arribas JR, Andrade -Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching 
from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral 
regimens for virologicall y suppressed adults with HIV -1 infection: a randomised, 
active-controlled, multicentre, open- label, phase 3, non- inferiority study. Lancet 
Infect Dis 2016;16 (1):43-52.
Murakami E, Wang T, Park Y, Hao J, L epi[INVESTIGATOR_132277], Babusis D, et al. I mplications of Efficie nt 
Hepatic Delivery  by [CONTACT_506490] (GS -7340) for Hepatitis B Virus 
Therapy [Accepted Manuscript]. Antimicrob Agents Chemother 2015;59 
(6):3563-
9.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epi[INVESTIGATOR_142058] B virus infection: 
new estimates of age -specific HBsAg seroprevalence and endemicit y. Vaccine 
2012;30 (12):2212 -9.
Robbins BL , Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti -human immunodeficiency  
virus activity  and cellular metabolism of a potential prodrug of the acy clic
nucleoside phosphonate 9- R-(2-phosphonomethoxy propyl)adenine (PMPA), 
Bis(isoprop yloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother 1998;42 
(3):612-7.
Ruane PJ, Dejesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral 
Activity, Safety, and Pharmacokinetics/Pharmacody namics of Tenofovir 
Alafenamide as [ADDRESS_653464] 2013;63 (4):449-55.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian -Pacific clinical practice 
guidelines on the management of hepatitis B: a [ADDRESS_653465] F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus 
tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and 
emtricitabine, for initial treatment of HIV -1 infection: two randomised, double -
blind, phase 3, non -inferiority  trials. Lancet 2015;385:2606 -15.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page102 30September 2016Schweitzer A, Horn J, Mikolajczy k RT, Krause G, Ott JJ. Estimations of worldwide prevalence 
of chronic hepatitis B virus inf ection: a sy stematic review of data published 
between 1965 and 2013. Lancet 2015;386:1546- 55.
Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, L acaille F, et al. Management of chronic 
hepatitis B in childhood: ESPGHAN clinical practice guidelines: consens us of an 
expert panel on behalf of the European Society  of Pediatric Gastroenterology , 
Hepatology  and Nutrition. J Hepatol 2013;59 (4):814 -29.
Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. L ong-term 
monitoring shows hepatitis B virus resistance to entecavir in nucleoside -naive 
patients is rare through 5 years of therap y. Hepatology  2009;49 (5):1503 -14.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASL D guidelines 
for treatment of chronic hepatitis B. Hepatology 2015.
U. S. Department of Health and Human Services, Food and Drug Administration (FDA), Center 
for Drug Evaluation and Research (CDER). Human I mmunodeficiency  Virus-1 
Infection: Developi[INVESTIGATOR_184804]. Guidance for Industry. 
Revision 1. November 2015.
Wiens BL , Dmitrienko A. The fallback procedure for evaluating a single family  of hypotheses. J 
Biopharm Stat 2005;15 (6):929-42.
World Health Organization (WHO). Guidelines for the Prevention, Care and Treatment of 
Persons with Chronic Hepatitis B I nfection. 2015a.
World Health Organization (WHO). Hepatitis B. Introduction. Available at: 
http://www.who.int/csr/disease/hepatitis/whocdscsrly o20022/en/index1.html. 
Accessed: [ADDRESS_653466] 2015b.
Wright TL . Introduction to chronic hepatitis B in fection. Am J Gastroenterol 2006;101:6.
Zuckerman AJ. Progress towards the comprehensive control of hepatitis B. Gut 1996;38 (2):S1.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page103 30September 201611. APPENDICES
Appendix 1.Investigator Signature [CONTACT_10882] 2.Study Procedures Table
Appendix 3.Management of Clinical and Laboratory Adverse Events
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]Tenofovir Alafenamide (T AF), GS-[ADDRESS_653467] 
FOSTER CITY, CA [ZIP_CODE] 
STUDY ACKNOWLEDGEMENT Final 
Original 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching 
from Tenofovir Disoproxi l Fumarate (TDF) 300 rng QD to Tenofovir Alafenarnide (T AF) 25mg 
QD in Subjects with Chronic Hepatitis B who arc Virologically Suppressed 
GS-US-320-4018, Original, [ADDRESS_653468] this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copi[INVESTIGATOR_506447], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) Signature 
[CONTACT_506495] 104 30 September 2016 
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page105 30 September 2016Appendix 2. Study Procedures Table
Study ProceduresScreening
(45 days)Baseline
(Day 1)Blinded(±3 days) Open Label (±7 days)
FollowUphWeek
4 812 24k36 48k60 72 96 EDg
Informed Consent x
Inclusion/Exclusion Criteria x x
Medical History (including HBV disease and treatment history ) x x
Concomitant Medications x x x x x x x x x x x x x
Adverse Events x x x x x x x x x x x x x
Complete PhysicalExamination withweightandvitalsigns x x x x x x x
Height x
Body Weight x x x x x x x x x x x x x
Vital Signsax x x x x x x x x x x x x
Symptom driven Physical Examination x x x x x x
HealthRelatedQualityofLife(CLDQ,SF-36,WPAI)mx x x x x
Serum Chemistry and Liver Testsbx x x x x x x x x x x x x
Hematology x x x x x x x x x x x x x
Fasting metabolic panelcx x x x x x x x x
Pregnancy testing (womenofchild-bearingpotentialonly)serum urine (+ve test to be confirmed with serum)
x x x x x x x x x x x x
Estimated CreatinineClearance by[CONTACT_3158]-Ga ultmethod(eGFR CG) x x x x x x x x x x x x x
HBVserology(qualitative HBsAgandHBeAg)andquantitative HBsAgix x x x x x x x x x x
HCV, HDV, HIV Testing x
α-fetoprotein (AFP) x
Urinalysis x x x x x x x x x x x x x
Urine drug screen x
DXA scans (Hip & Spi[INVESTIGATOR_050] )dx x x x x x
ECGex x x x
Plasma HBV DNA levels x x x x x x x x x x x x x
Randomization x
Study Drug Accountability x x x x x x x x x
Study Drug Dispensation x x x x x x x x x
FibroTest®x x x x x
Serum Cystatin Clx
Fasting Blood for Bone Biomarkerfx x x x x x x x
Fasting Urine for Renal Biomarkerfx x x x x x x x
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page106 30 September 2016Study ProceduresScreening
(45 days)Baseline
(Day 1)Blinded(±3 days) Open Label (±7 days)
FollowUphWeek
4 812 24k36 48k60 72 96 EDg
Fracture Risk Assessment (FRAX) x
Virology (Sequence analysis of HBV pol/RT for resistance surveillanc e)jx x x x x x x x x x x
Vitamin D x
aVital signs include blood pressure, pulse, respi[INVESTIGATOR_506448]: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, 
calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testi ng is performed in subjects with tota l amylase > 1.5×ULN), 
and PTH. PTH analyzed at all visits except for Screening. At Baseline, Weeks 24, 48, 72, 96, and ED, analyses of glucose will be done as part of the fasting metabolic assessments and not 
as part of the chemistry panel. Liver function tests: PT/INR will be done at Screening and then as a reflex only test for ALT flares.
cFasting glucose and lipid pane l (total cholesterol, HDL, direct LDL, triglycerides). At Baseline, Weeks 12, 24, 36, 48, 60, 72, and 96/ED analyses of glucose will be done as part of the 
fasting metabolic assessments and not as part of the chemistry panel.
dThe Baseline DXA can be perf ormed at any time during the Screening period, but should be completed at least [ADDRESS_653469] dose of study drug . The Week 24 DXA window is −14 days only and the Week 48 DXA window is −
6weeksonly. DXA required for Early Discontinuation (ED) visit if not 
done within the last 12 weeksand shouldbe done within ±14days of the expected ED visit date
eSubjects must rest quietly in the supi[INVESTIGATOR_19636] a minimum of [ADDRESS_653470] sample was collected > 12weeks
gThe Early Discontinuation (ED) visit should be performed within [ADDRESS_653471] study drug dose (+ 3 days)
hSubjects who discontinue study drug due to HBsAg loss with confirmed seroconversion to anti -HBs on or after the Week 24 visit, will be followed off treatment every 4 weeks for 
12weeks and then per t he original study visit schedule through Week 96/ED. Subjects who have received at least one dose of study drug and permanent ly discontinue study drug for 
reasons other than HBsAg loss with confirmed seroconversion to anti- HBs will be followed every [ADDRESS_653472]. Initiation of appropriate, alternative HBV therapy is highly encouraged.
iHBeAb and HBsAb reflex testing will be performed as needed .
jResistance sequence analysis may be performed at BL for subjects with HBV DNA ≥69 IU/mL and may be attempted for viremic (HBV DNA ≥ 69 IU/mL) at Wks 24, 48, and 96/ED. 
As it may not be known at the time of the visit whether a subject is viremic or if it will b e their last study visit, a virology sample will be collected as each visit . In the event of 
unconfirmed virologic rebound (HBV DNA ≥ 20IU/mL), subjects will be asked to return to the clinic for a sched uled or unscheduled blood draw. For virologic rebound occurring 
within the first [ADDRESS_653473] will be re -counseled on adherence to study medication.
kThe visit window for Week 24 visit is -14 daysonly. The visit window for Week 48 visit is −6 weekso nly.
lSerum Cystatin C will be done when eGFRCGfalls < 50 ml/min during blinded period of study .
mHealth Related Quality of Life surveys required for Early Discontinuation (ED) visit if not done within the last 24 weeks of the expected ED visit date
[COMPANY_003]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page107 30 September 2016Appendix 3. Management of Clinical and Laboratory Adverse Events
Grade 1 Grade 4 Grade 3 Grade 2
May continue 
dosing at the 
discretion of the 
investigatorRepeat lab to 
confirm toxicity 
gradeRepeat lab to 
confirm toxicity 
grade
If confirm ed and possibly and/or probably related to 
investigational m edicinal products:
1.Withhold investigational m edicinal products until Grade [ADDRESS_653474] 
weekly until a return 
to baseline or is 
otherwise explained
If Grade 3 or 4 recurrence that is confirm ed and possibly or 
probably related to investigational m edicinal products, discontinue 
all investigational m edicinalproducts dosing permanentlyIf Grade 3 or 4 recurrence that is considered unrelated to 
investigational m edicinal products, continue all investigational 
medicinal products at the same dose at the discretion of the 
investigator
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page108 30 September 2016Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0to10.9g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0g/dL
100 to 120g/L9.0 to 10.0g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 
≥ 7 Months#1000to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00to 1.30GI/L 0.75to 1.00 GI/L 0.50to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page109 30 September 2016HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00GI/Lto 2.50GI/L 1.50to 2.00GI/L 1.00 to 1.50GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/dL 50mg/dL
1.00to2.00g/L 0.75to 1.00g/L 0.50 to 0.75g/L 0.50g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40mg/L 40 to 50mg/L 50 to 60mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized 
Ratio of prothrombin time 
(INR)1.[ADDRESS_653475] >1.[ADDRESS_653476] >2.[ADDRESS_653477] >3.[ADDRESS_653478]
Activated Partial
Thromboplastin Time 
(APTT)1.00to 1.66ULN 1.66to 2.33ULN 2.33to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0to15.0% 15.0to20.0% 20.0%
#An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric su bjects.Please follow the [COMPANY_009] convention of grading 
any result within the LLN and ULN a 0.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page110 30 September 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLNmEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to<LLNmmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to  <LLNmEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to<LLNmmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Infant<1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to3.0mEq/L                
2.5 to <3.0 mmolL2.0 to2.5mEq/L                 
2.0 t o <2.5 mmolL2.0 mEq/L                          
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant<1 Year >ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L7.0 mEq/L                   
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64mg/dL
3.03 to 3.58 mmol/L40 to55mg/dL
2.20 to3.03mmol/L30 to40mg/dL
1.64 to2.20mmol/L30 mg/dL
1.64 mmol/L
Infant,1Month 50 to 54mg/dL
2.8 to 3.0mmol/L40 to 50mg/dL
2.2 to 2.8mmol/L30 to 40mg/dL
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90to 27.79mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page111 30 September 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypocalcemia 
(corrected for albumin if 
appropriate* )
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLNmmol/L7.0 to7.8 mg/dL
1.74 to1.94 mmol/L6.1 to7.0mg/dL
1.51 to1.74 mmol/L6.1mg/dL
1.51mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL                               
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL6.1 to  <7.0 mg/dL                         
1.51 to < 1.74 mmolL< 6.1 mg/dL                           
< 1.51 mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected for 
albuminif appropriate* )
Adult and Pediatric 7Days>ULNto 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to<LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to<LLNmmol/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page112 30 September 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to2.0 mg/dL
0.47 to0.63 mmol/L1.0 to1.5 mg/dL
0.31 to0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLNmmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLNmmol/L2.5 to 3.5mg/dL
0.80 to < 1.12mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Hyperuricemia >ULNto 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULNto 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year   
Infant  < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to1.5 mg/dL
57 to87 μmol/L0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page113 30 September 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Creatinine ** 1.50to 2.00 mg/dL
133to 177μmol/L2.00to 3.00 mg/dL
177to 265 μmol/L3.00 to 6.00 mg/dL 
265to 530μmol/L6.00 mg/dL
53 0μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
* Calc ium should be cor rected for albumin if albumin is < 4.0 g/dL
**An overlap between the Grade 1 scale and the Lab’ snormal range for creatinine may result for Male subjects >[ADDRESS_653479] a 0.  
Tenofovir Alafenamide (TAF), GS -[ADDRESS_653480] (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics < 16 years
≥ 16 years- 2.0 to LLNg/dL
20 to LLNg/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page115 30 September 2016URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hematuria (Dipstick) 1 2 3-4+ NA
Hematuria (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour 
Collection
Adult and Pediatric 
10 Years200 to999mg/24h >999to1999mg/24 h >1999to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499mg/m2/24h >499to799mg/m2/24 h >799to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by [CONTACT_10870], however for other laboratorie s, toxicity grades will only be assigned to 
Dipstick Hematuria.
With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page116 30 September 2016CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac A rrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -urgent 
medical intervention 
indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/I nfarction NA NA Symptomatic ischemia (stable 
angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant 
acute blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (wit h repeat 
testing at same visit)140–159mmHg systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening 
consequences ( eg, malignant 
hypertension) OR 
Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated
Pediatric 17Years 
(withrepeat testing at same 
visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted for 
age, height, and gender 
(systolic and/or diastolic)Life-threatening 
consequences ( eg, malignant 
hypertension) OR
Hospi[INVESTIGATOR_374] 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial E ffusion Asymptomatic, small eff usion 
requiring no interventionAsymptomatic, moderate or 
larger effusi on requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening 
consequences 
(eg,tamponade) OR Urgent 
intervention indicated
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page117 30 September 2016CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV block 
OR Ventricular pause 
3.0 secComplete AV block 
Pediatric [ADDRESS_653481] degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV block Complete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/E mbolism NA Deep vein thrombosis AND 
No intervention indicated 
(eg,anticoagulation, lysis 
filter, invasive procedure) Deep vein thrombosis AND 
Intervention indicated 
(eg,anticoagulation, lysis 
filter, invasive procedure) Embolic event 
(eg,pulmonary embolism, 
life-threatening thrombus) 
Vasovagal Epi[INVESTIGATOR_1865] 
(associated with a procedure 
of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page118 30 September 2016RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced 
to 70% to 80%FEV1 or peak flow  50% to 
69%FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak 
flow 25% OR Intubation
Dyspnea or Respi[INVESTIGATOR_10807] & functional 
activities Dyspnea on exertion causing 
greater than minimal 
interference with usual social 
& functional activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respi[INVESTIGATOR_10808] 14 Years Wheezing OR minimal 
increase in respi[INVESTIGATOR_506449] 90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respi[INVESTIGATOR_422258]/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis 
OR Medical intervention 
indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in 
affected eye(s) 
Visual Changes 
(frombaseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing 
greater than minimal 
interference with usual social 
& functional activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in 
affected eye(s )
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page119 30 September 2016SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by [CONTACT_143374] (for 
disabled adults)Thinning or patchy hair loss 
detectable by [CONTACT_10873] – RashLocalized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or 
morbilliform rash with 
vesicles or limited number of 
bullae OR Superficial 
ulcerations of mucous 
membrane limited to one siteExtensive or generalized 
bullous lesions OR Stevens -
Johnson syndrome OR 
Ulceration of mucous 
membrane involving two or 
more distinct mucosal sites 
OR Toxic epi[INVESTIGATOR_7387] (TEN)
Hyperpi[INVESTIGATOR_10810] 
(itching –no skin lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or minimal 
interference with usual social 
& functional activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activities NA
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page120 30 September 2016GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite without 
decreased oral intakeLoss of appetite associated 
with decreased oral intake 
without significant weight 
loss Loss of appetite associated 
with significant weight loss Life-threatening 
consequences OR Aggressive 
intervention indicated 
[eg,tube feeding or total 
parenteral nutrition]
Ascites Asymptomatic Symptomatic AND 
Intervention indicated ( eg, 
diuretics or therapeutic 
paracentesis)Symptomatic despi[INVESTIGATOR_10811]-threatening 
consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening 
consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation 
requiring regular use of 
dietary modifications, 
laxatives, or enemas Obstipation with manual 
evacuation indicatedLife-threatening 
consequences 
(eg,obstruction)
Diarrhea 
Adult and Pediatric 
1 YearTransient or intermittent 
epi[INVESTIGATOR_10812] 3stools 
over baseline/24 hrPersistent epi[INVESTIGATOR_143350] 4 –6 stools 
over baseline per 24 hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening 
consequences 
(eg,hypotensive shock)
Pediatric 1 Year Liquid stools (more unformed 
than usual) but usual number 
of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without 
medical intervention 
indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention 
indicatedLife-threatening reduction in 
oral intake
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page121 30 September 2016GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/S tomatitis 
(clinical exam)
See also Pr octitis, Dysphagia -
OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal 
bleeding OR Life -threatening 
consequences ( eg, aspi[INVESTIGATOR_1516], 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no or 
minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 
24-48 hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening 
consequences 
(eg,hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospi[INVESTIGATOR_10814] 
(other than ER visit)Symptomatic AND 
Hospi[INVESTIGATOR_374] 
(other than ER visit)Life-threatening 
consequences ( eg, sepsis, 
circulatory failure, 
hemorrhage )
Proctitis 
(functional -symptomatic)
Also see Mucositis/Stomati tis 
for Clinical E xamRectal discomfor t AND No 
intervention indicatedSymptoms causing greater 
than minimal interference 
with usual social & functional 
activities OR Medical 
intervention indicated Symptoms causing inability 
to perform usual social/
functional activities OR 
Operative intervention 
indicated Life-threatening 
consequences 
(eg,perforation)
Vomiting Transient or intermittent 
vomiting with no or minimal 
interference with oral intakeFrequent epi[INVESTIGATOR_506450]-threatening 
consequences ( eg, 
hypotensive shock)
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page122 30 September 2016NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in M ood 
(eg,agitation, anxiety, 
depression, mania, psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater 
than minimal interference 
with usual social & functional 
activities Alteration causing in ability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others 
(eg,suicidal/homicidal 
ideation or attempt, acute 
psychosis) OR Causing 
inability to perform basic 
self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, 
OR coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no or 
minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional ac tivities Disabling ataxia causing 
inability to perform basic 
self-care functions
Cognitive a nd 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater 
than minimal interference 
with usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the settingModerate developmental 
delay, either motor or 
cognitive, as determined by 
[CONTACT_7425] a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page123 30 September 2016NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & functional 
activitiesSymptoms causing inability 
to perform usual social & 
functional activitiesSymptoms causing inability 
to perform basic self -care 
functions OR Hospi[INVESTIGATOR_373] (other than ER 
visit) OR Headache with 
significant impairment of 
alertness or other neurologic 
function 
Insomnia NA Difficulty sleepi[INVESTIGATOR_10816]/functional activitiesDifficulty sleepi[INVESTIGATOR_10817] & functional activitiesDisabling insomnia causing 
inability to perform basic 
self-care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perfo rm usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respi[INVESTIGATOR_10818] 
(including paresthesia and 
painful neuropathy)Asymptoma tic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social & functional 
activities Sensory alteration or 
paresthesia causing greater 
than minimal interference 
with usual social & functional 
activities Sensory alteration or 
paresthesia causing inability 
to perform usual social & 
functional activitiesDisabling sensory alteration 
or paresthesia causing 
inability to perform basic 
self-care functions
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive 
(eg,status epi[INVESTIGATOR_7397]), or 
difficult to control 
(eg,refractory epi[INVESTIGATOR_002])
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page124 30 September 2016NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (pre- existing) 
For Worsening of Existing 
Epi[INVESTIGATOR_506451]-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure charact er 
from baseline either in 
duration or quality ( eg, 
severity or focality) Seizures of any kind that are 
prolonged, repetitive 
(eg,status epi[INVESTIGATOR_7397]), or 
difficult to control 
(eg,refractory epi[INVESTIGATOR_002])
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without second ary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary  
generalization, lasting 
5-20minutes with 
< [ADDRESS_653482] ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated with 
a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic 
self-care functions
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page125 30 September 2016MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater 
than minimal interference 
with usual social & functional 
activitiesJoint pain causing inability to 
perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic 
self-care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual social 
& functional activitiesStiffness or joint sw elling 
causing greater than minimal 
interference with usual social 
& functional activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform ba sic self-care 
functions
Bone Mineral Loss BMD t-score or z- score
–2.5 to –1.0 BMD t-score or z- score
–2.5Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z-score 
–2.5 to –1.0BMD z-score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater 
than minimal interference 
with usual social & functional 
activitiesMuscle pain causing inability 
to perform usual social & 
functional activitiesDisabling muscle pain 
causing inability to perform 
basic self -care functions
Osteonecrosis NA Asymptomatic with 
radiographic findings AND 
No operative intervention 
indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic 
self-care functions
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page126 30 September 2016SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria (wheals) 
with no medical intervention 
indicatedLocalized urticaria with 
medical intervention 
indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralize d urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR 
Life-threatening 
bronchospasm OR laryngeal 
edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & functional 
activities Symptoms causing inability 
to perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & functional 
activitiesSymptoms causing inability 
to perform usual social & 
functional activitiesIncapacitating fatigue/ malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain-Indicate Body Site
See also Injection Site P ain, 
Headache, Arthralgia, and 
MyalgiaPain causing no or minimal 
interference with usual social 
& functional activitiesPain causing greater than 
minimal interference with 
usual social & functional 
activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated
Unintentional Weight L ossNA 5% to 9% loss in body weight 
from baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  
Aggressive intervention 
indicated [ eg, tube feeding or 
total parenteral nutrition]
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page127 30 September 2016INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain 
(painwithout touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no or 
minimal limitation of use of 
limbPain/tenderness limiting use 
of limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing 
inability to perform basic 
self-care function OR 
Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated for 
management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm 
(or2581cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (invo lving dermis 
and deeper tissue)
Pediatric 15Years Erythema OR Induration OR 
Edema present but 2.5cm 
diameterErythema OR Induration OR 
Edema > 2.5cm diameter but 
<50% surface area of the 
extremity segment (eg, upper 
arm/thigh)Erythema OR Induration OR 
Edema involving 50% 
surface area of the extrem ity 
segment (eg, upper 
arm/thigh) OR Ulceration OR 
Secondary infection OR 
Phlebitis OR Sterile abscess 
OR DrainageNecrosis (involving dermis 
and deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 48h 
treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h 
treatment Generalized itching causing 
inability to perfo rm usual 
social & functional activitiesNA
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page128 30 September 2016ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy ( eg, back of 
neck, breasts, abdomen)Detectable by [CONTACT_10874] (for 
young children and disabled 
adults)Detectable on physical exam 
by [CONTACT_506491][INVESTIGATOR_111102]-threatening 
consequences 
(eg,ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by [CONTACT_10874] (for 
young children and disabled 
adults)Detectable on physical exam 
by [CONTACT_143376] & functional 
activities OR Thyroid 
suppression therapy indicatedSymptoms causing inability 
to perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_111103]-threatening 
consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater 
than minimal interference 
with usual social & functional 
activities OR Thyroid 
replacement therapy indicatedSymptoms causing inability 
to perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_111103]-threatening 
consequences
(eg, myxedema coma)
Lipoatrophy ( eg, fat loss from 
the face, extremities, 
buttocks)Detectable by [CONTACT_10874] (for 
young children and disabled 
adults)Detectable on physical exam 
by [CONTACT_506492] (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page129 30 September 2016GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by 
[CONTACT_506493]-threatening hypotension 
OR Operative intervention 
indicated
Urinary T ract obstruction 
(eg,stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing 
life-threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other than 
HIVinfection)Localized, no systemic 
antiμbial treatment indicated 
AND Symptoms causing no 
or minimal interference with 
usual social & functional 
activitiesSystemic anti μbial treatment 
indicated OR Symptoms 
causing greater tha n minimal 
interference with usual social 
& functional activitiesSystemic anti μbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than 
simple incision and drainage) 
indicatedLife-threatening 
consequences 
(eg, septic shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transportation, pursuing a hobby, e tc.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page130 30 September 2016Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medical ly documented ovarian failure.
Women are considered to be in a postmenopausal state when they  are ≥ 54 years of age with 
cessation of previously  occurring menses for 
≥ [ADDRESS_653483] is considered of fertile after the initiation of 
puberty unless permanently  sterile by [CONTACT_506494].
2)Contraception Requirements for Female Subjects
a.Study Drug Effects on Pregnancy and Hormonal Contraception
Data from clinical pharmacokinetic interaction studies of TAF have demonstrated that there is no 
reduction in the clinical efficacy  of hormonal contraception. Non -clinical toxicity  studies in 
animals (rats and rabbits) of TAF have demonstrated no adverse effect on fertility  orembryo-fetal 
development. However, there are no clinical studies of TAF in pregnant women. Please refer to 
the latest ve rsion of the investigator’s brochure for additional information.
b.Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires using at least an acceptable
effective contracepti ve measure. They  must have a negative serum pregnancy  test at Screening
and a negative pregnancy test on the Baseline/Day [ADDRESS_653484] will be performed at the end of relevant sy stemic exposure. In the event of a
delayed menstrual period (over one month between menstruations), a pregnancy  test must be
performed to rule out pregnancy . This is even true for women of childbearing potential with
infrequent or irregular periods. They  must also agree to one of the f ollowing from Screening
until the end of relevant systemic exposure.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page131 30 September 2016Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifestyle.
Or
Consistent and correct use of 1 of the following methods of birth control listed below.
Intrauterine device (IUD) with a failure rate of < 1% per year
Intrauterine hormone -releasing s ystem (IUS) with a failure rate of < 1% per y ear
Tubal sterilization
Essure micro- insert system (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and
had confirmation of surgical success 3 months after procedure)
Barrier methods (one female barrier and one male barrier must be used in combination)
■ Female barriers: Diaphragm with spermicide or Cervical cap with spermicide
■ Male barriers: Male condom (with or without spermicide)
Hormonal methods
■Oral contraceptives (eithe r combined or progesterone only )
■Injectable progesterone
■Implants of levonorgestrel
■Transdermal contraceptive patch
■Contraceptive vaginal ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment
and until at leas t 30 days after the end of relevant sy stemic exposure.
3)Contraception Requirements for Male Subjects
During the study , male subjects with female partners of childbearing potential should use
condoms when engaging in intercourse of reproductive potential.
Tenofovir Alafenamide (TAF), GS -7340
Protocol GS -US-320-4018 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page132 30 September [ZIP_CODE])Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM). Female condom and male condom should not 
be used together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study, or if they  become pregnan t within 30days of last study  drug dose. Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspects she is pregnant during the stud y must report the in formation to 
the investigator. Instructions for reporting pregnancy , partner pregnancy , and pregnancy
 outcome 
are outlined in Section [IP_ADDRESS].